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ABSTRACT
Clinically healthy horses were instrumented to measure hemodynamic,
metabolic, hematologic, and serum biochemical variables and monitor clinical signs
during and after IV infusion of ATP-MgCl2. Conscious horses were administered ATPMgCl2 (0.05 mg ATP/kg body weight/min; 0.05 mg/kg/min increments; maximum rate
-1.0 mg/kg/min), which caused a rate-dependent increase in cardiac output, decrease in
systemic vascular resistance, and mild pulmonary hypertension. The maximal safe
infusion rate was 0.3 mg ATP/kg body weight/min. Anesthetized horses administered
ATP-MgCl2(0.l to 1 mg/kg/min; 0.1 mg/kg/min increments) developed a ratedependent decrease in systemic and colonic vascular resistance via vasodilatation. In
conscious horses administered low-dose endotoxin, ATP-MgCl2 (dose - 100 pmole/kg
ATP and 100 pmole/kg MgCl2; rate - 0.3 mg/kg/min) failed to attenuate the clinical,
hemodynamic, metabolic, and hematologic alterations that occur secondary to endotoxin
exposure; ATP-MgCI2 infusion appeared to potentiate pulmonary hypertension,
leukopenia, and neutropenia observed with endotoxin.
Based on the results of the in vivo studies, the effects of ATP on vasomotor tone
of isolated equine colonic arterial and venous rings were studied. Non-cumulative dose
response curves o f vessel rings from normal horses to ATP (10'8 to 10‘3 M) were
generated in the presence and absence of endothelium and in the presence of a non
specific nitric oxide synthase inhibitor, L-NAME (10-4 M). ATP caused a biphasic
response at high doses (lO*4 and 10'3 M) in both vessel types, an initial transient
contraction followed by a slow, substantial and sustained relaxation, which was

xvi
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attenuated with endothelium removal. The endothelium-dependent relaxation
component was mediated by a mechanism other than nitric oxide.
A method to quantify adenine nucleotides in equine colonic mucosa was
validated. Adenine nucleotides were stable in lyophilized tissue stored at -70 C for at
least 54 days. Effects of an electron transport inhibitor (antimycin A) on mucosal
nucleotides was determined in a whole tissue model. In the presence of glucose and
oxygen, ATP was stable for up to 4 hrs, but ADP and AMP decreased. In the absence
o f glucose, ATP remained stable for only 3 hrs. Antimycin A (50 pM) caused a timedependent, irreversible decrease in adenine nucleotides.

xvii
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CHAPTER 1. INTRODUCTION/REVIEW OF LITERATURE

1
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1.1 Introduction
Acute gastrointestinal tract disease is the leading natural cause of death in adult
horses. Strangulating volvulus of the ascending colon is a common cause of
gastrointestinal tract ischemia and is associated with substantial morbidity and
mortality. Loss of fluid into the peritoneal cavity and intestinal lumen leads to
hypovolemia. Additionally, splanchnic ischemia causes mucosal barrier disruption and
transmural migration of bacteria and endotoxin into the systemic circulation. The
combination of endotoxemia and hypovolemia causes profound alterations in the
circulatory system with the development of circulatory shock. If left untreated, affected
animals will progress to multiple organ failure and death.
Adenosine triphosphate (ATP) is the principal immediate donor of free energy
for mammalian cells. Additionally, ATP and its catabolites, have profound effects on
vasomotor tone via interaction with specific purinergic receptors. During tissue
ischemia and shock, endogenous production of ATP is decreased, which can
profoundly alter the microcirculation, cell membrane transport and function and cellular
energy metabolism.
Administration of a combination of ATP and magnesium chloride (ATP-MgCy
has been demonstrated to alter vasomotor tone by producing vasodilatation, thereby
potentially enhancing blood flow, microcirculation and tissue perfusion. Additionally,
ATP-MgCl2 has been shown to improve tissue ATP content, organ function, and downregulate the synthesis of cytokines and inflammatory mediators. However, the efficacy
o f ATP-MgCl2 during gastrointestinal tract disease and endotoxemia in horses is not
known.

2
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1.2 Circulatory Shock
Despite many advances in cardiovascular support therapy, circulatory shock
remains an important cause of death in both humans and domestic animals. Circulatory
shock can be defined as “a general inadequacy of blood flow to tissues relative to their
metabolic demands” (1). If circulatory shock is inadequately managed, the result is
multiple organ failure, particularly the lung and splanchnic organs, and ultimately death
(1).
Two main classification systems have been proposed to categorize circulatory
shock. The first classification system ascribes the pathologic events to the initiating
insult, such as hemorrhage, trauma, sepsis, and myocardial infarction (1). The second
classification system groups the insult according to the character of the predominant
circulatory disturbance: cardiogenic, obstructive, hypovolemic, and distributive (2,3).
The most common forms o f shock observed in the horse are hypovolemic and
distributive (4). Hypovolemic shock refers to a loss of intravascular volume associated
with the loss o f whole blood, plasma, or largely protein-free fluid through sweat,
diarrhea, or urine (1). The principal alterations that occur during non-hemorrhagic
hypovolemic shock include arterial vasoconstriction, decreased venous pressure,
hemoconcentration, tachycardia and oliguria (S). Because of the decrease in vascular
filling volume, venous return to the heart decreases, with a subsequent decrease in
cardiac output (CO), arterial flow, and arterial pressure (1).
Distributive shock refers to an expansion of the vascular space owing to regional
or generalized loss o f vascular tone (1). Principal causes of distributive shock include
sepsis, neurologic disturbance, anaphylaxis or metabolic, toxic or endocrinologic
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depression o f vasomotor tone (5). A common feature o f distributive shock is
inappropriate vasodilatation, which leads to maldistribution of vascular volume and
impaired organ perfusion (S). In some forms of distributive shock, such as during the
early stages of septic shock, CO and total organ blood flows may be increased, but at the
microvascular level, there may be failure to match blood flow to local parenchymal
demands, which leads to tissue hypoxia and dysfunction (1).
From a clinical perspective, many diseases fit into more than one classification
system. For example, gastrointestinal tract ischemia associated with equine colic leads
to hypovolemic shock owing to loss of peritoneal and intestinal luminal fluid (1). When
gastrointestinal mucosal barrier disruption occurs secondary to ischemia, transmural
migration of bacteria and endotoxin into the portal and systemic circulations will lead to
distributive shock (1). In adult horses, the most common cause of distributive shock is
endotoxemia, which principally occurs secondary to splanchnic ischemia associated
with acute strangulating and nonstrangulating intestinal disease (1).
When endotoxin enters the portal and systemic circulations, it can induce an
inflammatory response via both direct and indirect mechanisms. Endotoxin can directly

activate the complement, coagulation and fibrinolytic cascades (6-10). Indirect
mechanisms include activation o f numerous cell types, such as lymphocytes,
neutrophils, endothelial cells, platelets and mononuclear cells, which perpetuate the
inflammatory response (11).

When mononuclear cells are activated by endotoxin, they liberate cytokines,
principally tumor necrosis factor (TNF), interleukin (IL)-l, and IL-6 (12). Cytokines are
small (8-30 k£>), intercellular messenger polypeptides that are active at low
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concentrations (12). Cytokines possess growth-promoting, proinflammatory or anti
inflammatory effects. The primary proinflammatory cytokines include IL-1, IL-8 and
TNF (12). When produced in excess, the primary cytokines initiating adverse effects
are IL-1 and TNF (13-17). The principal effects o f these cytokines are diffuse
microvascular plugging secondary to activation o f the coagulation system (9), loss of
vascular autoregulation, and increased vascular permeability (18).
The primary anti-inflammatory cytokines are EL-10, IL-6, IL-lra and
transforming growth factor (TGF)-P (12). In the course of overwhelming inflammation,
these natural anti-cytokine mediators are produced in insufficient quantities to be
capable o f effectively containing the insult (12).
Tumor necrosis factor is referred to as “THE shock cytokine” (12). There are 3
members o f the TNF gene family: TNF-a, TNF-P, and Iymphotoxin-P (19-23). The
pathogenic role o f TNF-a is well-documented (24). It is a 17 kD polypeptide released
principally by activated macrophages in response to lipopolysaccharide (LPS) (14,25).
This cytokine increases rapidly and peaks at 60-90 minutes after endotoxin exposure
(12). The principal activities of TNF-a include induction o f other cytokines such as IL1, IL-4 and IL-6; activation of T cells; endogenous pyrogen activity, induction of
endothelial cell surface antigens and procoagulation activity; eicosanoid synthesis;
activation o f osteoclastic bone resorption; inhibition of bone collagen synthesis;
induction o f acute-phase reactant synthesis and granulocyte/monocyte stimulating
factor; and inhibition o f enzymes involved in lipid metabolism (26-28). In neutrophils,
TNF-a stimulates activation of the respiratory burst, degranulation and adherence to
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vascular endothelium (29). Additionally, TNF-a can cause myocardial depression,
hypercoagulability, hypotension and death (12).
Interleukin-6 is a phosphoglycoprotein molecule synthesized by numerous cell
types in response to various stimuli, including endotoxin, IL-1, and TNF-a (30). It
peaks at 120-180 minutes following exposure to endotoxin and possesses both anti- and
proinflammatory activities (12). It functions as a suppressor of proinflammatory
cytokine production, a pyrogen, and an initiator of the acute-phase response (12). Since
IL-6 circulates in high concentrations, it is the best cytokine marker o f inflammatory
disease activity (12).
Interleukin-1 is generated primarily by mononuclear phagocytes (31). It
possesses many of the same biological activities of TNF-a, peaks at 180 minutes after
exposure to endotoxin, and can stimulate the synthesis and release production of TNFa,IL -8, and IL-6 (12,32).
Secretion of cytokines, most notably IL-1 and TNF-a, affect the temperature setpoint, vascular resistance and permeability, cardiac function, bone marrow and enzyme
systems (12). Many effects o f cytokines are mediated at the target tissues by other
inflammatory mediators, such as nitric oxide (NO) and eicosanoids (12). IL-1 and TNFa stimulate elaboration o f other cytokines, which then amplify and modulate the
cytokine response (33,34).
Other inflammatory mediators produced during endotoxic shock include
arachidonic acid metabolites (prostaglandins, thromboxanes, and leukotrienes), platelet
activating factor, NO, endothelin-1 (ET-1), proteases, and reactive oxygen species
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(11,12,35-39). These various mediators can profoundly affect vasomotor tone,
coagulation, and leukocyte-endothelial interactions.
When neutrophils are exposed to endotoxin and other inflammatory mediators,
they undergo functional alterations and release proteolytic enzymes (40) and reactive
oxygen radicals (41), which cause local endothelial and tissue injury. Endotoxin and
TNF stimulate neutrophil migration (42) and endothelial adhesion via up-regulation of
expression of adhesion molecules on the cell surface of both neutrophils and endothelial
cells (42-44). Additionally, neutrophil deformability decreases, which favors additional
sequestration in the microvasculature (45,46).
Vascular endothelium is one of the target organs that is adversely affected during
endotoxic shock (47,48). Release o f tissue thromboplastin and exposure of
subendothelial collagen that occurs secondary to endothelial cell damage activates both
the extrinsic and intrinsic coagulation cascades (31). Endotoxin causes both structural
and metabolic changes in endothelial cells and increases permeability of the endothelial
cell layer (49). Additionally, release o f endothelium-derived mediators, such as NO, ET1, and prostaglandins, contribute to the inflammatory and hemodynamic derangements
that occur during endotoxic shock.
During the initial stages o f shock (hyperdynamic phase), myocardial contractility
and heart rate increase and peripheral vasoconstriction occurs (5). These hemodynamic
alterations occur secondary to sympathetic activation in an attempt to maintain blood
pressure and increase vital organ perfusion by redistributing flow away from skin,
skeletal muscle, and renal and splanchnic beds (5). Activation o f the renin-angiotensin
system leads to additional vasoconstriction and increases in vascular volume due to
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sodium retention (5). Numerous other mediators are released in an attempt to maintain
an energy source for cells and intravascular volume to maintain blood flow (S).
An early consequence o f decreased oxygen availability during shock is a
reduction in cellular ATP content (5). When tissue oxygen tension decreases to a
critical level, oxidative phosphorylation is uncoupled and ATP production gradually
ceases (SO). Depletion o f ATP ultimately leads to mitochondrial swelling, cell
membrane deterioration, abnormalities in cellular calcium flux, intracellular
accumulation o fN a \ Ca**, and water, and lactic acidosis (5). In an attempt to offset the
changes that occur with decreased ATP content, administration o f ATP-MgCl2has been
shown to attenuate some o f the adverse metabolic alterations that occur during shock
(SO) (Refer to section on ATP-MgCl2for additional information).
Among adult horses, particularly if shock is associated with splanchnic
ischemia, many of the early hyperdynamic events are not observed (1). During the later
stages o f shock (hypodynamic phase), the alterations that occur in horses are similiar to
humans and other species. Hypovolemia develops secondary to arterial and venous
dilatation and leakage o f plasma into the extravascular space (51,52). Initially, despite a
normal or increased CO, ventricular function is abnormal leading to reduction in the
ejection fraction (52,53). The hypovolemia and vasodilatation decreases systemic
vascular resistance (SR J, and there is decreased peripheral use o f oxygen and other
nutrients by the cells (54-56). Perfusion may be normal or decreased but cellular
metabolism is decreased (52). Maldistribution of blood flow occurs due to constriction
o f some vascular beds and vasodilatation o f others (52). Enhanced leukocyte adherence
(53,57,58) and neutrophil and platelet aggregation can lead to a further decrease in

8
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blood flow owing to microvascular plugging (59). Additionally, increased intravascular
coagulation occurs (56-58). Eventually multiple organ failure develops (52,56). If the
hemodynamic derangements are not reversed, death ultimately ensues.
In horses, injection of lethal (50-200 |lg/kg) and sublethal (10-40 |ig/kg) doses
of endotoxin causes a decrease in systemic arterial pressure (SAP) and CO and an
increase in right atrial pressure, pulmonary artery pressure (PAP) and pulmonary
vascular resistance (PR J (60-63). The decreased CO output likely is associated with
depressed cardiac mechanical function, decreased venous return, increased PRLor a
combination (64-66). Splanchnic vasoconstriction occurs as part o f the compensatory
response to endotoxemia (66,67). Intestinal vasoconstriction has been documented in
other species administered low-dose endotoxin ( ).
6 8

The three main goals during the treatment of circulatory shock are: restoration of
organ perfusion; control or reversal o f the initiating cause; and prevention or
management o f the complications associated with shock (5). The first and most
important therapeutic goal is restoration of blood volume (69). The initial aim is to
restore organ perfusion in order to provide adequate oxygen delivery to the tissues to
meet their metabolic needs (5). Restoration of arterial blood pressure, vascular volume
and CO is of paramount importance in supporting tissue oxygenation (5). Frequently,
patients have maldistributed blood flow with decreased intravascular volume but with
increased interstitial water (70-73). Therapy should be aimed at improving circulatory
function by restoring plasma volume, not by overloading an already expanding
interstitial space (69).

9
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Blood volume expansion is the most important element of therapy for circulatory
shock (5). The easiest and most effective method to achieve intravascular volume
expansion is with colloids, which expands plasma volume without overexpanding
interstitial water (73-78). Plasma is the most effective colloid (5). Its effects are longlasting and if fresh or fresh frozen plasma is used, it also provides clotting factors (S). If
blood loss and hemodilution cause a significant decrease in oxygen-carrying capacity,
whole blood is indicated (5). The use of dextrans (high molecular weight
polysaccharides) or other synthetic colloid volume expanders, such as hydroxyethyl
starch, are helpful in the absence of plasma (S).
Crystalloids can also provide blood volume expansion. However, when they are
used, large fluid replacement volumes are required because only 25 to 30% o f the
crystalloid solution remains in the vascular space 30 minutes following administration
(79). Because of the rapid diffusion from the vascular space, further fluid
administration in the form of colloids may be needed if hypotension or vasoconstriction
persists (5). Interstitial edema may develop, which can subsequently cause disturbances
in organ function, especially the lung and splanchnic organs (80). The use of fluids high
in sodium, such as 0.9% NaCl (sodium chloride), help maintain the fluid in the
extracellular and intravascular space (5).
Measurement o f central venous pressure (CVP) and pulmonary wedge pressure
(PWP) are useful to determine the capacity of the vascular system to accept more
volume without producing pulmonary edema and to prevent acute blood volume
overload during rapid fluid restoration. Although CVP and PWP may accurately
measure venous pressures, they do not accurately reflect blood volume in most patients.
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The distribution of body water between plasma, interstitium and intracellular
compartments can only be definitively measured using isotopic body composition
studies (70-72).
In horses, the goal during volume replacement is to maintain a mean arterial
pressure (MAP) of 80 mm Hg or greater and a CVP between 10-15 cm H 0 . A rapid
2

increase in CVP may indicate too rapid hydration in the face of cardiac dysfunction.
The use o f hypertonic or hyperoncotic fluids during circulatory shock in horses will
transiently shift fluid from the extravascular, extracellular space to the vascular space,
thereby expanding plasma volume. The effect is temporary because the high
concentrations o f intravascular sodium and chloride ions rapidly traverse the vascular
bed into the interstitium, returning fluid to the interstitial compartment. Therefore,
administration of crystalloids or colloids along with hypertonic or hyperoncotic fluids is
vital to keep the fluids in the intravascular space ( ).
1

Under normal circumstances, the plasma acid-base status is maintained by
plasma bicarbonate (HC 3*) and protein buffering systems, with acute respiratory and
0

longer-term renal adjustments. Many cases of metabolic acidosis associated with
circulatory shock will self-correct after adequate intravascular volume replacement has
been effectively achieved (I).
The use o f antimicrobial agents does not alter survival rate in endotoxic animals
(81) but endotoxemia has been shown to cause translocation of bacteria from the
gastrointestinal tract to other organs (82). Severe, protracted hypovolemic shock has
been associated with impaired splanchnic perfusion with subsequent mucosal barrier
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disruption and bacterial translocation (83). Therefore, the use of prophylactic broadspectrum antimicrobial agents is advocated ( ).
1

The use of inotropic and/or vasoactive drugs during circulatory shock may be
warranted. If poor peripheral perfusion and low CO exists despite fluid therapy and
CVP is increased, positive inotropic therapy should be initiated (5). Following volume
expansion, the use of inotropic agents, such as dobutamine, may help achieve optimal
cardiac index (Cl), oxygen delivery (DOj), and oxygen consumption (69). Dobutamine
has been shown to cause a marked and significant increase in Cl and stroke index,
cardiac and stroke work, and D 0 and consumption. Additionally, dobutamine
2

decreases SRl and PRl, CVP, and PWP (78,84,85). Vasodilatory agents, such as
acepromazine, may be indicated if MAP is normal or increased and if there is a high
SRl (69). If hypotension persists following volume expansion, the use of vasopressor
agents may be warranted to maintain perfusion pressure (69).
The efficacy of corticosteroids to treat hypovolemic and septic shock has been
extensively studied. Corticosteroids mediate multiple anti-inflammatory effects through
alterations in gene transcription and translation (56). They significantly decrease the
synthesis of TNF-a, which results in significant down-regulation o f the inflammatory
response ( ). They increase the synthesis of lipocortin, a protein that inhibits
8 6

phospholipase (PL) A activity and the formation o f arachidonic acid-derived
2

eicosanoids (56). There are many potential disadvantages associated with the use of
corticosteroids for the treatment of sepsis (56). Profound immunosuppression results
from decreased neutrophil chemotaxis, antigen-antibody complexing, and opsonization,
thus leading to refractory or even secondary infections (56). Corticosteroid
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administration is reported to induce laminitis in some horses by potentiating
catecholamine-induced digital vasoconstriction (87). This may particularly be important
in patients that are already at risk o f developing laminitis (56).
Early studies in experimental animal models demonstrated beneficial effects of
corticosteroids during endotoxemia and septicemia (57). Clinical trials in humans did
not show beneficial effects and sometimes showed adverse effects ( ). Studies
8 8

investigating the application of corticosteroids in equine endotoxemia have failed to
show any therapeutic benefit (89,90). Additionally, most investigators agree that
systemic corticosteroids are contraindicated as treatment for severe sepsis and septic
shock in horses ( ).
1

In horses with shock, the use of anti-inflammatory agents is indicated. Non
steroidal anti-inflammatory drugs have been shown to have a protective effect during
endotoxic and splanchnic-ischemia shock via modulation of arachidonic acid pathway
mediators (91,92). Inhibition of cyclooxygenase results in decreased synthesis of
prostaglandins and thromboxanes, thereby improving vascular and coagulation function

(56). Leukotrienes contribute to hemodynamic, hematologic and pulmonary
manifestations during shock (56). The beneficial effects of lipoxygenase-inhibiting
drugs during shock have been demonstrated in other species but not in horses (56).
Finally, prevention o f multiple organ failure is critical. Supplemental
oxygenation via nasal insufflation may be necessary if arterial oxygen tension falls
below 85 mm Hg due to risk of hemoglobin desaturation, which leads to tissue hypoxia
(1). Additionally, renal and hepatic support is vital to help maintain water balance and
prevent accumulation o f toxic metabolites (5). The maintenance of intravascular fluid
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volume, glomerular filtration, and urine production is critical in the prevention o f renal
failure (93). Administration of intravenous (TV) fluids and maintenance of normal
electrolytes is vital. If renal perfusion is diminished and the animal remains oliguric 10
to

1 2

hours after starting fluid therapy, administration o f dopamine may improve renal

blood flow and urine output (93). The use of loop diuretics, such as furosemide, may be
indicated to promote diuresis (93). Additionally, blocking the Na7K72Cl' co
transporter in the kidney with loop diuretics may protect the renal tubule cells by
reducing their metabolic rate (93).
Management techniques for hepatic insufficiency are supportive. Fluid deficit
and acid-base or electrolyte imbalances should be corrected by intravenous fluids (94).
Administration of agents to reduce the production o f toxic protein metabolites by enteric
bacteria or interfering with their absorption may be indicated. Mineral oil, oral
administration of poorly absorbable antibiotics, or lactulose can be used (95-98).
Additionally, rations high in carbohydrates and low in protein are recommended
(94,97).
13 Equine Ascending Colon
The anatomy, physiology and pathophysiology o f the equine ascending colon is
complex. During disease, significant alterations in anatomical characteristics and
physiological functions occur. Knowledge of normal gross and microscopic anatomy,
as well as physiology o f digestion, absorption and secretion, provides the foundation for
understanding the mechanisms involved in disease processes.
The equine ascending colon is 3 to 4.5 meters in length with a capacity of 55 to
130 liters (99,100). It forms a double horseshoe-shaped loop consisting o f the right

14

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

ventral, left ventral, left dorsal and right dorsal components (101). The sternal and
diaphragmatic flexures are located at the cranial aspect of the ventral and dorsal loops,
respectively (101). The pelvic flexure (PF) joins the left ventral and left dorsal
segments caudally (101). The diameter of the ascending colon varies depending on the
segment, with the right dorsal component being the largest (SO cm) (101). The colon
has longitiudinal muscle bands, teniae coli, that vary in number depending on the
segment and these bands form sacculations called haustra coli (

1 0 1

).

The proximal (right ventral colon [RVC]) and terminal (right dorsal colon
[RDC]) regions o f the ascending colon are attached to the dorsal aspect of the
abdominal cavity by the ascending mesocolon (101). The vascular supply to the dorsal
colon arises from the right colic artery, which is a branch of the cranial mesenteric artery
(99,100,102). The ventral colon is supplied by the colic branch artery, which arises
from the ileocolic artery (99,100,102). Both arteries are located in the colonic
mesentery and travel parallel to the colon to anastomose at the pelvic flexure (99,102).
The arteries branch from the colonic vessels every 2 cm and anastomose with vessels
lying orally or aborally to form a colonic rete before continuing into the colonic tissue
(102). The function of the colonic rete is unknown, but may provide collateral blood
supply (103). Vessels enter the submucosa through the tunica muscularis to form a
submucosal arteriolar plexus (102). Arterioles ascend from the submucosal plexus to
the mucosa, where an extensive capillary network forms around the colonic glands
(102). The submucosal venous plexus and sparsely distributed venules drain the
capillary network (

1 0 2

).
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Histologically, the ascending colon has a thin mucosal layer with straight,
shallow colonic glands separated by extensive lamina propria. Goblet cells are
numerous. The outer muscularis externa is thickened into flat bands of smooth muscle
and elastic fibers, the taenia coli. Elastic fibers predominate over muscle in the taenia
coli. A thin, single-layered muscularis mucosa is present, and villi are absent. Scattered
lymphoid nodules are evident. The cells lining colonic glands, in addition to goblet
cells, are granular cells (

1 0 1

).

The equine ascending colon does not possess mucosal enzymes or an active
transport mechanism for hexoses, amino acids or B vitamins (104). The primary
function o f the large intestine in adult horses is the production and absorption o f volatile
fatty acids (VFAs) via microbial digestion o f soluble and insoluble carbohydrates (105).
Up to 75% o f energy requirements are met by products of microbial fermentation o f
carbohydrates in the cecum and ascending colon (106). Additionally, the large intestine
secretes a volume of fluid equal to the extracellular fluid volume and recovers
approximately 90 to 95% of it every 24 hours (107).
The normal colonic luminal microorganisms consist of ciliated protozoa,
anaerobic bacteria and small numbers of Enterobacteriaceae sp. (108,109). The normal
colonic pH is maintained at 6.0-6.8 and osmolarity of 300 mOsm/L (106,110,111). The
end products of fermentation o f soluble (starch) and insoluble (cellulose) carbohydrates
are the VFAs, acetate, butyrate, and propionate, and carbon dioxide, methane and small
amounts of lactate (112). Acetate is produced in the largest quantity but the ratio of
acetaterpropionate decreases as the ratio o f solublerinsoluble carbohydrate increases
(105). Periods o f high VFA production are associated with a rapid increase in fluid
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volume, production o f large quantities of osmotically active organic acids and gas
formation (105,107). Homeostatic mechanisms to buffer organic acids include transport
o f bicarbonate from the small intestine, secretion of bicarbonate from the large intestinal
mucosa and rapid absorption of VFAs (112).
Approximately 97% of VFAs are dissociated (ionized) at the average pH of the
equine large intestine (113). The ionized form is poorly absorbed compared with the
lipid-soluble unionized form (113). In the colonic lumen, carbon dioxide combines
with water to form carbonic acid, which dissociates into bicarbonate and hydrogen ions
(114). The ionized VFAs combine with the hydrogen ions to form undissociated
(unionized) VFAs, which are subsequently absorbed into the colonic epithelial cells
(115). Within the epithelial cells, the VFAs can be metabolized or transported into the
blood and carried to the liver for energy metabolism (115). As the VFAs are absorbed,
bicarbonate accumulates in the intestinal lumen (

1 1 1

).

Undigested protein entering the large intestine is digested by microbial flora to
ammonia (NH3) (104). The NH pools arise from microbial deamination of amino acids
3

and from hydrolysis of non-protein nitrogen such as urea (104). The NH together with
3

a carbon skeleton can be used to synthesize microbial protein (104). The rate of
microbial protein synthesis depends on readily available carbohydrate sources and
serves as a major route of NH disposal (104). The majority o f protein degraded is lost
3

in feces or the NH is absorbed into the blood and utilized by the horse (converted to
3

urea in the liver) (104,106).
The ascending colon undergoes periods o f net fluid and electrolyte secretion
alternating with periods of net absorption. Absorptive processes are confined to the
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surface epithelium o f the colon while the crypts are secretory. Large volumes o f water
and sodium are secreted. Net secretion occurs at a time when VFAs are rapidly
produced and provide additional fluid and bicarbonate buffer to facilitate fermentation
(104).
Gastrointestinal transport of fluid and electrolytes involve both passive and
active mechanisms. Passive forces include the intrinsic permeability o f the intestinal
epithelial cells, the osmotic pressure gradient exerted by intestinal luminal contents, the
electrical potential difference across the intestinal epithelial cells, the concentration
gradient of solutes across the intestinal epithelial cells, and the pH of the luminal
contents (116). Luminal pH affects the absorption of weak acids and bases because only
nonionized acids or bases can passively diffuse across cell membranes (117).
The electrical potential gradient across the cell promotes the movement of an ion
toward the side of the cell with the opposite electrical charge. In the equine colon, the
potential gradient is 35 to 40 mV, with the serosal side being positively charged. In
horses, the potential gradient favors passive chloride absorption but restricts passive
sodium absorption (115).
Both primary and secondary mechanisms exist for active transport of ions (116).
Primary active transport involves transport of an ion against its electrochemical gradient
using energy derived from another cell membrane transport process or from glucose
metabolism (114). The interior o f the mucosal cell is approximately 30 mV negative
with respect to the mucosal surface (114). This charge difference promotes sodium
entry into the cell from the intestinal lumen (114). In the equine colon, sodium is
proposed to be actively transported into the epithelial cell secondary to Na+, BC+-ATPase
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pump activity (114). The pump actively transports sodium out of the cell across the
basolateral membrane and brings potassium into the cell (118). Additionally, sodium
transport into the cell is enhanced in the presence of glucose (113). The energy for this
transport is derived from the intracellular metabolism of glucose (

1 1 1

).

Secondary active transport systems utilize the free energy derived from passive
diffusion o f one ion down its electrochemical gradient to transport another ion against
its electrochemical gradient (116). In horses, Na+-H+ and Cr-HC03‘ exchange systems
have been identified (114).
Acute gastrointestinal tract disease (colic) is the leading natural cause of death in
adult horses (119,120). Gastrointestinal tract ischemia commonly develops secondary
to low-flow/no-flow conditions, with small intestinal volvulus or incarceration
(121,122) and large colon volvulus (123-125) being common causes. In one study,
strangulating obstructive lesions were associated with the highest mortality (75%) of all
types o f colic (126). Large colon abnormalities account for up to 50% of the horses that
die or are euthanatized subsequent to colic (

1 2 0

-

1 2 2

).

In horses, strangulating volvulus o f the ascending colon has been reported to
have a mortality approaching 80% (125). The disease is characterized by colonic
luminal obstruction and vascular occlusion secondary to the volvulus, thereby resulting
in colonic ischemia, mucosal necrosis and vascular thrombosis (127). Colonic blood
flow has been shown to remain significantly below baseline values for at least 4 hours
after correction o f complete arteriovenous occlusion in horses (128). The high mortality
associated with colonic volvulus may be related to a sustained reduction o f blood flow
and hypoperfusion (due to increased vascular resistance) after surgical correction and
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continued ischemic injury. Endothelial damage occurs in the colonic vasculature
subsequent to ischemia-reperfusion and can be exacerbated by endotoxin (129). The
sustained decrease in colonic blood flow may be associated with endothelial damage in
the colonic circulation, leading to a loss of endothelium-derived vasorelaxants and
subsequent vasoconstriction. Many o f these horses develop systemic hypotension
owing to hypovolemia and endotoxemia, which contribute to decreased splanchnic
blood flow. Additionally, equine colonic mucosal ATP content has been shown to
decrease 92% during ischemia and recovers to only 44% of control value after
reperfusion, thereby limiting substrate availability for cellular metabolic functions
(130). The decreased blood flow and tissue ATP content that occurs during colonic
ischemia can lead to disruption of the mucosal barrier and transmural passage of
endotoxin into the systemic circulation. If sufficient endotoxin enters the systemic
circulation, death can ensue.
1.4 Biochemistry of ATP
Mammalian cells require a continuous supply o f energy to perform three basic
functions: mechanical work, active transport of molecules and ions, and synthesis of
biomolecules. Oxidation of foodstuffs provides free energy, which is subsequently
transformed into a highly accessible and efficient energy form that is utilized by cells to
perform the above-mentioned tasks. The free-energy donor in most energy-requiring
processes is ATP. In 1941, Fritz Lipmann and Herman Kalckar first perceived the
central role that ATP plays in energy exchange in biological systems (131).
ATP is an adenine nucleotide containing an adenine, a ribose, and a triphosphate
unit (Figure 1.1). The active form of ATP is usually a complex of ATP with a co-factor,
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Figure 1.1 - Chemical structure of ATP, ADP, AMP and adenosine.
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either Mg2* or Mn2+. ATP contains two phosphoanhydride bonds in its triphosphate
unit, which makes it a rich source of energy. When ATP is hydrolyzed to adenosine
diphosphate (ADP) (Figure 1.1) and orthophosphate (Pf) or adenosine monophosphate
(AMP) (Figure 1.1) and pyrophosphate (PPj), large quantities o f free energy are released
(131).
The adenine nucleotides are interconvertible. When ATP is hydrolyzed, the free
energy liberated is used to drive reactions that require an input o f free energy. When
fuel molecules are oxidized, ATP is regenerated from ADP and P*. This ATP-ADP
cycle is the fundamental mode of energy exchange in biological systems (131).
In biological systems, ATP serves as the principal immediate donor of free
energy rather than as a long-term storage form of energy. The turnover of ATP is
immense. Motion, active transport, signal amplification and biosynthesis can occur only
if ATP is continuously regenerated from ADP. Generation of a proton-motive force,
which occurs when protons are pumped across a membrane, provides the power
necessary to synthesize ATP. This is an extremely efficient, energy-conserving event
that can generate large quantities of ATP (131).
Degradation of glucose to carbon dioxide and water is the principal source of
ATP. Glycolysis is the initial step in which energy is released from the glucose
molecule. The end products of glycolysis are then oxidized to provide energy. During
glycolysis, one molecule of glucose is used to form two molecules of pyruvate (Figure
1.2). This process requires the input of two ATP molecules and a total of four
molecules of ATP are formed. Therefore, the net ATP production per molecule of
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Figure 1.2 - Glycolysis

24

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Glycolysis
a-D-Glucose

ATP " n|

Mg++

ADP + H+

Hexokinasc

a-D-Glucose-6-phosphate
Phosphoglucose isomerase
(J-D-Fructose-6-phosphate
ATP - - J
ADP + H+

Mg++
Phosphofructokinase

•</ ±

P-D-Fructose-1,6-bisphosphate
Aldolase
Glyceraldehyde-3-phosphate

+

*

Dihydroxyacetone phosphate

' /
Glyceraldehyde-3-phosphate
NAD++I

Glyceraldehyde-3-phosphate
dehydrogenase

l’+ P i' S f

NADH- —

tH~ 1 l

1,3-Bisphosphoglycerate
ADP

11 M g ^
Phosphoglycerate kinase

3-PhosphogIycerate
Phosphoglycerate mutase
2-Phosphoglycerate
I I Mg++

H E
,

* Enolase
Phosphoenolpyruvate
ADP + H+

I

£\TP>

M8++
Pyruvate kinase

Pyruvate

25
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

glucose utilized is two, with an overall efficiency of 43%. The remaining 57% of energy
is lost in the form of heat (132).
Pyruvate formed from glycolysis is converted to acetyl-CoA, which enters the
Citric Acid Cycle (Figure 1.3). This sequence of reactions in which the acetyl portion of
acetyl-CoA is degraded to carbon dioxide and hydrogen atoms occurs in the
mitochondrial matrix. Only one molecule of ATP is formed during each revolution of
the cycle so a net of two ATP/glucose molecule is formed in this fashion (132).
As stated previously, generation of a proton motive force provides the energy to
drive the formation of ATP. Almost 90% of the total ATP formed by glucose
metabolism is formed during subsequent oxidation of the hydrogen atoms that were
released during the earlier stages of glucose degradation. During the breakdown of one
glucose molecule, a total of 24 hydrogen atoms are formed. The hydrogen atoms are
released in packets of two, and in each instance, the release is catalyzed by a
dehydrogenase enzyme. Twenty of the 24 hydrogen atoms are immediately ionized.
Both the free hydrogen ion and the hydrogen bound with nicotinamide adenine
dinucleotide (NAD+) subsequently enter into the electron transport chain. The
remaining four hydrogen atoms combine with a specific dehydrogenase and pass

directly from the dehydrogenase into the oxidative process (132).
Oxidation of hydrogen is accomplished by a series o f enzymatically catalyzed
reactions that split each hydrogen atom into a hydrogen ion and an electron. The
electrons eventually combine oxygen with water to form hydroxyl ions. The hydrogen
and hydroxyl ions then combine with each other to form water. During the sequence of
oxidative reactions, tremendous quantities o f energy are released to form ATP.
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Formation of ATP in this manner is called oxidative phosphorylation, which occurs in
the mitochondria by the chemiosmotic mechanism (Figure 1.4) (132).
The electrons immediately enter an electron transport chain of electron
acceptors, which include membrane flavoprotein, several iron sulfide proteins,
ubiquinone, and cytochromes B, C, C„ A, and A3. All are an integral part of the inner
mitochondrial membrane. When the electrons reach cytochrome A (cytochrome
3

oxidase), elemental oxygen is reduced to form ionic oxygen, which then combines with
hydrogen ions to form water. During transport of these electrons through the electron
transport chain, large amounts of energy are released to drive the synthesis of ATP. The
energy generated during the chemiosmotic mechanism is used to pump hydrogen ions
from the inner mitochondrial membrane into the outer chamber between the inner and
outer mitochondrial membranes. This creates a high concentration of positively charged
hydrogen ions in the outer chamber and a strong negative electrical potential in the inner
mitochondrial matrix (132).
The next step is the conversion of ADP to ATP. This process involves ATP
synthetase, a large protein molecule that protrudes through the inner mitochondrial
membrane and into the inner matrix. The high concentration of positively charged
hydrogen ions in the outer chamber and the large electrical potential difference across
the inner membrane cause the hydrogen ions to flow into the mitochondrial matrix
through the ATPase molecule. This proton-motive force provides the energy necessary
to convert ADP into ATP (132).
The final step in the process is the transfer of the ATP from the mitochondrion
to the cytoplasm. This occurs by facilitated diffusion through the inner mitochondrial
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Figure 1.4 - Electron transport chain. IMM = inner mitochondrial matrix; FMN
flavoprotein; FeS = iron sulfide proteins; CoQ = ubiquinone; Cyt = cytochrome.
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membrane and simple diffusion through the outer mitochondrial membrane. In turn,
ADP is transferred in the opposite direction to allow for continual conversion into ATP.
For each pair of electrons that pass through the electron transport chain, three ATP
molecules are synthesized (132).
In all, 38 molecules of ATP are formed for each molecule o f glucose that is
degraded to carbon dioxide and water. Thus, 456,000 calories of energy can be stored
in the form o f ATP, whereas 686,000 calories are released during the complete
oxidation of one molecule o f glucose. The overall efficiency of energy transfer is

6 6

%,

with the remaining 34% of energy being lost in the form of heat (132).
1.5 Purines and Purinergic Receptors
Extracellular purines (ATP, ADP, AMP and adenosine) (Figure 1.1) are
important signaling molecules that are involved in numerous biological processes,
including smooth muscle contraction and relaxation, neurotransmission, exocrine and
endocrine secretion, the immune response, inflammation, platelet aggregration, pain,
and modulation of cardiac function (133). In 1929, Drury and Szent-Gydrgyi suggested
that purines may serve as extracellular signaling molecules based on their studies which
demonstrated that adenosine and AMP extracted from heart muscle could induce heart
block, arterial dilatation, hypotension, and inhibition of intestinal smooth muscle
contraction (134). Gillespie, in 1934, demonstrated that the potency and response to
extracellular purines was influenced by the presence or absence o f the phosphate units
o f adenine nucleotides (135). Phosphate removal increased the ability o f adenine
compounds to cause vasodilatation and hypotension, whereas ATP, which contains 3
phosphate units, increased blood pressure in the cat and rabbit that was rarely or never
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observed with AMP or adenosine. Furthermore, ATP was shown to be more potent than
AMP and adenosine in causing contraction o f the guinea pig ileum and uterus smooth
muscle (135). These results supported the concept that different purine receptors exist
and that different adenine nucleotides have different mechanisms o f action.
“Purinergic” receptors were first formally recognized by Bumstock in 1978 and
were divided into two main categories: “P,-purinoceptors’\ which adenosine is the
principal natural ligand, and “P -purinoceptors”, which recognize ATP and ADP (136).
2

The division was based on several criteria including relative potencies of the adenine
nucleotides; selective antagonism of the effects of adenosine by methylxanthines;
activation of adenylate cyclase by adenosine; and stimulation o f prostaglandin synthesis
by ATP and ADP.
Adenosine/Pl and P2Y receptors couple to G proteins. G-protein receptors,
which constitute the largest category of receptors, have a conserved structure consisting
o f seven transmembrane (TM) domains o f hydrophobic amino acids. The N-terminal is
on the extracellular side and the C-terminal is on the cytoplasmic side of the cell
membrane. The TM domains form a pocket where the ligand binding site is located.
Purinergic agonists are believed to bind within the upper half o f this pocket. Three
extracellular and three cytoplasmic hydrophilic loops connect the TM domains.
Following ligand binding to the receptor, the intracellular segment o f the receptor
interacts with the appropriate G protein to activate specific intracellular signal
transduction pathways (Figure 1.5) (133).
The TM regions are generally highly conserved and are crucial for ligand
binding and specificity (133). Specifically, the carboxyl region of the second EC loop is
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Figure 1.5 - G-Protein receptors and their signal transduction mechanism. y^CC = G
protein heterotrimer, GDP = guanosine diphosphate; GTP - guanosine triphosphate; E
effector; S = substrate; P = product; Pi = orthophosphate.
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EFFECTOR ACTIVATION

I

primarily involved in ligand recognition (137,138) and the histidine residues in TM6
and TM7 in ligand binding (138).
To date, four subtypes o f adenosine/Pl receptors have been identified: A„ A ^,
Ajb, and A (139). The predominant adenosine/Pl receptor type on blood vessels are
3

the Aja and A2B receptors, which are located on the smooth muscle and endothelium.
Ligand binding with subsequent receptor activation in the vasculature produces
vasodilatation (133). The AM receptors have a wide-ranging but restricted distribution
that includes immune tissue, platelets, the central nervous system (CNS) and vascular
smooth muscle and endothelium (133). The most commonly recognized signal
transduction mechanism for the A,* receptors is activation of adenylate cyclase via
coupling with the G protein, Gs. The receptor/protein coupling is tight; therefore,
agonist dissociation is slow (140). Some A ^ receptors may activate KATPchannels,
which may involve a cAMP-dependent protein kinase (PK) (141). Short-term
desensitization of the A ^ receptor involves receptor phosphorylation with subsequent
dissociation o f the receptor from the G protein. Long-term desensitization involves
inhibition o f adenylate cyclase activity, down-regulation of receptor number, or upregulation of inhibitory G proteins (Gj) (142-144).
The other major adenosine/Pl receptor subtype associated with blood vessels is
the Ajg. This receptor couples to different signaling pathways including activation of
adenylate cyclase, Gq/Gn-mediated coupling to PLC and inositol 1,4,5-triphosphate
(IP3)-dependent increase in Ca2+, and coupling to PLC (145,146). Owing to the lack of
selective antagonists for this receptor subtype, little is known about receptor
desensitization; however, it may involve inhibition of adenylate cyclase and receptor
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phosphorylation and uncoupling from G proteins (142,147). This receptor subtype is
important for mediating vasodilatation in some vessels, whereas the

predominates in

other vessels (148,149).
Categorization of the P2 receptors has been difficult. Recent discoveries have
included: (1) multiple P2X receptors are often co-expressed in different proportions in
different tissues; (2) P2X receptors can exist as heteromers or homomers; (3) cations
can affect P2X channel activity; (4) 2-methylthio ATP, which was previously regarded
as a selective P2Y agonist, additionally has profound effects on P2X receptors also; (5)
ecto-nucleotidases can affect agonist potencies; ( ) antagonists that were previously
6

thought as P2 receptor blockers are non-selective. The lack of selective agonists and
antagonists, the coexistence of different P2 receptors, and the degradation and
interconversion of purines has prompted re-evaluation o f previous conclusions about P2
receptors and has markedly hindered advances in P2 receptor characterization (133).
P2X receptors are ATP-gated ion channels which mediate rapid and selective
permeability to cations (N a\ K+ and Ca2+) (150-152). To date, seven mammalian P2X
receptors (P2X,_7) have been cloned and characterized (133). The most significant P2X
subtype on vascular smooth muscle is the P2X, homomer (153).
Ligand binding to the P2X receptor results in the rapid, non-selective passage of
cations (Na+, K+ and Ca+) across the cell membrane resulting in an increase in
intracellular Ca2+and depolarization (150,151). Membrane depolarization subsequently
activates voltage-dependent Ca2+channels, which further contributes to the increase in
intracellular Ca2*. Since this pathway does not involve a second-messenger system, the
response time is rapid. The concentrations of extracellular cations can markedly
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influence the receptor’s response since it is a ligand-gated ion channel (133).
Desensitization of P2X, receptor is rapid and will terminate the purinergic response
(133). The mechanism o f desensitization is not well understood but may involve the
hydrophobic domains of the P2X, receptor (154).
P2X receptors are involved in the generation of excitatory junction potentials
(EJP), depolarization, and constriction (155,156). Sympathetic stimulation o f blood
vessels leads to the development of a rapid EJP that can be blocked by P2 receptor
antagonists and desensitization o f the P2X,-like receptor. Prolonged periods of
stimulation cause summation o f the EJPs and the membrane depolarization, which
allows opening of voltage-dependent Ca2+ channels, Ca2+entry, and contraction
(155,157).
P2Y purine receptors couple to G proteins. Currently, they include five
mammalian cloned receptors (P2Y„ P2Y2, P2Y4, P2Y6, and P2Y,,) and the uncloned
P2YADP. P2Y receptors are 308-377 amino acid proteins with a mass of 41 to 53 kDa
after glycosylation. The seven TM domains are common to that of other G proteincoupled receptors (133).
Coupling o f most P2Y receptors to the G^,, protein activates PLC, which
stimulates membrane phosphoinositide metabolism and increased production o f IP and
3

diacylglycerol (DAG) and mobilization o f intracellular Ca2+. Coupling to adenylate
cyclase, which involves Gsproteins, by some P2Y receptors has also been described.
Since activation of this receptor leads to generation o f second messengers, the response
time is longer (133).
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The P2Y, and P2Y receptors are the most prevalent P2Y receptors located on
2

blood vessels. Other P2Y receptors that have been identified on blood vessels but play
only minor roles in the control o f vascular tone include the P2Y and P2Y (133). The
4

6

P2Y, receptor is activated by ADP, ATP and certain diadenosine polyphosphates. The
receptor exhibits h e te ro g e n e ity which is most likely attributable to small differences in
the structure of the receptor. There is only a sequence homology of 84% between the
turkey and human P2Y, receptor (158). The heterogeneity in ligand binding includes
both agonists and antagonists (133). The receptor appears to be more sensitive to
adenine nucleotide diphosphates than to triphosphates, and the sensivity to ATP is
variable (159-161). Additionally, the electrical charge of the molecule can influence the
potency o f agonists (162,163).
The principal signal transduction pathway involves activation of PLC.
Formation of IP and mobilization of Ca2+ stimulates a variety of signaling pathways,
3

including PKC, PLA2, Ca2+-dependent K+channels, nitric oxide synthase (NOS) with
subsequent formation of NO, and generation of endothelium-derived hyperpolarizing
factor (EDHF). The main physiological target o f DAG is stimulation of PKC, which in
turn may stimulate phosphatidyl choline-specific PLC, PLD, the mitogen-activated
protein kinase (MAPK) pathway, and Ca2+ influx via voltage-gated Ca2+channels.
Generation o f PKC and subsequent phosphorylation of MAPK appears to be the
pathway by which these receptors on endothelial cells mediate prostacyclin production
(164,165). A second signaling pathway may be inhibition of adenylate cyclase (166).
These two pathways are expressed independently (166).
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In general, P2Y, receptors do not readily desensitize. However, when
desensitization does occur, it may involve phosphorylation of the receptor by protein
kinases and uncoupling o f the G protein (133).
P2Y, receptors are widely distributed and have been described in heart, vascular,
connective, immune and neural tissues (133). Their distribution on vascular endothelial
and smooth muscle cells implies a role in the regulation of vascular tone. In most blood
vessels, P2Y,-like receptors are located primarily on the endothelium and mediate
vasodilatation by Ca2+-dependent activation of endothelial NOS with subsequent
generation of NO and by generation of EDRF. Endothelial prostacyclin synthesis and
release is also stimulated, but appears to play a minor role in the relaxation response
(167).
P2Y( receptors are also present on the smooth muscle of a number of blood
vessels and mediate vasodilatation (168-170). The pathway involved in the relaxation
response is not known but may involve activation of K+ channels (171). The
significance of these receptors on vascular smooth muscle may be in mediation of nonadrenergic non-cholinergic (NANC) relaxation. ATP released as a neurotransmitter
from sensory-motor nerves may activate P2Y, receptors on the vascular smooth muscle
leading to relaxation (170,172,173).
The P2Y receptor is activated by ATP and is insensitive or only weakly
2

sensitive to ADP (133). Similar to P2Y„ the P2Y leads to phosphoinositide
2

metabolism and Ca2+ mobilization but via PLCP (151). IP formation and Ca2+
3

mobilization stimulate the same signaling pathways as the P2Y, receptors (133).
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Another reported signal transduction pathway involves PLD and stimulation of
phosphatidylcholine breakdown (174,175). The mechanism of activation o f PLD is
unclear but may involve the combined actions o f PKC, Ca2+, and G proteins (175). The
major route for prostacyclin production in endothelial cells involves protein tyrosine
phosphorylation and MAPK activation, which occurs subsequent to activation o f PKC
but does not involve IPjOr cytosolic Ca2+(164,165).
P2Y receptors are widely distributed and ATP is the natural ligand (133). In the
2

vasculature, they are generally present on the endothelium. Synthesis and release of
prostacyclin (PGIj) and NO results in vascular relaxation (160,176-178). Similar to
P2Y, receptors, P2Y receptors do not readily desensitize. Tachyphylaxis has been
2

shown to occur and may involve phosphorylation of the intracellular regions of the
receptor (179).
In general, many cells express more than one P2 receptor type. Receptor co
expression permits potential regulation of multiple effectors, fine tuning o f agonistevoked responses, and/or synergy. For example, P2X, and P2Y, receptors co-exist on
the smooth muscle in some vessels where they may reciprocally control vascular tone by
acting as mediators of vasoconstriction and vasodilatation, respectively. Patterns of co
expression may be altered under different physiological and pathophysiological
conditions (133).
The local control o f vascular tone is regulated by the integrated effects o f
Adenosine/Pl and P2 receptors (155). For example, P2Y„ P2Y2, AM and A2Breceptors
are located on endothelial cells while Al and P2X| receptors are on smooth muscle cells.
Normal patterns o f purinergic signaling may alter dramatically under pathophysiological
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conditions. The net effect of purine receptors may be vasodilatation if endothelial cells
are intact, but vasoconstriction may predominate if the endothelium is damaged, hi
addition, the metabolic relationship between purines, where ATP is catabolized to ADP
and adenosine, has important implications for co-localized adenosine/Pl and P2
receptors as there may be an interplay between these receptors (133).
1.6 ATP and ATP-MgCl*
Depletion o f ATP in shocked animals was first noted in 1945 by McShan and
co-workers (180). During shock, low-flow conditions and organ ischemia, anaerobic
glycolysis is activated, which is an inefficient system for the synthesis of ATP (179).
During anaerobic glycolysis, ATP utilization exceeds production, resulting in decreased
intracellular ATP concentrations (181). If oxygen is not available, pyruvate is unable to
follow its normal pathway via acetyl coenzyme A into the Citric Acid Cycle, which
results in accumulation of lactic acid within the cell (182). This block in the glycolytic
pathway leads to a tendency for glucose to exit the cell, which further reduces substrate
availability for ATP production (183).
Under basal metabolic conditions, low levels of ATP are released from cells into
the extracellular space. However, when hypoxic conditions exist, the quantity o f ATP
released is appreciably increased. Upon reoxygenation, ATP release returns to basal
levels (184). When myocardium is rendered hypoxic, the large quantities of ATP
released can cause profound vasodilatory effects, with subsequent alterations in
hemodynamic status (185). Additionally, skeletal and cardiac muscle and brain tissue
have been shown to release substantial quantities o f ATP into the extracellular space,
and these concentrations can profoundly affect vasomotor tone and local blood flow
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(183-187). During shock, progressive failure o f vital organs occurs, with cardiac failure
frequently being the terminal event Cell membranes begin to depolarize, which leads
to intracellular accumulation o f sodium and water and decreased intracellular potassium
(187-191). These electrolyte/water alterations are suggestive of disruption o f the cell
membrane and inactivation o f the N a\ K+-ATPase pump. Depletion o f intracellular
energy stores, namely ATP, with subsequent inhibition of ATP-dependent cellular
responses may occur as a result o f alterations in cell membrane transport that occurs
during shock (192,193).
Both oxygen and substrate deprivation prevent cells from regenerating ATP,
which is required to maintain ionic gradients and structural integrity. Since shock and
ischemia can deplete intracellular stores of ATP, the use of exogenously administered
ATP to maintain energy stores for cellular metabolism and survival has been
investigated. Extracellular ATP can influence many biological processes. When ATP
is applied externally to a cell, profound changes in permeability are observed in
monolayer cell cultures (194). Upon depletion of intracellular stores of ATP, a marked
increase in the sensitivity of cells to external ATP occurs (195). When low
concentrations of ATP are added to culture medium, a profound change in cellular
permeability of monolayer cell cultures is observed (194). In cell culture, exogenous
ATP decreases leakage of intracellular enzymes from human white blood cells and rat
lymphocytes (196). This protective effect of ATP appears to be concentrationdependent. At physiological concentrations, the action of ATP is slight and relatively
short-lived. However, when higher concentrations are used, the membrane-stabilizing
effects are more pronounced and the response persists for a longer period (196).
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During shock, administration of ATP has been shown to be protective (197201). The protective effects o f ATP may be due to: myocardial support; replacement of
deficient high-energy phosphate stores; and metabolic support by bypassing
mitochondrial deficits in electron transport-phosphorylation system (197-200).
During hemorrhage, cellular ATP content is markedly reduced. Administration
of ATP during hemorrhagic shock has been shown to improve survival and increase
ATP content of heart and liver compared with untreated rats subjected to hemorrhage.
When ATP was administered prior to hemorrhage, survival rate was 80% compared
with 30% in control animals. If ATP was administered after hemorrhage, survival
decreased to 60%. The beneficial effects of ATP on survival following hemorrhage was
not due solely to its vasodilatatory action, since other hypotensive drugs failed to be
protective. Since administration of pyrophosphate and AMP was not protective, the
beneficial effects of ATP may be due to the terminal high energy phosphate bond (197).
Glucose homeostasis and insulin dynamics play a critical role in the
pathogenesis of endotoxin shock (202). During experimentally-induced endotoxic
shock, both dogs and rats develop hypoglycemia and hyperinsulinemia (203,204).
Phosphorylation of cell membranes occurs with administration of ATP, which markedly
depresses insulin-stimulated glucose transport and metabolism (205). Administration of
ATP during experimentally-induced endotoxic shock in rats depressed the
hypercatabolism o f glucose that occurs (

2

0

1

).

Both vascular endothelial and cardiac smooth muscle cells contain high levels of
ecto-ATPases on their membrane surface. The loss o f intracellular ATP during
ischemia may be partially mediated through these enzymes. One proposed mechanism
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to explain the beneficial effects of exogenous ATP may be that ATP binds receptors
involved in activation of ectoenzymes and blocks them, thereby sparing intracellular
adenine nucleotides from degradation (206).
Another proposed mechanism may involve direct entrance o f ATP, or other
adenine nucleotides, into the cell to restore depleted energy stores. In isolated canine
hearts, the inability o f myocardial cells to regenerate ATP may be due to loss of
nucleotide precursors through metabolism of these substances to inosine, with
subsequent loss o f inosine to the extracellular space (207). Addition of exogenous ATP,
but not ADP or AMP, was found to increase the ATP and total adenine nucleotide
content of hypoxic myocardium (208).
Substantial evidence that exogenous ATP can influence many biological
functions has existed for a long time, but whether ATP exerts its effects by gaining
access to the intracellular compartment is not known. In studies utilizing isolated
skeletal muscle preparations, exogenous ATP induced muscle contraction (209).
However, whether the response was due to a surface effect or an intracellular effect was
not known. In 1970, l C-ATP was shown to enter intact skeletal muscle cells in vitro
4

and the labeled intracellular ATP was due to transport of ATP itself and not due to
formation o f ATP from its breakdown products (210). Further studies have
demonstrated that both ATP and ADP can enter the cell but that AMP remains in the
extracellular compartment (211). Evidence to support this claim was obtained by use of
ADP, which decreased the ATPrADP ratio. This was further substantiated with an ATP
regenerating system, which increased the ATPrADP ratio (210). However, whether
ATP is intracellular or is binding to specific membrane sites and concentrating on the
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surface remains unknown. Surface binding is unlikely due to extensive degradation of
ATP in the tissues; the volume of distribution of ADP is less than ATP; and external
AMP remains extracellular (210,212). Substantial evidence supports the claim that
ATP can enter the cell membrane o f tissues (213,214) and that the process is enhanced
during adverse circulatory conditions (215,216). Studies also provide evidence for
intracellular uptake of ATP (217).
The mechanism of how ATP enters the cell is not understood but may involve a
carrier-mediated transport system (212,218). Small quantities of exogenous ATP (I
mM), but not ADP or AMP, increases ATP and total adenine nucleotide content in
hypoxic myocardium (208). Furthermore, addition of ATP, but not ADP or adenosine,
to culture medium increased ATP content of cultured myocardial cells (219). There is
some evidence to support the concept that ATP translocation is associated with a Na+,
K+-ATPase (220).
Inside o f the cell, both ATP and ADP complex with magnesium (221). Most
ATP reactions require ATP as a substrate and magnesium as a cofactor (221).
Therefore, the reported beneficial effects of exogenous ATP may be enhanced with
addition of magnesium. A complex o f ATP-MgCl has been shown to be capable of
2

entering intact cells (210). A study in rabbits showed that injected ATP-MgCl is
2

retained in the circulation and is present in sufficient qunatities to provide beneficial
effects to cells (222). When ATP was combined with magnesium-chloride (MgClj), the
effect of ATP on cellular function and microcirculatory blood flow during shock and
ischemia was enhanced (206). Beneficial effects were not observed if ATP or MgCl

2

alone or adenosine-MgCl were infused (206). ATP is a biological complexing agent
2
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and if given alone, may chelate divalent cations in the vascular system and cause
different hemodynamic effects than those that are observed when ATP is complexed
with MgCl (221).
2

The mechanism of how MgCl enhances the effect of ATP is unknown; however,
2

it has been shown both in vivo and in vitro that magnesium may inhibit deamination and
dephosphorylation o f ATP by tissues (221) and prevent the ATP from coupling with
other ions (223). Thus, if ATP is administered in conjunction with MgCl,, a higher
concentration of ATP could be available for the tissues to utilize (221). In addition,
MgCl may help replenish cellular magnesium levels that are decreased during shock
2

states (206,224) and enhance several important reactions that involve ATP (225).
Tissue and mitochondrial magnesium levels have been shown to significantly decrease
following ischemia and reperfusion and ATP-MgCl2, but not ATP or MgCl alone,
2

substantially improves tissue and mitochondrial magnesium levels (

2 2 1

).

The hemodynamic alterations associated with administration of ATP-MgCl

2

have been studied in both normal and pathophysiological situations. In man, ATPMgCl (0.1-0.4 mg/kg/min) increased CO by 76%, principally by increasing heart rate
2

(43%). However, stroke volume index was also increased (14%). The increase in CO
was correlated with rate of infusion (0.1-0.4 mg/kg/min), not the total dose. Changes in
MAP were not observed in the study. At the highest infusion rate (0.4 mg/kg/min), SRL
decreased (226).
During ischemia, oxygen and substrate deprivation leads to a decrease in cellular
ATP production. Since ATP is necessary to maintain ionic gradients and structural
integrity, cellular damage ensues (227). Utilizing intravital fluorescence microscopy,
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Clemens and colleagues demonstrated that administration o f ATP-MgCl following
2

hepatic ischemia improved microcirculatory blood flow to the surface of the liver.
Specifically, the improvement in blood flow was due to a decrease in the loss of
perfused capillaries during reperfusion (227). Additionally, leakage of intracellular
enzymes (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) were
reduced (228). In a canine hypothermic heart ischemia/reperfusion model,
administration o f 1 mg/kg/min ATP and 0.33 mg/kg/min MgCl during reperfusion
2

resulted in complete functional recovery, whereas control animals showed marked
reduction in hemodynamic performance and myocardial compliance (229). Fedelesova
and colleagues demonstrated in isolated, nonperfused hypothermic canine hearts that a
portion o f exogenous ATP was broken down to ADP and AMP and that some o f the
ADP entered the cell and became phosphorylated to regenerate ATP (230).
In an isolated perfused rat kidney model, ischemia caused a rapid decline in ATP
levels, as assessed with high-resolution P-nuclear magnetic resonance spectroscopy
3 1

(231). Upon reperfusion, a 56% increase in tissue ATP content was observed within 10
min. Thereafter, a slow decline in ATP content occurred, and by 75 min, the ATP
content had decreased to approximately 33% of normal values. When the kidney was
perfused with 0.3 mM ATP-MgCl2, renal ATP levels increased to 69% o f normal values
within 10 min, and by 75 min they were normal. Additionally, the intracellular acidosis
and decreased blood flow induced by ischemia/reperfusion was reversed. Cessation of
blood flow to the kidney leads to a depletion of high-energy phosphate stores and a
steady rise in Pi levels. The improvement in renal ATP content may be due to direct
entry of ATP into tubular epithelial cells to provide metabolic energy (216) or to a
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priming effect on the resynthesis of adenine nucleotides (232) and repletion of the
precursor pool (231).
Mesenteric ischemia with subsequent reperfusion results in mucosal barrier
dysfunction, manifested by transcellular movement of fluid from the microcirculation
and, in the reverse direction, translocation of endotoxin from the bowel lumen to the
lymphatic vessels (233) and portal blood (234). Depletion of cellular energy stores
(ATP) contributes to the cellular dysfunction (235-238). The effects of ATP-MgCl on
2

intestinal permeability, ATP content, and blood flow during ischemia has been
evaluated. In a rat model o f intestinal ischemia, plasma to lumen clearance of Cr51

EDTA was used as a marker of altered permeability. Ischemia induced by mesenteric
arterial occlusion for 90 min increased permeability, and this was associated with a
significant reduction in blood flow as assessed by radiolabeled microspheres. Rats
pretreated with ATP-MgCl demonstrated no increase in ,Cr-EDTA clearance over 90
2

5

min. However, the decrease in blood flow induced by ischemia was not reversed.
Tissue ATP levels were reduced within 5 min of ischemia and remained decreased
throughout 90 min. Administration of ATP-MgCl did not significantly alter tissue ATP
2

levels (239). ATP-MgCl improved survival in neonatal rats exposed to intestinal
2

ischemia (240) and improved intestinal mucosal function as assessed by absorptive
capacity (241).
In vitro studies using intestinal epithelial cells have demonstrated that hypoxia
decreases ATP content in conjunction with increases in paracellular permeability (242).
Depletion of ATP produces disruption o f cortical actin and actin stress fibers in
epithelial cells, which results in a decrease in epithelial monolayer integrity (243). In

48

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

the study by Kreienberg and colleagues, the effects of ATP-MgCl appear to be through
2

a mechanism other than providing cells with an energy source (239). ATP-MgCl may
2

exert a priming effect or it may enter the cell to provide sufficient high-energy
phosphates to prevent dephosphorylation of key structural proteins. Improvement in
mucosal barrier function may be mediated through activation of P2 receptors and
increased cAMP, which subsequently increases junctional integrity of epithelial cells
(244). Alternatively, the ATP may degrade to adenosine, bind PI receptors and increase
cAMP to produce a similar effect (245-247).
In a canine hemorrhage shock model, Horton and colleagues demonstrated that
dogs administered lactated Ringer’s solution and ATP-MgCl (100 |imole/kg each)
2

following hemorrhage had lower mean arterial pressure, cardiac output, stroke volume
and rate of left ventricular pressure rise compared with dogs given lactated Ringer’s
solution alone (248). The reduced cardiac performance after ATP-MgCl administration
2

occurred despite adequate coronary blood flow and adequate myocardial oxygen
delivery. A decreased myocardial oxygen extraction and a negative myocardial lactate
balance after intravenous ATP-MgCl indicate a cellular metabolic defect (248). These
2

results contradict observations of another report that indicated ATP-MgCl2-glucose
improved cardiac filling, stroke volume and Cl despite a fall in heart rate (HR) and SRL
(249). Additionally, administration of ATP, regardless of concomittant blood
replacement, failed to appreciably alter CO in hemorrhaged dogs (197).
Hypoxia and shock have been found to be potent stimulants o f inflammatory
cytokine production (250). In a study of hemorrhage and resuscitation in rats,
administration of ATP-MgCl markedly decreased TNF and IL
2

- 6

levels to those
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comparable with sham controls. ATP-MgCl also restored hepatic blood flow and
2

hepatic function (as assessed using the extraction ratio for indocyanine green), which
was decreased with hemorrhage (251). Thus, downregulation of the synthesis and/or
release o f inflammatory cytokines, TNF and IL- , may be one of the mechanisms
6

responsible for the beneficial effects observed with ATP-MgCl following trauma2

hemorrhage and crystalloid resuscitation (251). The agent may appreciably improve
microcirculation and thus prevent continued hypoxic insult following ischemia and
hemorrhagic shock (252-254). Another potential effect of ATP-MgCl on cytokine
2

production results from suppression of the respective gene transcription and/or
translation (251). Conversely, the downregulation might be caused by an increase in
circulating cytokine receptor or inhibitor levels (255). ATP-MgCL could directly or
indirectly decrease TNF and IL

- 6

synthesis by Kupffer cells and consequently prevent

the deleterious effects of TNF or IL

- 6

on hepatocytes (251).

The efficacy of ATP-MgCl during sepsis has been evaluated. Using a cecal
2

ligation and puncture model o f sepsis in rats, administration of saline, glucose (lg), lowdose ATP-MgCl (12.5 pmole each), or low-dose ATP-MgCl plus glucose did not alter
2

2

survival rates. However, when high-dose ATP-MgCl (100 pmole ATP and 50 pinole
2

MgCl,) plus glucose was used, a significant increase in survival was observed (256).
Upon induction of sepsis, both hepatic and renal ATP levels were decreased
(256). High dose ATP-MgCl alone or in conjunction with glucose restored cellular
2

ATP within 3 hours, as determined by spectrophotometric methods. During sepsis,
animals develop hypoglycemia. If glucose is administered alone, the cells are unable to

utilize it so hyperglycemia develops. If ATP-MgCl2and glucose are administered, cells
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ace capable of utilizing glucose (257). Additionally, reticuloendothelial system
dysfunction occurred during sepsis, which was restored with administration of highdose ATP-MgCl plus glucose (256).
2

During Group B streptococcal sepsis in piglets, increases in MAP and PAP, SRL
and PRl and PRl:SRl ratios were observed. Additionally, CO and stroke volume
decreased. Administration of a continuous infusion of ATP-MgCl (0.6 (Xmole/kg/min)
2

reversed the hemodynamic alterations that were induced by sepsis. Also, the median
survival was longer for the piglets treated with ATP-MgCl2. Finally, lung compliance
was higher and pulmonary airway resistance was lower in treated piglets (258).
1.7 Summary of Literature and Hypotheses for Present Studies
During shock, there are alterations in organ blood flow, which affect cell
membrane transport and function, energy metabolism, and mitochondrial function. ATP
utilization exceeds it production, which results in depletion of intracellular ATP stores.
Therefore, a major rate-limiting factor in shock and ischemia, and thus resuscitation, is
resynthesis o f ATP.
Administration o f exogenous ATP, primarily complexed with MgCl (ATP2

MgClj) has been demonstrated to decrease morbidity and improve survival in various
shock models. The use of ATP-MgCl after hemorrhagic shock or other adverse
2

circulatory conditions improves mitochondrial function and tissue ATP content; restores
organ function, blood flow, and microcirculation; improves survival time and survival
rate; and down-regulates the synthesis and release of inflammatory cytokines.
Adenine nucleotides can alter vasomotor tone through interaction with
purinergic receptors located on the vascular endothelium and smooth muscle cells.
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Activation o f the P2X receptor (predominantly smooth muscle) by ATP opens ATPgated ion channels, resulting in changes in intracellular Ca2+concentrations with
subsequent membrane depolarization and contraction o f the smooth muscle. Activation
o f the P2Y receptor (predominantly on the endothelium) by ATP or the A receptors
2

(smooth muscle) by adenosine results in receptor coupling to G proteins and activation
o f second messenger systems leading to vasodilatation. Since the predominant
vasomotor effect of adenine nucleotides is vasodilatation, administration of exogenous
ATP may enhance organ blood flow and microcirculation during shock and ischemia.
In adult horses, acute gastrointestinal tract disease is the leading natural cause of
death. Strangulating volvulus o f the ascending colon occurs frequently and is associated
with a high mortality rate. The volvulus creates colonic luminal obstruction and
vascular occlusion, with subsequent colonic ischemia, mucosal necrosis and vascular
thrombosis. Despite surgical correction, many horses die; this may be due to a sustained
decrease in blood flow and lack of substrate availability for cellular metabolic functions.
Additionally, disruption o f the mucosal barrier leads to translocation o f bacteria and
endotoxin into the splanchnic and systemic circulation. If sufficient endotoxin enters
the systemic circulation, death can ensue.
Administration of ATP-MgCl2, which has vasodilatory actions, increases CO
and delivers energy substrate (ATP) and co-factor (Mg) directly to tissues, may offer a
potential therapy for horses with intestinal ischemia, endotoxemia and shock. However,
no information is presently available on the effects o f ATP-MgCl in horses. The
2

hypotheses o f the studies presented in this dissertation include:
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Stwfy 1 - IV infusion of ATP-MgCl will cause rate-dependent alterations in
2

hemodynamic variables with minimal changes in metabolic, hematologic and serum
biochemical variables and no detrimental effects in clinically healthy, conscious, adult
horses.
Study 2 - IV infusion of ATP-MgCl will cause a rate-dependent decrease in
2

systemic and colonic vascular resistance, principally via vasodilatation, in clinically
healthy, anesthetized, adult horses.
Study 3 - IV infusion of ATP-MgCU will significantly attenuate the
pathophysiologic alterations in clinical signs; cardiopulmonary, metabolic, hematologic,
and serum biochemical variables; and serum cytokines subsequent to low-dose
endotoxin infusion in conscious, adult horses.
Study 4 - The vasomotor tone of isolated equine colonic arterial and venous
rings in response to administration o f exogenous ATP will be significantly attenuated
with endothelium removal and incubation with a non-specific NOS inhibitor, N“-nitroL-arginine methyl ester (L-NAME).
Study 5 - An established method for adenine nucleotide quantitation, using high
performance liquid chromatography, can be modified and validated for use on equine
colonic mucosal tissue.
Study

6

- Using an electron transport inhibitor (antimycin A) and physiologic

solution devoid o f substrate, equine colonic mucosal adenine nucleotide content can
be depleted in vitro and then repleted upon removal of the antimycin A and addition of
substrate.
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CHAPTER 2. HEMODYNAMIC AND METABOLIC
ALTERATIONS ASSOCIATED WITH INTRAVENOUS INFUSION
OF A COMBINATION OF ADENOSINE TRIPHOSPHATE AND
MAGNESIUM CHLORIDE IN CONSCIOUS HORSES*

* Reprinted by permission o f the American Journal o f Veterinary Research
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2.1 Introduction
Shock can be defined as “inadequate blood flow to vital organs or the inability
o f the body cell mass to metabolize nutrients normally” (1). The predominant changes
during shock develop in the microcirculation, affecting cell membrane transport and
function, energy metabolism, and mitochondrial function (2). During hypoxic
conditions, endogenous production o f ATP is decreased (3). A major rate-limiting
factor in shock and ischemia, and thus resuscitation, is resynthesis of ATP (4).
Therefore, a logical therapeutic approach to increase tissue ATP concentrations is to
infuse the substrate (ATP) directly, rather than administer agents that would lead to
ATP synthesis (5).
Administration of a combination of ATP and MgCl in humans results in
2

peripheral vasodilatation and increase in cardiac output ( ). These findings suggest its
6

potential beneficial use in patients with hypoperfusion (low-flow) or organ ischemia.
Use of an ATP-MgCl combination after hemorrhagic shock and other adverse
2

circulatory conditions in humans and laboratory animals improves mitochondrial
function and tissue ATP content (2,7); restores organ function, blood flow, and
microcirculation (7-12); improves reticuloendothelial function, survival time, and
survival rate (13,14); and down-regulates synthesis and release of inflammatory
cytokines (IS).
Low-flow conditions and organ ischemia develop commonly in horses
subsequent to intestinal strangulation, enterocolitis and proximal enteritis, laminitis,
endotoxemia, sepsis, and severe dehydration and exhaustion (16). Anaerobic glycolysis
is activated during ischemia but is an inefficient system for production of ATP (17).

75

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

During anaerobic glycolysis, ATP utilization exceeds production, resulting in decreased
ATP concentrations (17). If oxygen is not available, pyruvate is unable to follow its
normal pathway via acetyl coenzyme A into the Krebs-citric acid cycle, which results in
accumulation o f lactic acid within the cell (18). This block in the glycolytic pathway
leads to a tendency for glucose to exit the cell, which further reduces substrate
availability for ATP production (19). If ATP-requiring processes increase to maintain
cellular integrity and function in the presence of reduced ATP production, a further
oxygen deficit would be expected (17).
The purposes of the study reported here were to determine the hemodynamic and
metabolic effects of IV infusion o f ATP-MgCl combination in clinically normal,
2

conscious adult horses, and to determine a maximal safe IV infusion rate.
2.2 M aterials and Methods
2.2.1

Horses — The study was approved by the Institutional Animal Care and

Use Committee of Louisiana State University. Six clinically normal female horses (4
Thoroughbreds and 2 Quarter Horses), ranging in age from 3 to 13 (median, 10.5) years
old and weighing from 439 to 549 kg (median, 490 kg), were studied. Horses were
maintained on a routine preventive health care program and were vaccinated and

dewormed 2 weeks prior to the study. All horses were kept on pasture and conditioned
to stand in the study area. On the day o f study, horses were placed in a research stall
(1.82 x 1.82 m), and crossed tied. Hay and water were provided ad libitum.
23.3. Instrum entation — Horses were instrumented, using described
techniques (20). All catheters were placed percutaneously after aseptic preparation of
the skin and SC infiltration o f lidocaine. A 14-gauge, 13.3-cm Teflon catheter* was
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inserted into the left jugular vein for infusion o f the ATP-MgCl combination. A 142

gauge, 5.1-cm Teflon catheter1*was inserted proximal to the first catheter for collection
of jugular venous blood. A balloon-tipped, flow-directed thermodilution catheter

, 6

which was used for measurement of cardiac output (CO) and pulmonary artery pressures
(PAP), was inserted into the right jugular vein and advanced until the distal port was
positioned in the pulmonary artery. Polyethylene tubing* (outside diameter [OD], 1.77
mm) was inserted into the right jugular vein proximal to the thermodilution catheter and
advanced until the tip was positioned in the right ventricle for infusion of ice-cold
polyionic fluids for measurement of CO. A 55-ml volume of fluid was infused over 4
6

seconds into the right ventricle, using a carbon dioxide-driven injector/and the CO was
derived on the basis of thermodilution (21). The CO meter* was connected to a
polygraph,1*and CO curves were generated and recorded on a chart recorder Arterial
. 1

blood pressures were measured by use of a 20-gauge, 5.1-cm Teflon catheter placed in
1

the transverse facial or facial artery. All catheter positions were confirmed by evidence
o f characteristic pressure wave forms. All pressures (systemic and pulmonary artery)
were measured, using a pressure monitor with the transducer positioned at the level of
11

the point of the shoulder. A silicone catheter (OD, 12 mm) with a balloon was placed
1

securely in the urinary bladder for urine collection. A continuous base-apex ECGk also
was obtained.
2.23 The ATP-MgCl formulation — The formulation o f ATP-MgCl, has
2

been described (22). On the basis o f450 kg of body weight, 100 jxmole of ATP/kg"*
(27.225 g) and 100 llmole ofMgClj/kg" (9.1485 g) were weighed and placed in separate
sterile beakers. Sterile water (50 ml) was added to the ATP and stirred until the ATP
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was completely dissolved. The pH o f the ATP solution was adjusted to 6.5, by addition
o f 5ATsodium hydroxide (NaOH), then to 7.0, using IN NaOH, and to final pH of 7.4,
using 0. IN NaOH. It is extremely important not to exceed a pH of 7.4 because the ATP
will be degraded (22). Sterile water (100 ml) was added to the MgCl2, and the mixture
was stirred until the MgCl dissolved. The MgCl solution was then slowly added to the
2

2

ATP solution. The pH was adjusted again to 7.4, using IN initially then 0. IN NaOH.
The ATP-MgCl solution was passed through a 0.22-p.m filtration unit and stored at 4
2

0

C until used. To calculate appropriate infusion rates for each horse, the ATP-MgCl

2

solution (200 ml) was added to saline (0.9% NaCl) solution (800 ml) to produce a final
concentration o f27.225 mg of ATP/ml of solution.
2.2.4 Experimental design — All horses received an IV infusion of the ATPMgCl combination via an infusion pump,pbeginning at a rate o f 0.05 mg of ATP/kg of
2

body weight/min. The infusion rate was increased by 0.05 mg/kg/min increments at 10minute intervals until a maximal rate of 1.0 mg/kg/min (maximum volume of 16.65
ml/horse/min) was achieved. Unless otherwise stated, data were collected prior to the
start of the infusion (time = ), at the end o f each infusion rate, and at 15-minute
0

intervals for the next hour after discontinuation of the infusion. Because hemodynamic
effects have been documented to be dependent on the rate of infusion rather than the
dose of ATP-MgCl preparation (Chaudry, 1982b), baseline data (time = 0) served as a
2

control for each horse.
2.2.5 Clinical signs of disease — Heart rate (beats/min), respiratory rate
(breaths/min), mucous membrane color, capillary refill time (seconds), rectal
temperature (°C), gastrointestinal borborygmi, and behavior were monitored. Rectal

7*
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temperature was obtained, using a mercury-containing thermometer. Gastrointestinal
borborygmi were assessed subjectively (increased, normal, decreased, or absent) by the
same investigator by auscultation (30 s/quadrant) o f the abdominal cavity in 4 quadrants
(right dorsal, right ventral, left dorsal, and left ventral). Specific behavioral alterations
were recorded.
2.2.6 Hemodynamic variables — Hemodynamic variables that were measured
included systolic, diastolic, and mean systemic and pulmonary arterial pressures (SAP,
DAP, MAP and SPAP, DPAP, MPAP, respectively; mm Hg) and CO (L/min). Three
measurements were taken at each time for each pulmonary and facial arterial pressure.
Five measurements were taken for CO at each time, and the 3 middle values were used
for analysis. Cardiac index (Cl; CO -*■kg of body weight; ml/min/kg), stroke volume
(SV; CO -5- heart rate [HR]; L/beat), systemic vascular resistance (SRl; MAP
Hg/L/min), and pulmonary vascular resistance (PRL; MPAP

CO; mm

CO; mm Hg/L/min) were

calculated (23). Specific ECG alterations were recorded.
2.2.7 Metabolic variables — Facial arterial blood samples (2 ml each) were
anaerobically collected into separate heparinized syringes and stored on ice until
analyzed for pH, partial pressure o f carbon dioxide (Pacc^; mm Hg), partial pressure of
4

oxygen (Pao^ mm Hg), percentage oxygen saturation (Sac^; %), bicarbonate
concentration (HC03‘; mEq/L), total C 0 (TC02; mmol/L) and base excess. All samples
2

were analyzed within 1 hour o f collection. Systemic arterial oxygen content (Ca02;
ml/dl) was calculated as the sum of oxygen bound to hemoglobin (Hb) and oxygen
dissolved in plasma ([Hb x %Sao

2

x

1.34] + [Pac^ x 0.003]) (24). Oxygen delivery

(D 02; ml/min) was estimated as the product o f Ca0 and CO (D 0 = Ca0 x CO) (24).
2

2

2
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Since Hb concentrations did not significantly change across time for any horse in the
study, each horse’s baseline Hb value was used in the calculations o f Ca02.
2.2.8

Hematologic variables — Jugular venous blood (3 ml) was collected into

tubes containing EDTA for analysis of PCV (%) and total solids concentration (g/dl).
Complete blood count and fibrinogen concentration were determinedr prior to the start
o f the infusion, at

1 . 0

mg/kg/min infusion rate, and hour after discontinuation of the
1

infusion. Red and WBC indices also were determined at 2 , , and 24 hours after
6

discontinuation of the infusion.
22.9 Seram biochemical variables — Jugular venous blood

( 6

ml) was

collected into tubes containing lithium heparin and was analyzed for sodium (mmol/L),
1

potassium (mmol/L), chloride (mmol/L), phosphorus (mg/dl), calcium (mg/dl), total
protein (g/dl), albumin (g/dl), globulin (g/dl), BUN (mg/dl), creatinine (mg/dl), glucose
(mg/dl), aspartate transaminase (AST; U/L), y-glutamyl transferase (GGT; U/L),
alkaline phosphatase (ALP; U/L), total bilirubin (mg/dl), creatine kinase (CK; U/L),
TC0 (mmol/L), and anion gap (mmol/L). Samples were collected prior to the start of
2

the infusion, at

1 . 0

mg/kg/min infusion rate, and hour after discontinuation of the
1

infusion.
2.2.10 Urine output— The urinary bladder was emptied, urine volume (ml)
was quantified, and specific gravity was determined.
2 J t.ll Statistical analyses — All data were considered continuous and
evaluated for normality, using the Shapiro-Wilk statistic. Data were considered to
follow a normal distribution, with failure to reject the null hypothesis o f normality at P
£ 0.05. Normal data were summarized and graphed as mean ± SEM.
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All quantitative data were analyzed, using the model y = u + horse + time +
horse * time + , where the effect of horse was considered random, and the interaction
6

term was used as the error term for the evaluation o f time. A two-sided hypothesis with
a = 0.05 was used to determine significance of the main effect o f time. A statistical
software package' was used for the analyses. Where there was a significant effect of
time, comparisons with baseline (time= ) were made, using adjusted least squares
0

means with a Dunnett’s test maintaining an experiment-wise error o f a = 0.05. Thus,
where a difference from baseline was noted, the / ’-value was £ 0.05.
2 3 Results
23.1 Clinical signs of disease — Mucous membrane color and capillary refill
time did not change across time. Respiratory rate (baseline, 12 breaths/min) was
significantly increased at the 0.6 mg/kg/min (25.5 breaths/min) and 0.75 to 1.0
mg/kg/min infusion rates, but returned to pre-infusion values on discontinuation o f the
ATP-MgCl infusion. Rectal temperature (baseline = 38.08 °C) decreased significantly
2

during the 0.9 mg/kg/min infusion rate (37.72 °C) and remained decreased throughout
the study.
There was a change in gastrointestinal borborygmi activity across time for all
quadrants. Intestinal motility decreased, starting at the 0.6 mg/kg/min rate, and were
absent from 0.8-1.0 mg/kg/min. Borborygmi were detected but decreased at 15 minutes
after infusion and were back to normal by 30 minutes after infusion. Five horses had
signs o f mild abdominal discomfort at infusion rates > 0.70 mg/kg/min; 2 of these
horses became extremely agitated and uncomfortable during the maximal infusion rate.
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All signs o f abdominal discomfort and agitation ceased immediately on discontinuation
of the ATP-MgClj infusion.
Sweating in the flank region was observed in all horses as the infusion rate
increased. Infusion rate at which flank sweating was observed varied among horses;
however, lowest infusion rate at which it was observed was 0.45 mg/kg/min. One horse
developed muscle fasciculations and profuse, whole-body sweating during the 0.85 to
1.0 mg/kg/min infusion rates. Two horses developed jugular pulses at the higher
infusion rates (> 0.75 mg/kg/min). All horses appeared lethargic, and their appetites
diminished at infusion rates £ 0.40 mg/kg/min. Once infusion was stopped, all horses
began to eat, and their overall demeanor improved.
2.3.2

Hemodynamic variables — Cardiac index and HR were significantly

increased during infusion (Fig 2.1). Cardiac index returned to preinfusion values at 0.85
mg/kg/min, while HR returned to preinfusion values upon discontinuation of the ATPMgCl infusion. Stroke volume decreased across time, but was significantly decreased
2

only at the 1.0 mg/kg/min infusion rate. Cardiac output was significantly increased
between 0.35 and 0.8 mg/kg/min infusion rates. Three horses developed intermittent
premature ventricular contractions (PVC) during the study period that seemed to be
associated with cardiac instrumentation rather than ATP-MgCl infusion, because they
2

were evident prior to the start of the infusion. Systemic vascular resistance and MAP
were significantly decreased during the infusion and returned to preinfusion values on
discontinuation o f ATP-MgCl infusion (Fig . ). Systolic and diastolic systemic
2

2

2

arterial pressures followed a pattern similar to that of MAP. Pulmonary vascular
resistance did not change across time; however, MPAP was significantly increased
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Figure 2.1 - Mean (±SEM) cardiac index, heart rate, and stroke volume before, during,
and after IV infusion o f an ATP-MgCU solution. *Significant (P l 0.05) difference from
preinfusion values. Notice the difference in the x-axis scale dining and after infusion.
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during the infusion (Fig 2.3). Systolic PAP was significantly increased at the 0.45, 0.55,
0.60, and 0.7 mg/kg/min infusion rates, and DPAP was significantly increased during
the 0.35 and 0.45 to 0.80 mg/kg/min infusion rates and at 15 minutes after
discontinuation of the infusion.
2 3 3 Metabolic variables — Arterial blood gas values indicated a significant
decrease in PaC

0

2

and HC0 concentrations during the infusion. Once ATP-MgCl
3

2

infusion was stopped, Paco, returned to preinfusion values. However, HC0

3

concentration remained decreased throughout the study. Arterial pH was significantly
increased during the 0.75 and 0.8 mg/kg/min infusion rates, then significantly decreased
from baseline at all times after discontinuation of infusion (Fig 2.4). The Pa

0

2

and Sa

0

2

were significantly increased during the 0.7 and 0.95 mg/kg/min and 0.75 mg/kg/min
infusion rates, respectively. The C a0 did not significantly change across time;
2

however, D 0 was significantly increased between 0.35 and 0.8 mg/kg/min infusion
2

rates (Fig 2.5).
23.4

Hematologic variables — Packed cell volume was significantly increased

dining the 1.0 mg/kg/min infusion rate. Plasma total solids concentration was
significantly decreased beginning at

0 . 2

mg/kg/min and remained decreased throughout

the study (Fig 2.6). Total WBC count was significantly increased at 2 and hours after
6

discontinuation of infusion, but it returned to preinfusion values by 24 hours. At the 1.0
mg/kg/min infusion rate, eosinophils and lymphocytes were significantly decreased.
Lymphocytes remained decreased at 1 hour after discontinuation o f the infusion. There
were no significant changes across time for segmented or band neutrophils, monocytes,
basophils, RBC indices, platelets, or fibrinogen concentration.

86

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

1.6e
« I
3 ^

1j4-

postinfusion
period

I*

3 z 1.0> E
0.8<
e ®
2 r 0.6'
I f
0. 7 0.4
•
K 0.2
0.0

[

Till

, i Tll

o!o '

h 1 o!i

1 o!e 1 oJ, 1 i!o 1

Infusion rate (mg/kg/min)

r i sh

Time (min)

45-i

o —* 40-

Sf

postinfusion
period

* * * w
*

35-

- r *

*
T

* * *

1

§•
a •»

Q. £
S*
e
2

30-

{ I , }-'T
* !1

25
2 0

15

:i

o'o1 o?2 ' o i ' o i '" a ' i r T
Infusion rate (mg/kg/min)

Time (min)

Figure 23 - Mean (± SEM) pulmonary vascular resistance and pulmonary arterial
pressure before, during and after IV infusion o f an ATP-MgCl solution. See Figure 1
for key.
2

87

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 2.4 - Mean (± SEM) systemic arterial pH, PaC02, and HC0 concentration
before, during, and after IV infusion of an ATP-MgCl solution. See Figure I for key.
3

2
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23.5 Seram biochemical variables — There were no significant differences
across time for glucose and creatinine concentrations or GGT, ALP or CK activities.
Albumin concentration and AST activity were significantly decreased at the 1.0
mg/kg/min infusion rate, and BUN and anion gap were significantly increased at the 1.0
mg/kg/min infusion rate. Bilirubin, globulin, and calcium concentrations were
significantly decreased, and phosphorus, sodium, and chloride concentrations were
significantly increased at the

1 . 0

mg/kg/min infusion rate and 60 minutes after

discontinuation o f infusion. Potassium concentration was significantly decreased at 60
minutes after infusion (Table 2.1).
23.6 Urine output — Urine volume was significantly decreased at all infusion
rates and returned to preinfusion values once ATP-MgCl infusion was discontinued.
2

Urine specific gravity was significantly increased between the 0.3 and 0.85 mg/kg/min
infusion rates, then significantly decreased from baseline at 30,45, and 60 minutes after
discontinuation o f infusion (Fig 2.7).
2.4 Discussion
Intravenous infusion o f a combination of ATP and MgCI in clinically normal,
2

conscious, adult horses increased CO, decreased systemic vascular resistance and
caused mild pulmonary hypertension. Magnitude o f the hemodynamic alterations was
dependent on the rate o f infusion. For the horses o f this study, maximal safe infusion
rate was 0.3 mg/kg/min.
Adenosine triphosphate is principally an endothelium-dependent vasodilator that
is rapidly metabolized and has a short duration of action (25). It binds to
purinoreceptors (Pj) located on vascular smooth muscle (P ^ receptor) and endothelial

92

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 2.1 - Seram biochemical variables (mean ±SEM) before infusion o f an ATPMgCl solution, at a rate of 1.0 mg/kg/min and at 60 minutes after discontinuation of
the infusion.
2

V ariable

Pre-Infusion

1.0 mg/kg/min
Infusion Rate

Post-infusion
(60 min)

Glucose (mg/dL)

113.00±8.50

129.17 ±10.29

138.17±8.13

Aspartate
aminotransferase (U/L)

354.33 ±91.03

♦313.50±81.32

329.00±74.18

Gamma glutamyl
transferase (U/L)

12.67 ±0.92

11.83 ±0.87

13.67±1.12

Alkaline phosphatase
(U/L)

247.67±39.80

271.50±45.01

293.50±59.43

Creatine phosphokinase
(U/L)

234.33 ±34.27

258.67±35.84

280.00±36.82

Bilirubin (mg/dL)

2.28 ±0.44

♦1.93 ±0.39

♦2.02 ±0.45

Albumin (g/dL)

3.45 ±0.12

♦3.08 ±

3.30 ±0.12

Globulin (g/dL)

3.97 ±0.37

♦3.52 ±0.39

♦3.75 ±0.36

Blood urea nitrogen
(mg/dL)

17.17 ±0.98

♦18.67±1.09

18.17 ±0.95

Creatinine (mg/dL)

1.47 ±0.11

1.67±0.07

1.53 ±0.05

Calcium (mg/dL)

12.02 ±0.24

♦10.33 ±0.08

♦11.05±0.21

Phosphorus (mg/dL)

3.12 ±0.34

♦9.53 ±1.02

♦6.73 ±0.66

Sodium (mmol/L)

135.17±0.83

Potassium (mmol/L)

3.62 ±0.12

3.68±0.14

♦3.10±0.13

Chloride (mmol/L)

99.83 ±0.83

♦101.33 ±0.76

♦101.67± 1.15

Anion Gap (mmol/L)

6.60±0.96

0

. 1

0

♦137.00 ±0.52

♦10.33 ±0.88

♦137.17±0.31

7.77 ±1.46

♦Significant (P £ 0.05) difference from preinfusion values.
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IV infusion o f an ATP-MgCl solution. See Figure 1 for key.
2

94

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

(P2Yreceptor) cells (26). Activation o f the excitatory P ^ receptor causes
vasoconstriction, whereas activation of the inhibitory P2Yreceptor causes vasodilatation
(26). The vasodilatory effects are attributable to increased formation of nitric oxide,
which increases smooth muscle cell concentration of cyclic GMP, the intracellular
messenger involved in smooth muscle relaxation (25). When ATP is degraded by
ectonucleotidases into adenosine, a P,-purinoreceptor (A,-A3) is activated, leading to
vascular smooth muscle relaxation (27). Magnesium also is a potent vasodilator via its
important role in regulating arteriolar tone and calcium exchange in vascular smooth
muscle (28).
Results of studies have indicated that administration of ATP or MgCl alone
2

after shock or ischemia fails to improve organ or animal survival, or both (2). Therefore,
it appears that ATP, together with MgCl treatment after shock and ischemia, is required
2

for its effectiveness (5). Because ATP and ADP exist in cells as magnesium complexes,
and because most ATP reactions require not only ATP as a substrate but also
magnesium as a cofactor, administration of magnesium in conjuction with ATP is
required for preservation of cell and organ function after a variety of insults (5). Results
o f other studies have indicated that tissue and mitochondrial magnesium concentrations
decrease appreciably after ischemia and reperfusion and that the ATP-MgCl

2

combination, but not ATP or MgCl alone, substantially increases tissue and
2

mitochondrial magnesium concentrations after ischemia (29).
In clinically normal, conscious, adult males, ATP-MgCl, infusion (0.2 to 0.4
mg/kg/min) increases CO and HR and causes peripheral vasodilatation without
accompanying systemic hypotension ( ). Stroke volume also increases by 14%,
6
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suggesting that the ATP-MgCl combination may have mild inotropic effects ( ).
2

6

Tachycardia that develops in association with ATP-MgCl infusion may be attributed to
2

sympathetic nervous system stimulation ( ). Similar increases in CO and HR were
6

observed in our horses at comparable infusion rates. Appreciable changes in HR were
not observed during ATP-MgCl infusion in rats during shock (11). However, rats were
2

anesthetized, and their baseline HR were higher subsequent to shock. Effects o f ATPMgCl administration to horses during hemorrhagic or endotoxic shock or in
2

anesthetized horses may be different than those observed in the study reported here. The
hemodynamic effects o f IV infusion of ATP-MgCl combination during shock in horses
2

warrants further investigation.
As the maximal infusion rate was approached, CO was no longer different from
preinfusion values. Stroke volume decreased across time; therefore, despite the
sustained increase in HR, CO returned to baseline. The HR may have been too high to
allow sufficient atrial and ventricular filling, leading to a decrease in CO (23).
In a study evaluating cardiac catheterization in humans, incidence of
complications associated with the procedure was approximately 23% (30). Severity of
the complications ranged from mild arrhythmias to acute cardiac perforation (30).
A r r h y t h m ia s

associated with cardiac catheterization procedures in children developed

with a frequency of 6.5% (31). Three o f horses in the study reported here developed
6

transient PVC without any noticeable deleterious effects.
Infusion of the ATP-MgCI combination into the pulmonary artery is a
2

recognized treatment for pulmonary hypertension in children (32). Additionally,
pulmonary hypertension secondary to sepsis can be successfully reversed by
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administration o f the ATP-MgCl combination (33). In contrast, horses of this study
2

developed mild pulmonary hypertension during infusion. Despite pulmonary
hypertension, pulmonary vascular resistance did not change subsequent to the increase
in CO. Results o f in vitro studies have indicated that a variation in response to ATP
administration can develop in different vascular beds and in vessels under different
vascular tensions (26). In certain blood vessels, ATP can stimulate smooth muscle
directly (via P Xreceptors), causing vasoconstriction (34). In other vascular beds, ATP
2

stimulates the endothelial P2Yreceptor, causing vasodilatation (26). If ATP is
metabolized to adenosine, activation o f the P,-purinoreceptors can lead to vascular
relaxation (27). Under resting tension, ATP induces vasoconstriction in certain vascular
beds; however, if tension is increased, vasodilatation occurs (26). Responsiveness of
vessels to ATP also differs, depending on the concentration of ATP administered. Low
concentrations cause vasodilatation, whereas high concentrations cause transient
contraction followed by relaxation (27).
Another explanation for the pulmonary hypertension that developed in our
horses is that ATP and norepinephrine can act as cotransmitters from the sympathetic
nerves in some tissues (27). This cotransmission enhances norepinephrine- and ATPinduced vasoconstriction. However, ATP-induced vasoconstriction may be masked by
its potent relaxant effects mediated by the endothelium (27).
All horses became lethargic, and their appetites diminished as the infusion rate
increased. Five of six horses manifested signs of abdominal discomfort Gastrointestinal
borborygmi decreased during higher infusion rates. In humans, transient nausea was
observed at infusion rates greater than 0.3 mg/kg/min ( ). The exact mechanism for
6
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nausea observed in humans and alterations in behavior and appetite observed in our
horses is not known, but could be associated with decreased gastrointestinal motility.
As the rate of the infusion increased, respiratory rate increased and Paco

2

decreased. The increase in respiratory rate likely was attributable to sympathetic nervous
system stimulation and pulmonary hypertension. The decreased Paco values and
2

resultant increase in pH likely were associated with tachypnea. Bicarbonate
concentration decreased over time. On discontinuation of the infusion, PaC

0

2

returned to

baseline values and HC0 concentration remained decreased, which ultimately resulted
3

in decreased pH. The decrease in HC03’ concentration in our horses may have been
related to fluid administration during CO determination. Changes in D 0 paralleled
2

changes in CO, which was expected, because Ca0 was not significantly altered across
2

time, and because D 0 is the product of Ca0 and CO. Similar results were obtained in
2

2

a canine hemorrhagic shock model in which Ca0 did not change across time; however,
2

myocardial oxygen delivery was increased because of an increase in coronary arterial
blood flow (35).
Although total solids concentration decreased over time, PCV was only
significantly different from the preinfusion value during the maximal infusion rate. The
decrease in total solids concentration was likely associated with hemodilution secondary
to fluid administration associated with CO determination (minimum of 1,650 ml/h). A
possible reason why PCV did not change accordingly is because o f splenic contraction.
This became evident when PCV significantly increased at the 1.0 mg/kg/min infusion
rate. The leukocytosis observed at 2 and hours after discontinuation o f the infusion
6
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may have been associated with a stress or inflammatory response secondary to drug
administration.
Numerous serum biochemical alterations were observed in our horses. High
phosphorus and sodium concentrations likely were associated with administration of the
ATP disodium salt. Chloride concentration likely increased subsequent to
administration o f the MgCl2. In healthy, conscious humans, significant electrolyte
alterations were not observed during ATP-MgCl infusion at the recommended
2

therapeutic dose ( ). However, our horses received approximately 2.5-fold the
6

recommended therapeutic dose of the ATP-MgCl, combination over the course o f the
study. The decrease in potassium concentration could be secondary to the increased
sodium concentration or alkalosis. Albumin and globulin concentrations likely
decreased because of hemodilution. Reasons for alterations in AST, bilirubin, calcium,
and BUN values observed in our horses are not known. In another study in humans ( ),
6

infusion o f ATP-MgCl did not alter chemistry variables.
2

The substantial decrease in urine volume after the start of the infusion was
related to incorrect determination of baseline urine volume. The urinary bladder should
have been emptied several times at

1 0

-minute intervals prior to determining the baseline

urine volume, because urine volume was quantified at

1 0

-minute intervals during

infusion. The increase in urine specific gravity during infusion may be related to
vasoconstriction o f the renal vasculature (36). Once infusion was stopped, rebound
vasodilatation may have developed, resulting in renal diuresis and a subsequent decrease
in urine specific gravity. Results o f numerous studies have documented that adenyl
compounds have variable and inconsistent effects on the net flow of blood through the
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kidney (36). The inconsistency in results suggest that different segments of the renal
vasculature may have different responses to adenyl compounds, and responses also vary
among species (36).
The effects o f volume of ATP-MgCl infused during the study may have biased
2

the results obtained, because incremental increases in infusion rate of ATP-MgCl are
2

paralleled by increasing volumes of infusion. However, the authors do not believe that
the volume of the ATP-MgCU preparation infused (maximum of 16.65 ml/horse/min)
was sufficient to significantly affect the results obtained in this study.
The maximal safe infusion rate for the horses of the study reported here was 0.3
mg/kg/min. Our criteria for determination of this maximum rate were based on the
maximal value prior to which significant alterations in hemodynamic variables were
observed. At a rate of 0.35 mg/kg/min, Cl, MAP, and SRlwere significantly different
from baseline values. Therefore, we selected the 0.3 mg/kg/min rate as our maximal,
safe infusion rate.
In conclusion, IV administration of an ATP-MgCl combination in healthy,
2

conscious, adult horses resulted in various metabolic and hemodynamic alterations that
are without appreciable detrimental effects. Further investigation into the various
responses of regional vascular beds and tissues to ATP-MgCl administration in horses
2

are necessary before this combination can be recommended clinically as a therapeutic
agent during low-flow or septic conditions.
2.5 Product Information
“Angiocath, Becton Dickson Infusion Therapy Systems Inc, Sandy, Utah.
bQuik-Cath, Baxter Healthcare Corporation, Deerfield, 111.
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Tentalumen thermodilution catheter 41216-01, Abbott Critical Care Systems, Abbott
Laboratories, Hospital Products Division, North Chicago, 111.
‘‘Intramedic polyethylene tubing model PE260, Becton Dickson, Sparks, Md.
'Normosol, Abbott Laboratories, North Chicago, Ql.
Injector 500, Columbus Instruments, Columbus, Ohio.
BCardio Max H model 85 thermodilution cardiac output computer, Columbus
Instruments, Columbus, Ohio.
’’Polygraph model 7D, Grass Instruments, Quincy, Mass.
'Chart recorder model 25-60, Grass Instruments, Quincy, Mass.
jInsyte-A arterial catheterization unit model 5820, Becton Dickinson Deseret Medical,
Sandy, Utah.
kPressure/ECG monitor model 90602A, Spacelabs Inc, Redmond, Wash.
'Uterine flushing catheter model V-PUF-150, Cook Veterinary Products, Bloomington,
Ind.
'"Adenosine 5’-triphosphate disodium salt A3377, Sigma-Aldrich, Inc, St Louis, Mo.
"Magnesium chloride hexahydrate M2670, Sigma-Aldrich, Inc, St Louis, Mo.
"Cellular acetate filter system 25932-200, Coming, Coming, NY.
Tlo-gard6000 volumetric infusion pump, Travenol Laboratories Inc, Deerfield, 111.
'’pH/blood gas analyzer model 238, Chiron Diagnostics Corporation, East Walpole,
Mass.
'System 9000 automated cell counter, Biochem Immunosystems Inc, Allentown, Pa.
S0lympus Reply, Olympus Corporation Clinical Instrument Division, Irving, Tex.
*Proc mixed SAS version 6.12, SAS Institute, Cary, NC.
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CHAPTER 3. SYSTEMIC AND LOCAL COLONIC
HEMODYNAMIC ALTERATIONS DURING INTRAVENOUS
INFUSION OF ATP-MgCl2 IN CLINICALLY HEALTHY
ANESTHETIZED HORSES*

♦Reprinted by permission of the American Journal o f Veterinary Research
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3.1 Introduction
Acute gastrointestinal tract disease (colic) is the leading natural cause of death in
adult horses (1,2). Gastrointestinal tract ischemia commonly develops secondary to
low-flow/no-flow conditions, with small intestinal volvulus or incarceration (3,4) and
large colon volvulus (5-7) being common causes. In one study, strangulating
obstructive lesions were associated with the highest mortality (75%) o f all types o f colic
( ). Large colon abnormalities account for up to 50% of the horses that die or are
8

euthanatized subsequent to colic (2-4).
In horses, strangulating volvulus of the ascending colon has been reported to
have a mortality approaching 80% (7). The disease is characterized by colonic luminal
obstruction and vascular occlusion secondary to the volvulus, thereby resulting in
colonic ischemia, mucosal necrosis and vascular thrombosis (9). Colonic blood flow
has been shown to remain significantly below baseline values for at least 4 hours after
correction o f complete arteriovenous occlusion in horses (10). The high mortality
associated with colonic volvulus may be related to a sustained reduction of blood flow
and hypoperfusion (due to increased vascular resistance) after surgical correction and
continued ischemic injury. Endothelial damage occurs in the colonic vasculature
subsequent to ischemia-reperfusion and can be exacerbated by endotoxin (11). The
sustained decrease in colonic blood flow may be associated with endothelial damage in
the colonic circulation, leading to a loss of endothelium-derived vasorelaxants and
subsequent vasoconstriction. Many of these horses develop systemic hypotension
owing to hypovolemia and endotoxemia, which contribute to decreased splanchnic
blood flow. Additionally, colonic mucosal ATP content has been shown to decrease
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92% during ischemia and recovers to only 44% of control value after reperfusion,
thereby limiting substrate availability for cellular metabolic functions (12). The
decreased blood flow and tissue ATP content that occurs during colonic ischemia can
lead to disruption of the mucosal barrier and transmural passage of endotoxin into the
systemic circulation. If sufficient endotoxin enters the systemic circulation, death can
ensue.
Adenosine triphosphate is principally an endothelium-dependent vasodilator that
is rapidly metabolized and has a short duration of action (13). The vasodilatory effects
o f ATP are mediated primarily through activation of purinoreceptors located on
endothelial cells (P2Y) (14). The P2Yreceptors are coupled to G-proteins and involve
second messenger systems (15). Activation of the inhibitory P2Yreceptor results in
increased formation o f nitric oxide (NO), which increases smooth muscle cell
concentrations of cyclic GMP, the intracellular messenger involved in smooth muscle
relaxation (13). Endothelial-derived hyperpolarizing factor, and possibly prostacyclin,
are also generated which contributes to the relaxation response (15). When ATP is
degraded by ectonucleotidases into adenosine, an adenosine purinoreceptor (A^ is
activated, leading to vascular smooth muscle relaxation (16). The A receptors are also
2

coupled to G-proteins (15). Magnesium is also a potent vasodilator via its important
role in regulating arteriolar tone and calcium exchange in vascular smooth muscle (17).
Administration o f adenosine trisphosphate-magnesium chloride combination

(ATP-MgCy in humans results in peripheral vasodilatation and increased cardiac
output (CO) (18). These findings suggest its potential beneficial use in patients with
hypoperfusion (low-flow) or organ ischemia. The use of ATP-MgCI following
2
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hemorrhagic shock and other adverse circulatory conditions in both humans and
laboratory animals has been shown to improve mitochondrial function and tissue ATP
content (19,20); restore organ function, blood flow, and perfusion (20-23); improve
reticuloendothelial function, survival time, and survival rate (24,25); and down regulate
the synthesis and release of inflammatory cytokines (26).
We have recently investigated the hemodynamic and metabolic alterations
associated with intravenous infusion of ATP-MgCl in clinically healthy, conscious,
2

adult horses (27). Intravenous administration o f ATP-MgCl caused a rate-dependent
2

increase in CO and decrease in systemic vascular resistance (SR J without any
appreciable detrimental effects. Based on these results, ATP-MgCl infusion may
2

potentially increase perfusion to the gastrointestinal tract. Administration of ATPMgCl2, which has vasodilatory actions, increases CO and delivers an energy substrate
(ATP) and co-factor (Mg) directly to the tissues, may offer a potential therapy for horses
with intestinal ischemia, endotoxemia and shock. Therefore, the purpose of this study
was to characterize the local colonic and systemic hemodynamic alterations associated
with intravenous infusion of ATP-MgCl in clinically normal, anesthetized horses. We
2

hypothesized that administration of ATP-MgCl would cause a rate-dependent decrease
2

in colonic and systemic vascular resistance, principally via vasodilatation.
3.2 M aterial and Methods
3.2.1

Horses - The study was approved by the Institutional Animal Care and Use

Committee o f Louisiana State University. Twelve clinically healthy grade horses (9
females and 3 castrated males), ranging in age from 3 to 13 (median, 7) years and in
body weight from 315 to 461 (median, 395) kg, were studied. All horses were
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vaccinated for eastern and western encephalitis and tetanus toxoid 3 months prior to the
start o f the study. Horses were maintained on pasture prior to the study. Food, but not
water, was withheld for

1 2

hours prior to the study to decrease the colon contents, which

facilitated its manipulation.
3.2.2

Instrum entation - Horses were sedated with xylazine hydrochloride (O.S
1

mg/kg, IV) and butorphanol tartrateb (0.02 mg/kg, IV). All catheters were placed
percutaneously after aseptic preparation o f the skin and desensitization by subcutaneous
infiltration of lidocaine. A 14-gauge, 13.3-cm Teflon catheter® was inserted into the left
jugular vein for administration o f anesthetic drugs and isotonic polyionic fluids. A
balloon-tipped, flow-directed thermodilution catheter*, which was used for measurement
of CO and pulmonary artery pressures (PAP), was inserted into the right jugular vein
and advanced until the distal port was positioned in the main pulmonary artery.
Polyethylene tubing (1.77 mm OD) was inserted distal to the left jugular catheter and
1

advanced until the tip was positioned in the right ventricle for infusion of ice-cold
polyionic fluidsf for measurement o f CO. A 55-ml volume of fluid was infused over 4
seconds into the right ventricle, using a carbon dioxide-driven injector*, and the CO was
derived on the basis o f thermodilution (28). The dead space o f the injection catheter
was 5 ml. Cardiac output and PAP were recorded, using a CO meter1*. Thermodilution
signal curves were recorded for each cardiac output measurement Polyethylene tubing*
(1.57 mm OD) was inserted into the right jugular vein proximal to the thermodilution
catheter and was advanced until the tip was positioned in the right atrium for
determination o f mean right atrial pressure (MRAP). All catheter positions were
confirmed by the presence o f characteristic pressure wave forms.
"f
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General anesthesia was induced with guaifenesin* (50 mg/kg, IV)and sodium
thiopental (4.4 mg/kg, IV). After anesthesia induction, a loading dose o f sodium
pentobarbital (7.5 mg/kg, IV) was administered and general anesthesia was maintained
1

by a continuous infusion of sodium pentobarbital (5 to 15 mg/kg/h). Horses were
mechanically ventilated1” with

1 0 0

% oxygen at a rate of to
6

1 2

breaths/min to a peak

inspiratory pressure o f approximately 20 cm of H 0. Arterial blood gas analyses, packed
2

cell volume (%) and total plasma protein concentrations (g/dl) were monitored during
the study to assess each horse’s metabolic/anesthetic status and to make adjustments in
anesthetic management if necessary. Isotonic polyionic fluids were administered at a
rate o f 5 to 10 ml/kg/h. Arterial blood pressures were measured, using a 20-gauge, 5.1cm Teflon catheter" placed in the facial artery. A 14-gauge, 5.1-cm Teflon catheter" was
inserted proximally into both the left and right jugular veins for infusion of the ATPM gC l/ combination and for collection of jugular venous blood, respectively.
All horses were positioned in dorsal recumbency and prepared for surgery. After
performing a ventral median celiotomy, the ascending colon was exteriorized, placed on
a warm water heating padq, and instrumented (Fig 3.1). Doppler ultrasound flow probes
(3 mm)r were placed externally around the right ventral and dorsal colonic arteries, and
colonic blood flow was measured continuously and recorded. A 20-gauge, 5.1-cm
Teflon catheter was placed in each artery and vein of the ventral and dorsal colon, distal
to the flow probes, for determination of ventral and dorsal colonic arterial and venous
pressures. A 14-gauge, 5.1-cm Teflon catheter was placed in the ventral colon vein and
a 20-gauge, 5.1-cm Teflon catheter was placed in the ventral colon artery, both distal to
the pressure catheters, for collection o f colonic venous and arterial blood, respectively.
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Figure 3.1 - Instrumentation o f the equine ascending colon to measure arterial blood
flow, arterial and venous pressures, mucosal and serosal perfusion, and collect arterial
and venous blood. DBFP = Doppler ultrasound blood flow probes; VCAC = ventral
colon arterial catheter; VCVC = ventral colon venous catheter; DCAC = dorsal colon
arterial catheter; DCVC = dorsal colon venous catheter; VC = ventral colon; DC =
dorsal colon; PF = pelvic flexure; LDSFP = laser Doppler serosal flow probe; LDMFP
laser Doppler mucosal flow probe.
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A surface laser Doppler flow probe was positioned on the serosal surface and a needle
1

probe was positioned in the mucosaof the pelvic flexure of the ascending colon to
1

measure seromuscular and mucosal perfusion, respectively. All blood flow probes and
pressure transducers were interfaced with physiographs", and flow and pressure curves
were generated and recorded on chart recordersv. A continuous base-apex ECG was also
obtained.
32 3 Experimental design - The formulation o f ATP-MgCl has been described
2

(29). Twelve horses were equally and randomly assigned to 1 of 2 groups. Group-1
horses served as saline controls. Group-2 horses received an IV infusion o f the ATPMgCl preparation via an infusion pumpw, beginning at a rate o f 0.1 mg of ATP/kg of
2

body weight/min. The infusion rate was increased by 0.1 mg/kg/min increments at 10minute intervals until a maximum rate of 1.0 mg/kg/min was achieved. Unless
otherwise stated, data were collected prior to the start of the infusion (time= ), at the
0

end o f each infusion rate, at 1-minute intervals for the first 5 minutes after
discontinuation of the infusion, and then at IS, 30,45, and 60 minutes after
discontinuation o f the infusion. Control horses received an equivalent volume of 0.9%
NaCl over the same time. The horses were euthanatized at the conclusion o f the study
with an overdose o f sodium pentobarbital (100 mg/kg, IV).
3.2.4

Systemic hemodynamic variables - Systemic hemodynamic variables that

were measured included systolic, diastolic, and mean systemic and pulmonary arterial
pressures (SAP, DAP, MAP and SPAP, DPAP, MPAP; mm Hg, respectively), MRAP
(mm Hg), and CO (L/min). Three measurements were taken at each time for each
pulmonary and facial arterial and right atrial pressure and were used in the analyses.
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Five measurements were taken for CO at each time, and the 3 middle values were used
in our analyses. Cardiac index (Cl; CO -5- kg of body weight;ml/min/kg), systemic
vascular resistance (SRL; [MAP - MRAP] - - CO; mm Hg/L/min), and pulmonary
5

vascular resistance (PR,,; MPAP -5- CO; mm Hg/L/min) were calculated. Specific ECG
alterations were recorded.
3.2.5 Colonic hemodynamic variables - Colonic hemodynamic variables that
were measured included mean ventral and dorsal colonic arterial and venous pressures
(VCAP, DCAP, VCVP, DCVP; mm Hg, respectively), ventral and dorsal colonic blood
flow (VCF and DCF; ml/min), colonic mucosal perfusion (CMP; capillary perfusion
units [cpu]), and colonic serosal perfusion (CSP; cpu). Variables that were calculated
included overall mean colonic arterial and venous pressures (OCAP; [DCAP + VCAP]
-5- 2 and OCVP; [VCAP - VCVP] -*• 2; mm Hg), overall mean colonic arterial blood
flow (OCF; [VCF + DCF] -5- 2; ml/min), ventral and dorsal colonic vascular resistances
(DCRl; [DCAP - DCVP] - DCF; mm Hg/ml/min, and VCR,.; [VCAP - VCVP] + VCF;
mm Hg/ml/min, respectively), and overall colonic vascular resistance (OCRL;
[DCRt+VCRJ -- ; mm Hg/ml/min).
5 2

3.2.6 Nitric oxide analyses - Ventral colonic arterial and venous blood

( 6

ml

each) were collected into tubes containing lithium heparin and processed for immediate
analysis of NO concentrations in fresh plasma. Samples were centrifuged at 1,500 X g
for 5 minutes and the plasma was harvested and deproteinized by adding 100 pi of
trichloroacetic acid (10%) solution to 100 pi of the sample. The samples were vortexed
for 30 seconds and then allowed to stand for 15 minutes. The samples were centrifuged
at 14,000 x g for 5 minutes. The supernatant was removed for analysis. Aliquots (3 pi)
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of plasma were added to a purge chamber of vanadium chloride (100 C) in IN HC1
under a nitrogen atmosphere. Nitric oxide (bound or in the form o f nitrate) liberated
from the samples into the gaseous headspace was conducted to the NO analyzer11, where
it reacted with ozone to produce a chemiluminescent signal in the 6500-8000 A range.
The amount of light generated was proportional to the NO concentrations, which was
calculated from a standard curve of known nitrate concentrations. Each sample was
analyzed in triplicate. The limit of detection for the analysis is 1 picomole (1 pM of
nitric oxide in
3.2.7

1

pi of plasma).
Statistical analyses - All data were considered continuous and evaluated

for normality, using the Shapiro-Wilk statistic. The data were considered to follow a
normal distribution if there was failure to reject the null hypothesis o f normality at p 5
0.05. Data that were not normally distributed were log transformed, such that they
followed a normal distribution. Data were summarized and graphed as mean ± SEM.
All data were analyzed, using the model: y = p + Group + Horse(Group) + Time
+ Group*Time + Horse*Time + , where y = dependent variable; |i = overall mean;
6

Group = fixed effect of group (0.9% NaCl or ATP); Horse(Group) = random effect of
horse nested within Group; Time = fixed effect of time of measurement; GroupTime =
fixed effect of Group interaction with Time; HorseTim e = random effect of Horse
interaction with Time; and € = residual error.
In this model, the effect of Horse was considered random and was the error term
for the evaluation of Group. All other fixed effects were evaluated, using the combined
variance o f the Horse interaction term and the residual error. A two-sided hypothesis
with p £ 0.05 was used to determine significance o f the fixed model effects (Group,
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Time, Group*Time). Where there were significant model effects, multiple comparisons
were made between groups at different time periods, and within groups compared to
baseline, using adjusted least squares means, maintaining an experiment-wise error of
0.05. Thus, where a significant difference is noted between time periods and compared
to baseline, the p value was £ 0.05. Proc univariate and Proc mixedy was used for the
analyses.
3 3 Results
33.1

Systemic hemodynamic variables - There were no significant differences

between the control and treatment groups for any measured or calculated variable pre
infusion (baseline). There were no consistently significant changes across time for any
measured or calculated systemic hemodynamic variable in group

- 1

horses with the

exception o f MRAP (Table 3.1). In group-2 horses, significant changes across time
were present for several systemic hemodynamic variables (Table 3.2; Fig 3.2).
3 3 3 Colonic hemodynamic variables - There were no significant differences
between the control and treatment groups for any measured or calculated variable preinfusion. No significant alterations were observed for any local colonic hemodynamic
variable across time in group-1 horses (Table 3.3). In group-2 horses, significant
decreases in dorsal, ventral, and overall colonic hemodynamic variables were observed
across time (Table 3.4, Figs 3.3-3.5). Colonic seromuscular perfusion was significantly
decreased across time (Table 3.5).
3 3 3 N itric oxide analyses - There were no significant differences in colonic
arterial or venous plasma NO concentrations across time for group-1 horses. However,
significant decreases in colonic arterial and venous plasma NO concentrations were
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Table 3.1 - Systemic hemodynamic variables (mean ± SEM) before, during, and after
IV infusion of 0.9% NaCI.
Infusion Rate
(mg ATP/kg/min)t

Cl
(mmHg/ml/min)

SAP
(mmHg)

DAP
(mmHg)

MAP
(mmHg)

0.0

43.00tfc2.00

113.67±5.40

94.72±5.86

100.48±5.76

0.1

42.88±1.83

107.06±5.55

86.06±5.95

93.03±5.78

0.2

41.71±2.13

105.0d=b4.36

85.50±5.63

92.0l±5.16

03

43.20±2.44

111.67±4.02

91.50±5.16

98.22±4.74

0.4

40.59fcl.74

113.83±5.42

92.56±6.09

99.64±5.79

0.5

45.19±2.40

105.44±5.14

86.28fc5.56

92.68±5.36

0.6

43.56±2.52

110.33±6.00

87.72±6.23

95.24±6.14

0.7

42.00±1.96

111.72±5.13

88.11±5.50

95.97±5.37

0.8

44.7l±3.28

I15.94fc5.02

89.83±5.29

98.53±5.16

0.9

44.75±2.43

112.61±5.28

87.89±5.31

96.13±5.27

1.0

43.29±3.08

112.44±4.92

86.94±5.31

95.44±5.15

113.50±5.29

89.61±5.23

97.57±5.23

112.61±5.30

88.78±5.55

96.72±5.45

112.67±5.37

87.72±5.50

96.06±5.45

45.47±2.06

109.78±538

86.89fc5.41

94.49±5.37

15

42.06±1.78

108.61fc5.05

86.28±4.99

93.73±4.98

30

44.60±2.7I

106.61±4.43

8I.72±4.45

90.01±4.4I

45

37.88±2.51

124.42±1.81

100.00fcl.55

108.13±1.60

60

4U9±5.00

126.83±1.57

104.17±1.18

U1.73±1.25

Time Post-infusion
(min)_____

♦Significant (P s 0.05) difference from pre-infusion values. tEquivalent volume of
0.9% NaCI over the same time period. Cl = cardiac index; SAP, DAP, MAP = systolic,
diastolic, mean arterial pressure.
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Table 3.1 - continued
Infusion Rate
(mg ATP/kg/min)t

SPAP
(mmHg)

DPAP
(mmHg)

MPAP
(mmHg)

MRAP
(mmHg)

0.0

24.40±4.09

I1.97±l.l5

17.58±2.18

4.49t0.94

0.1

2i.38±2.91

13.15±2.05

16.68±237

2.99±1.08*

0.2

23.67±3.31

13.17±2.27

18.58±2.50

3.07±1.08*

J

27.35±2.86

16.20±3.3l

21.33±2.60

3.46±1.04

0.4

28.17±3.17

16.55±2.45

21.83±2.26

3.38±0.99

0.5

26.38^2.86

15.97±1.22

20.633k1.20

3.71±1.02

0.6

25.80±3.18

16.77±1.63

20.75±1.79

420±0.96

0.7

25.63±3.78

I3.23fcl.32

19.08fcl.88

4.01±0.88

0.8

28.47±3.69

14.28±2.24

20.93±1.53

3.66dtl .10

0.9

28.20±4.24

13.00±0.89

19.88fcl.55

4.56±0.87

1.0

28.l0fc3.67

13.02±1.47

20.22±0.99

4.61±0.89

0

Time Post-infusion
(min)_____
4.80±0.86
3.90±1.02
3.77±0.95
25.83±3.16

I3.20tfcl.46

18.93±1.39

3.87±0.84

15

26.57±2.06

16.03±1.89

20.60±l.l5

4.24±0.87

30

27.73±1.95

17.67±2.06

2232±1.46

4.59±0.93

45

30.33±3.84

15.67*5.24

22.67±2.60

4.53*1.23

60

29.58±236

15.90±4.15

22.83±2.46

3.42*1.09*

SPAP, DPAP, MPAP = systolic, diastolic, mean pulmonary arterial pressure; MRAP =
mean right atrial pressure.

117
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Table 3.2 - Systemic hemodynamic variables (mean ± SEM) before, during, and after
IV infusion of ATP-MgCl2.
Infusion Rate
(mg ATP/kg/min)

Cl
(mmHg/ml/min)

SAP
(mmHg)

DAP
(mmHg)

MAP
(mmHg)

0.0

46 .6 l± l3 8

120.89±4.28

99.44±3.90

106.60±3.90

0.1

43.50±2.64

11739±2.88

95.78±2.78

102.99±2.63

0.2

39.78±2.25

H5.50±3.9l

86.78±2.48*

9634±2.74*

03

4l.89±2.30

103.22±5.07*

71.17±3.86*

81.85±4.08*

0.4

45.83±2.02

78.61±4.20*

47.6l±3.80*

57.94±3.87*

OS

48.28±4.49

72.44±4.81 *

43.83±4.24*

53.83±4.35*

0.6

52.06±3.6t

6639±5.43*

38.56±4.18*

47.65±4.55*

0.7

53.78±4.09

6l.22±5.40*

34.06±2.71*

43.12±3.54*

0.8

53.06±3.84

53.33±5.74*

30.72±2.90*

38.25±3.80*

0.9

44.61 ±232

48.72±5.79*

27.44±2.73*

34.48±3.72*

1.0

44.28±2.6I

4l.56±5.65*

23.56±2.74*

29.56±3.66*

74.94±9.23*

4339±5.83*

53.91±6.89*

96.00±7.32*

6138±5.94*

72.86±6.26*

9620±8.26*

6230±6.95*

73.54±724*

49.40±3.0l

102.47±7.99*

65.80±6.11*

78.03±6.56*

15

46.73±1.80

98.93±6.33*

65.00±4.78*

7631±5.14*

30

46.93±130

10530±3.58*

7433±2.40*

84.62±2.65*

45

46.09±1.74

98.67±4.77*

70.50±2.91*

79.88±3.47*

60

43.90±0.97

99.08±1.88*

74.00±1.45*

8238±1.28*

Time Postinfnsion (min)

See Table 3.1 legend for key.
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Table 3.2 - continued
Infusion Rate
(mg ATP/kg/min)

SPAP
(mmHg)

DPAP
(mmHg)

MPAP
(mmHg)

MRAP
(mmHg)

0.0

24.12±3.47

15.80tfc2.43

19.02±2.73

0.75±1.02

0.1

39.22±8.54*

2737±6.62*

33.70±8.10*

0.0t±1.03

02

35.48±4.15*

2033±0.97

2832±3.00*

0.55±0.88

0J

3l.22±2.64

19.15±2.64

25.12±1.94

l.30±0.60

0.4

33.83±2.6l

20.40±2.77

26.15±1.87

0.94±0.8l

0.5

25.73±4.93

20.88^1.56

25.95±1.68

0.31±0.93

0.6

28.95±2.89

18.40^2.46

24.03±2.56

0.46±0.80

0.7

26.38±1.25

17.22±1.57

22.27±1.60

1.56±0.62

0.8

23.83±2.12

16.12±2.30

20.30±2.31

0.93±1.01

0.9

20.63^1.60

12.50±1.9l

17.82±2.I0

l.57±0.78

1.0

20.95±1.45

13.83fcl.49

18.20±1.81

I.33±0.96

Time Post-infusion
(min)

0.26±1.07

1

-0.86±0.87*
-0.92±1.07*
22.34±1.87

16.72±2.16

19.26±1.73

-1.57±0.95*

15

2620±1.96

17.20±2.54

22.26fcl.89

-0.65±0.78

30

24.06±0.42

17.46±0.99

21.66fc0.80

-1.82±1.00*

45

24.33±233

14.67±1.45

22.00fc2.08

•0.18±0.60

60

28.00±4.04

17J3±2J3

22.67±2.60

-137±0.89*

See Table 3.1 legend for key.
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Table 3 3 - Colonic hemodynamic variables (mean ± SEM) before, during, and after IV
infusion o f 0.9% NaCI.
Infusion Rate
(mg ATP/kg/min)t

DCAP
(mmHg)

VCAP
(mmHg)

DCVP
(mmHg)

VCVP
(mmHg)

0.0

77.00±6.79

92.67i3.13

9.59±1J2

8 .9 7 il.l4

0.1

69.89±6.58

8433i4.66

9.72il.l5

8.73±1.15

03

68.61±737

89.00i5.68

9.86±1.23

9 3 lil.1 7

03

70.94±533

87.56±4.40

9.09±1.07

8.18il.0l

0.4

75.39*6.53

88.06i3.92

9.49il.l7

8.67±1.13

03

74.00±6.55

89.50±5.32

9.85±1.21

9.12±1.09

0.6

73.22i7.05

8833±4.42

9.62±1.18

9.1 lil.0 4

0.7

71.67±731

91.11±3.59

9.81±1.13

9.18±1.13

0.8

72.94±6.82

89.06i4.20

0.9

7l.61i730

90.83i4.41

9.95il.09

9.28il.I0

1.0

70.39i7.18

89.28i4.16

I0.32il.16

9 3 1 il.l4

75.93i5.70

90.93i5.62

10.67±1.16

9.49±1.06

76.53i6.18

8930tk5.63

10.52±1.16

9.44±1.18

70.83i5.78

88.88±4.83

9.86il.20

9 3 3 il.l4

66.00i5.95

88.61i4.68

I0 .0 lit3 9

9.28il.20

15

66.72i5.01

8738i437

I0.I7iI35

9.46il.25

30

70.67i532

89.83i4.47

9.94il31

9.44il.l2

45

85.67i2.66

94.00il.99

I2 3 9 il3 0

12.88i0.51

60

82.83i3.57

95.75i2.54

1235il.l9

11.83i0.85

9.13il.08

Time Post-infusion
(min)______

^Significant (P £ 0.05) difference from pre-infusion values. tEquivalent volume of
0.9% NaCI over the same time period. DCAP = dorsal colon arterial pressure; VCAP =
ventral colon arterial pressure; DCVP = dorsal colon venous pressure; VCVP = ventral
colon venous pressure
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Table 3 3 - continued
Infusion Rate
(mg
ATP/kg/min)t

DCF
(ml/min)

VCF
(ml/min)

DCR
(mmHg/ml/min)

VCR
(mmHg/ml/min)

0.0

128.83±6.96

434.56±24.66

037±0.14

0.20±0.02

0.1

122.28±7.57

435.78±24.77

0.5l±0.11

0.18±0.03

03

122.11±6.23

419.83±24.09

0.52±0.13

0.20±0.03

03

124.94±8.00

395.83±24.17

0.52 ±0.09

0.22±0.03

0.4

123.6l±6.21

433.17±2034

0.55 ±0.11

0.19±0.02

03

113.28±2.00

416.11±18.23

0.56 ±0.09

0.20±0.03

0.6

114.33±4.10

402.17±12.08

0.54 ±0.08

0 .20± 0.02

0.7

112.72±3.68

43033±15.41

0.53 ±0.09

0.19±0.02

0.8

131.67±4.37

463.83±23.35

0.49 ±0.09

0.18±0.02

0.9

15028±13.92

437.17±23.14

0.44 ±0.10

0.20±0.03

1.0

I6039±14.01

46332±33.4I

038 ±0.08

0.19±0.03

148.94±15.06

439.67±23.98

0.48±0.06

030±0.04

162.89±15.79

433.83±25.03

0.44±0.05

030±0.04

144.00±12.05

420.56±29.22

0.44±0.06

0.2I±0.04

15239±13.99

412.94±28.94

0.39 ±0.06

0.2I±0.04

15

140.00±11.19

437.61±26.10

0.42 ±0.06

0.19±0.03

30

135.89±1130

421.00±22.85

0.47 ±0.07

0.20±0.03

45

135.50±3.95

465.58±3136

0.55 ±0.06

0.18±0.02

60

141.83±6.76

478.75±29.63

0.51 ±0.07

0.18±0.01

Time Postinfusion (min)

DCF = dorsal colon blood flow; VCF = ventral colon blood flow; DCR = dorsal colon
resistance; VCR = ventral colon resistance
V T
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Table 3.4 - Colonic hemodynamic variables (mean * SEM) before, during, and after IV
infusion of ATP-MgCl2.
Infusion Rate
(mg ATP/kg/min)

DCAP
(mmHg)

VCAP
(mmHg)

DCVP
(mmHg)

VCVP
(mmHg)

0.0

88.28*2.64

88.56*2.44

9.38*0.93

10.41*1.12

0.1

84.67*2.33

85.72*2.06

8.14*0.95

8.91*1.19*

0.2

7933*2.50

79.33*2.70

8.43*1.01

9.20*1.25*

03

61.61*2.68*

64.83*2.56*

8.22*0.92

8.94*1.06*

0.4

42.78*2.19*

45.22*3.09*

7.87*0.77*

9.00*0.96*

03

40.94*3.93*

42.11*3.69*

8.74*0.72

9.66*0.95

0.6

36.11*4.36*

36.89*4.23*

9.42*0.84

9.80*1.05

0.7

35.11*3.72*

36.11*4.49*

8.64*0.81

9.54*0.98

0.8

29.00*2.98*

29.22*3.09*

7.51*0.76*

8.71*1.03*

0.9

2333*1.45*

26.22*2.64*

7.57*0.80*

8.36*0.95*

1.0

20.70*1.45*

22.28*2.59*

6.59*0.77*

7.54*0.91*

40.78*531*

41.72*5.96*

836*0.97

931*1.09*

57.94*5.87*

61.50*5.80*

7.91*0.85*

8.91*0.98*

63.27*6.90*

62.40*7.07*

8.39*1.15*

8.75*133

66.40*5.91*

66.33*6.70*

9.57*1.65

9.65*1.67

IS

63.93*4.44*

66.07*4.80*

7.77*1.10*

835*139*

30

70.27*237*

73.60*3.04*

836*138*

7.81*1.39*

45

69.17*2.49*

6833*3.51*

9.66*0.68

9.50*0.80*

60

69.08*1.18*

74.08*3.07*

10.67*1.00

10.13*1.10

Time Post-infosion
(min)______

See Table 3.3 legend for key.
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Table 3.4 - Continued
Infusion Rate
(mg
ATP/kg/min)

DCF
(ml/min)

VCF
(ml/min)

DCR
(mmHg/ml/min)

VCR
(mmHg/ml/min)

0.0

129.67± 12.72

592.00±54.80

0.73±0.I5

0.16±0.03

0.1

139.28 ±14.45

571.67±52.29

0.69±0.16

0.16±0.03

0.2

133.56 ±13.46

514.39±46.27

0.64±0.I3

0.16±0.02

03

135.61 ±13.42

502.56±70.56

0.43 ±0.05*

0.14±0.02

0.4

115.67±6.86

460.72±41.70*

0.31 ±0.03*

0.09±0.01

0.5

121.33±10.96

431.06±42.24*

0.29 ±0.04*

0.09±0.02

0.6

120.06±12.79

418.00±56.14*

0.23 ±0.04*

0.09±0.02

0.7

I29.72±12.07

411.94±59.14*

022 ±0.04*

0.10±0.03

0.8

105.33± 10.43

374.11±46.17*

022 ±0.03*

0.07±0.02*

0.9

93.78±12.16

358J9±46.17*

023 ±0.06*

0.06±0.01*

1.0

90.78±12.77*

316.61±41.54*

026 ±0.10*

0.09±0.04

I33.61±19.65

393.33±34.81*

028±0.04*

0.09±0.02

118.00±1123

418.56±39.90*

0.44±0.07*

0.13±0.02

132.47±16.00

462.73±57.08*

0.45±0.09*

0.12±0.02

142.93±1339

523.20±55.05

0.42 ±0.07*

0. 12± 0.02

15

146.40±14.14

529.73±64.80

0.42 ±0.07*

0. 12± 0.02

30

140.00±I2.15

512.07±5823

0.49 ±0.10

0.15±0.03

45

130.83±13.64

496.75±73.68

0.53 ±0.14

0.14±0.02

60

120.75±11.97

536.67±76.04

0.55 ±0.12

0.14±0.02

Time Post
infusion (min)

See Table 3.3 legend for key.
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Table 3.5 - Colonic mucosal and seromuscular perfusion (meaniSEM) before, during,
and after IV infusion of 0.9% NaCI (Group 1) or ATP-MgCl2(Group 2).
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|
|
Infusion Rate
1 (mg ATP/kgAnin)t

Group 1

Group 2

CMP (cpu)

CSP (cpu)

CMP (cpu)

0.0

14.65±1.61

17.69±238

20.51±236

25.03±4.09

0.1

I3.53±136

18.82±2.51

28.4l±3.19*

2136±2.35

02

12.06dfc0.97

18.45±2.00

25.49±330

2530±2.65

03

13.01±1.08

16.97±2.14

25.78±2.92

I7.72=kl.90’*

0.4

15.06±1.03

19.56±3.03

2438±335

13.98±0.86*

0.5

12.72±1.16

17.69±333

2036±3.00

16.23±2.57*

0.6

16.79±1.64

18.32dfc3.08

26.68±5.59

1234±1.31*

on

14.91±1.60

1635±3.01

22.57±4.86

12.17±1.78*

0.8

I636±137

19.19±3.49

18.01±2.46

I0.81=bl.59*

0.9

I4.69dfcl.93

20.04±3.60

21.04±4.83

9.68±133*

1.0

15.4l±l.99

16.73±3.42

18.32±4.08

9.37±1.13*

15.17±1.42

17.92±2.69

22.90±4.52

13.74±1.64*

16.56±1.65

18.18±3.04

20.62±2.90

16.52±2.49*

15.96±2.05

19.57±3.53

24.11±2.28

21.27±3.44

16.04±1.28

18.32±3.ll

20.74±2.26

15.60±2.44*

15

18.25±1.60

16.45±2.73

19.71±2.14

16.71±1.69*

30

15.24±1.98

17.61±2.64

29.76±5.57*

14.69±1.37*

45

I7.82±l.l3

21.64±338

15.00±1.17

lt.35±2.07*

60

16.20±2.19

18.71±2.67

16.55±2.65

12.07±1.50*

CSP (cpu)

Time Post-infusion
(min)______

1

Significant (P s 0.05) from preinfusion value

t Equivalent volume o f 0.9% NaCI over the same time period for Group 1. CMP =
colonic mucosal perfusion; CSP - colonic seromuscular perfusion.
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observed in group-2 horses at 45 and 60 minutes after discontinuation of the ATPMgCl2 infusion.
33.4

ECG abnormalities - Six of the 12 horses developed cardiac arrhythmias

during the study. Arrhythmias were detected in 1 group-1 horse and 5 group-2 horses.
The group-l horse had atrial premature contractions (APC) prior to the start o f the
infusion, at the 0.2 and 1.0 mg/kg/min equivalent infusion rates and at 3 minutes post
infusion.
Two group-2 horses developed periods of transient sinus arrest, which were
detected in one horse prior to and one horse after the start of the infusion. A third horse
had intermittent 2° atrioventricular (AV) block before and after the start of the infusion.
A fourth horse had ventricular premature contractions (VPC) prior to the start of the
infusion, during the 0.1 to 0.5 mg/kg/min infusion rates and from 0.9 mg/kg/min until
the end of the study. At 2 minutes 45 seconds after discontinuation o f the infusion, this
animal developed ventricular fibrillation and died. The fifth horse had an undefined
atrial arrhythmia before and after the start of the infusion.
3.4 Discussion
Intravenous infusion o f ATP-MgCl2in clinically normal, anesthetized adult
horses caused a rate-dependent decrease in systemic and colonic vascular resistance,
principally via its vasodilatory effects. In contrast to studies performed in other species,
mild transient pulmonary hypertension developed in the group-2 horses during the 0.1
and 0.2 mg/kg/min infusion rates. In a previous study, we determined the maximum
safe intravenous infusion rate in conscious adult horses to be 0.3 mg ATP/kg/min (27).
Administration o f ATP-MgCl2 at 0.3 mg/kg/min in the present study caused a
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significant decrease in colonic arterial pressure and vascular resistance without a
significant decrease in colonic arterial blood flow. However, at rates of 0.4 mg/kg/min
or higher, blood flow to the colonic vasculature could not be maintained due to lack of
driving pressure secondary to the marked decrease in MAP. Below a critical
intravascular pressure, blood flow will not be maintained without increasing driving
pressure. The mean MAP pressure during the 0.3 mg/kg/min infusion rate in the
previous and present study was 121.9 and 81.85 mm of Hg, respectively (27). The
systemic arterial pressure below which insufficient driving pressure is available to
maintain blood flow to the splanchnic circulation is not known in horses. In clinical
situations, systemic hypotension during general anesthesia is generally not treated until
MAP reaches 60 mm of Hg or below. During the infusion rate at which a significant
alteration in colonic arterial blood flow was observed (0.4 mg/kg/min), mean MAP was
58 mm of Hg. The results of the present study suggest that an infusion rate of 0.3 mg
ATP/kg/min may be beneficial to improve tissue perfusion to the ascending colon
following an ischemic insult as long as driving pressure is maintained. However, the
rate o f infusion o f ATP-MgCU may need to be lowered in horses with hypotension
secondary to hypovolemia or endotoxemia, which occurs commonly with intestinal
ischemic diseases.
The systemic and colonic hemodynamic alterations observed in group-2 horses
was directly related to administration of ATP-MgCl2. We did not observe significant
differences in any measured or calculated variable between the two groups prior to the
start o f the infusion. Also, there were no consistent significant changes across time in
the group-1 horses. Therefore, the hemodynamic alterations that were observed in the
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group-2 horses were due to the effects o f the ATP-MgCl2 administration and not due to
differences between groups, effect of anesthesia or effect o f time.
The mechanism of ATP-MgCl2-induced vasodilatation has been investigated. In
lambs, administration o f N“-nitro-L-arginine (30) or methylene blue (31) (nitric oxide
inhibitor or scavenger) inhibited vasodilatation, whereas indomethacin (prostacyclin
inhibitor) and theophylline (32) (adenosine inhibitor) administration did not. Based on
these findings, the authors concluded that ATP-MgCl2exerts its vasodilatory effects
through endothelial-derived NO rather than prostacyclin, adenosine or MgCl, (30,31).
Magnesium has been reported to be a potent vasodilating agent and has been
demonstrated to potentiate vasodilatation when combined with ATP in vivo (19).
However, we do not believe that magnesium was a major contributor to the
vasodilatation response observed in the colonic vasculature in this study. In an in vitro
pilot study, we have documented that addition of MgCl2 (10',2to lO^M) to ATP
(equimolar concentrations) did not enhance the relaxation response o f equine colonic
arterial and venous rings (with intact and denuded endothelium) precontracted with
endothelin-1, compared with ATP alone (unpublished data). Additionally, MgCl2 alone
did not cause appreciable relaxation of colonic vascular rings (with intact and denuded
endothelium) precontracted with endothelin-1. Based on this information, the systemic
and colonic vasodilatory responses observed in this study were likely mediated through
ATP directly and/or one of its metabolites. However, we do not know whether the in
vivo and in vitro vascular response to magnesium are similar. Whether magnesium
contributed to the vasodilatory response observed in the systemic circulation in this
study is not known.
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The magnitude o f the hemodynamic alterations produced by intravenous
administration o f ATP-MgCI2 are dependent on rate of administration, site of infusion,
species being studied, whether the subjects are conscious or anesthetized and whether
the subjects are clinically healthy or exhibiting signs of systemic disease. In contrast to
our conscious horse study where we observed significant increases in CO, Cl, HR and
PAP across time (27), the group-2 horses in this study did not follow a similar pattern.
General anesthesia may override the presumed sympathetic stimulation that
accompanies ATP-MgCl2administration. In healthy, conscious men, rates of 0.1 to 0.4
mg ATP/kg/min resulted in significant increases in CO and HR with no change in MAP
(18). A study in healthy, conscious lambs receiving 3 rates o f intravenous ATP-MgCl2
(0.1,0.5, or 1.0 mg/kg/min) revealed no change in HR and MPAP but CO was increased
during the highest rate and MAP was decreased at the 0.5 and 1.0 mg/kg/min rates (33).
In healthy, anesthetized dogs, rates o f 0.6-2.5 mg/kg/min increased CO and decreased
MAP (21).
The anesthetized horses in the present study and the conscious horses in our
previous study developed pulmonary hypertension, which is in contrast to a study in
resting lambs documenting no change in pulmonary artery pressure with ATP-MgCl2
administration (30). The reason for the pulmonary hypertension is not known, however,
several possibilities exist. In order for the action of a vasodilating agent to be
demonstrated, tissue vasoconstriction may have to occur (14). Results of in vitro
studies have indicated that a variation in response to ATP administration can occur in
different vascular beds and in vessels under different vascular tensions (14). In certain
blood vessels, ATP can stimulate the smooth muscle directly (via P ^ receptors),
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causing vasoconstriction (34). In other vascular beds, ATP stimulates the endothelial
P2Yreceptor, causing vasodilatation (14). If ATP is metabolized to adenosine,
activation o f the A2 purinoreceptor can lead to vascular relaxation (16). Under resting
tension, ATP induces vasoconstriction in some vascular beds; however, if tension is
increased, vasodilatation occurs (14).
The data obtained from the laser Doppler flow probes located on the serosal and
mucosal surfaces of the ascending colon revealed large variation in recorded values.
The most likely explanation for this variation is that the intestine is a continually motile
organ. A disadvantage of the technique is its high sensitivity to motion-produced
disturbances (35,36). If the laser beam is not directed perpendicular to the tissue, loss of
intimate contact of the probe with the tissue occurs resulting in inaccurate values being
recorded (35,36). Therefore, the method used in the present study to assess serosal and
mucosal blood flow cannot currently be recommended. A superior method to assess
blood flow distribution to the different layers of the intestinal tract would be to
use either radiolabeled or colored microspheres (37,38).
As previously stated, the mechanism of ATP-induced vasodilatation in other
species is through increased production o f NO. We did not observe a significant
increase in either colonic arterial or venous plasma NO concentrations in our group-2
horses despite significant vasodilatation in the colonic vasculature. Potential reasons for
the apparent lack of increase in NO production during ATP-MgCl2 administration
include: lack o f sensitivity of the assaying method; NO being released on the basalar
rather than apical surface o f the cell where it could escape more readily into the vascular
lumen; ATP-induced vasodilatation occurs via a different mechanism in the horse; or
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vasodilatation is a result o f the MgCl2or breakdown products o f ATP. Nitric oxide
production can occur constitutively or inducibly (39). Adenosine triphosphate-induced
vasodilatation occurs through induction of the constitutive form of NO synthase (cNOS)
in the endothelium (13). Only picomole quantities of NO are released via cNOS,
thereby making small changes in concentrations of NO difficult to detect. The
mechanism o f action o f ATP-induced vasodilatation in isolated equine colonic vascular
rings is currently being investigated by our laboratory. The reason for the decrease in
NO concentrations observed in the group-2 horses after discontinuation of the infusion
is not known but may be due to cessation of stimulation of cNOS.
Short-term control of arterial blood pressure homeostasis is mediated primarily
by the baroreceptor reflex (40,41). Acute decreases (increases) in arterial pressure are
detected by the arterial baroreceptors and result in reflex increases (decreases) in heart
rate (40,41). In the present study, there was failure o f the arterial baroreceptor reflex to
respond to ATP-MgCU-induced hypotension. Baroreflex sensitivity is depressed by IV
and inhalation-administered anesthetics in numerous species (42-45). Although IVadministered anesthetic-induced depression of the baroreflex has been shown to be less
than inhalants (46,47), there was failure of the baroreflex to correct the profound
decrease in systemic arterial pressure that occurred in the horses in this study.
Cardiac arrhythmias were observed in 6 o f 12 horses in this study. The majority
(5 o f 6) of arrhythmias occurred in horses administered ATP-MgCl2. However, 4 of 5
horses that received ATP-MgCl2 had evidence of cardiac arrhythmias prior to the start
o f the infusion. The exact etiology of the arrhythmias in the horses is not known but
may be associated with administration of preanesthetic and anesthetic agents and/or
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cardiac catheterization. In humans, cardiac catheterization has a reported complication
rate o f approximately 23% (48). In our previous study, 3 of 6 conscious horses
receiving ATP-MgCl2 had cardiac arrhythmias; all o f which were present prior to the
start o f the infusion (27). In those horses, the arrhythmias were suspected to be
associated with the cardiac catheters.
The most common cardiac disturbance detected in this group involved slowing
o f conduction through the heart Administration of ATP-MgCl2 should be used with
caution in horses with pre-existing AV conduction disturbances because both ATP and
adenosine are biological compounds with potent depressant activity on the
atrioventricular (AV) node (49-51). Because of this effect, ATP has been used to treat
supraventricular arrhythmias (52). The antiarrhythmic effects of ATP are produced by
blocking the reentry circuit in the AV node (53). Atrioventricular conduction
disturbances (1°, 2°, 3° AV block) have been observed during continuous IV infusion of
ATP (50). In contrast, ATP has been documented to exert an excitatory effect on
intraventricular automaticity (49).
Arrhythmias may be associated with reperfusion of ischemic myocardium and
this may be a major progenitor for sudden cardiac death in people (54). The
electrophysiological basis for arrhythmias associated with reperfusion appears to be
heterogenous electrical recovery, but the precise alterations responsible for malignant
versus nonmalignant arrhythmias are unknown (54). The cause of ventricular fibrillation
and death in one horse in the current study is not known, but we speculate was attributed
to a reperfusion phenomenon of the hypoxic myocardium secondary to the profound
systemic hypotension (22.9 mm of Hg MAP during maximal infusion rate) that occurred
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during the higher infusion rates. This horse had evidence o f premature ventriuclar
contractions prior to the start of the infusion, which can be indicative o f pre-existing
myocardial disease or electrolyte imbalances (55). Electrolyte abnormalities were not
detected. Therefore, pre-existing myocardial disease which was exacerbated by
profound hypotension and secondary hypoxia may have been the cause of ventricular
fibrillation in this horse. Because of the potential for atrioventricular conduction
disturbances and the increased potential for arrhythmias to develop secondary to
systemic hypotension and myocardial ischemia, heart rate and rhythm should be
monitored in horses, especially critically-ill horses, receiving an IV infusion of ATPMgCl2.
In conclusion, IV administration o f ATP-MgCl2 to clinically healthy,
anesthetized horses caused a rate-dependent decrease in systemic and colonic vascular
resistance. Further studies are required to determine the efficacy of ATP-MgCl2in the
treatment of intestinal ischemia in horses. The reduction in blood flow and decreased
mucosal ATP content that persists following correction of experimentally-induced
ascending colon ischemia may be attenuated with administration of ATP-MgCl2 by
improving blood flow and supplying substrate (ATP) and cofactor (Mg) to the highly
metabolically-active mucosal layer.
3.5 Product Information
“Rompun, Mobay Corp, Animal Health Division, Shawnee, Kan.
bTorbugesic, Fort Dodge Animal Health, Fort Dodge, Iowa.
cAngiocath 382269, Becton Dickson Infusion Therapy Systems Inc, Sandy, Utah.
dPentalumen thermodilution catheter 41216-01, Abbott Critical Care Systems, Abbott
Laboratories, Hospital Products Division, North Chicago, 111.
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Tntramedic polyethylene tubing model PE260, Becton Dickson, Sparks, Md.
‘Normosol, Abbott Laboratories, North Chicago, 111.
‘Injector 500, Columbus Instruments, Columbus, Ohio.
hCardio Max II model 85 thermodilution cardiac output computer, Columbus
Instruments, Columbus, Ohio.
'Intramedic polyethylene tubing model PE205, Becton Dickson, Sparks, Md.
'Guaifenesin 0190-8, Puger Chemical Company Inc, Irvington, NJ.
kPentothal 8912, Abbott Laboratories, North Chicago, 111.
'Sodium pentobarbital injection, The Butler Company, Columbus, Ohio.
"Anesthesia Ventilator model NELAC-E, North American Drager, Telford, Pa.
"Quick-Cath 2N-11-13, Baxter Healthcare Corporation, Deerfield, HI.
°Quik-Cath 2N-11-10, Baxter Healthcare Corporation, Deerfield, 111.
pAdenosine 5'-triphosphate disodium salt A3377 and magnesium chloride hexahydrate
M2670, Sigma-Aldrich Inc, St Louis, Mo.
qK module model K-20, Baxter Healthcare Corporation, Pharmaseal Division, Valencia,
Ca.
Trobe #3S1174 model T206, Transonic Systems Inc, Ithaca, NY.
*Probe #HLR1143 model BLF-21D, Transonic Systems Inc, Ithaca, NY.
'Probe #HLN1110 model BLF-21D, Transonic Systems Inc, Ithaca, NY.
“Polygraph model 7D, Grass Instruments, Quincy, Mass.
vChart recorder model 25-60, Grass Instruments, Quincy, Mass.
wLife care pump model 4, Abbott Laboratories, North Chicago, 111.
xModel 280 (NOA), Sievers Instruments Inc, Boulder, Colo.
yProc mixed SAS version 6.12, SAS Institute, Cary, NC.
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CHAPTER 4. EFFECTS OF ATP-MgCl2COMBINATION ON
CLINICAL SIGNS, HEMODYNAMIC, METABOLIC,
HEMATOLOGIC, AND SERUM BIOCHEMICAL VARIABLES
IN CLINICALLY, HEALTHY, CONSCIOUS HORSES
ADMINISTERED LOW-DOSE ENDOTOXIN
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4.1 Introduction
Endotoxemia remains the leading cause of death in horses (1,2). Endotoxemia
affects all horses regardless of age, breed, gender, or geographic location. The
prevalence of endotoxemia in horses with acute gastrointestinal tract disease (colic)
admitted to referral veterinary hospitals has been estimated to be approximately 25%,
and it represents a major cause o f mortality in horses with colic (1,3,4). The most
common gastrointestinal tract diseases associated with endotoxemia include
enterocolitis/enteritis and intestinal strangulation obstruction, and are often associated
with complications such as laminitis and gastrointestinal ileus (5).
There are several inherent mechanisms that restrict transmural movement of
endotoxins and bacteria from the gastrointestinal tract lumen, including epithelial cells
and intercellular tight junctions, cellular secretions, and lamina propria (2). Disruption
o f the intestinal mucosal barrier allows transmural passage of endotoxin into the
systemic circulation. If sufficient endotoxin enters the portal circulation, the ability of
the liver to remove it may be overwhelmed, resulting in systemic endotoxemia (6). In
comparison with other species, horses are exquisitely sensitive to the effects of
endotoxin (7).
Experimental models o f endotoxemia produce clinicopathologic alterations that
parallel the changes that occur during the naturally acquired disease (7-9). In an
experimental study utilizing an intravenous endotoxin dose o f 35 ng/kg, a marked, acute
inflammatory response was observed (9). Increases in serum inflammatory cytokines

were noted, as well as alterations in clinical signs and hematologic variables, and these
changes mimicked the naturally acquired disease (9).
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Studies evaluating the efficacy of ATP-MgCl2 combination suggest it has
potential beneficial effects in patients with hypoperfusion (low-flow) or organ ischemia.
The use o f ATP-MgCl2 following hemorrhagic shock and other adverse circulatory
conditions in both humans and laboratory animals has been shown to improve
mitochondrial function and tissue ATP content (10,11); restore organ function, blood
flow, and perfusion (11-14); improve reticuloendothelial function, survival time, and
survival rate (15,16); and down-regulate the synthesis and release o f inflammatory
cytokines (TNF and EL-6) (17).
In our laboratory, IV administration o f ATP-MgCl2 to clinically healthy,
conscious horses was associated with a rate-dependent increase in cardiac output,
decrease in systemic vascular resistance and mild pulmonary hypertension without any
appreciable detrimental effects (18). In a second study, IV infusion of ATP-MgCL at an
infusion rate of 0.3 mg of ATP/kg o f body weight/min to clinically healthy, anesthetized
horses, caused a significant decrease in colonic vascular resistance without a
corresponding decrease in colonic arterial blood flow (19). These results suggest that IV
infusion of ATP-MgCl2 could have beneficial effects during low-flow conditions by
improving tissue perfusion and providing an energy substrate (ATP) directly to ischemic
tissues for maintenance of cellular metabolism.
Administration o f ATP-MgCl2, which has vasodilatory actions, increases cardiac
output and delivers an energy substrate directly to the tissues, offers a potential therapy
for horses with gastrointestinal tract ischemia and endotoxic shock. We hypothesized
that IV infusion o f ATP-MgC^ would significantly attenuate the pathophysiologic
alterations in clinical signs and cardiopulmonary, metabolic, hematologic, and serum
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biochemical variables subsequent to low-dose endotoxin infusion in clinically normal,
conscious adult horses. The purpose of the study reported here was to evaluate the
effects o f IV ATP-MgCl2 on hemodynamic, hematologic, and metabolic alterations
during low-dose endotoxin infusion in horses.
42 Materials and Methods
42.1

Horses - The study was approved by the Institutional Animal Care and Use

Committee of Louisiana State University. Twelve clinically normal horses (8
Thoroughbreds and 4 Quarter Horses; 8 castrated males and 4 females), ranging in age
from 6 to 15 (median, 13) years old and weighing 465.9 to 604.5 kg (median, 505.7 kg)
were studied. Horses were maintained on a routine preventive health care program.
Horses were housed in a box stall and acclimated to the study area (1.82 X 1.82 m) for a
minimum o f 10 days prior to the start of the study.
4.2.2

Instrumentation - Horses were instrumented, using described techniques

(18). All catheters were placed percutaneously after aseptic preparation o f the skin and
SC infiltration o f lidocaine. A 14-gauge, 5.1-cm Teflon-coated catheter* was inserted
into the left jugular vein for infusion of the pretreatment (LPS or 0.9 % NaCl) and the
treatment (0.9% NaCl or ATP-MgCy solutions. Polyethylene tubingb (outside diameter
[OD], 1.57 mm) was inserted distal to the first catheter and advanced until the tip was
positioned in the right atrium for determination of mean right atrial pressure (MRAP). A
balloon-tipped, flow-directed thermodilution catheter,0which was used for measurement
o f cardiac output (CO) and pulmonary artery pressures (PAP), was inserted distal to the
first two catheters and advanced until the distal port was positioned in the pulmonary
artery. A 14-gauge, 13.3-cm Teflon-coated catheter* was inserted into the right jugular
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vein for collection of jugular venous blood. Polyethylene tubing* (OD, 1.77 mm) was
inserted distal to first catheter and advanced until the tip was positioned in the right
ventricle for infusion of ice-cold polyionic fluidsf for measurement of CO. A 55-ml
volume of fluid was infused over 4 seconds into the right ventricle, using a carbon
dioxide-driven injector,8 and the CO was derived on the basis of thermodilution (18). A
second polyethylene tubing (OD, 1.77 mm) was placed distal to the first and advanced
until the tip was positioned in the pulmonary artery for collection of pulmonary artery
blood. Arterial blood pressures were measured by use of a 20-gauge, 4.45-cm
Polyurethane-coated catheter1*placed in the transverse facial artery. All catheter
positions were confirmed by presence of characteristic pressure wave forms. All
pressure transducers' were positioned at the point of the shoulder. The pressure
transducers and CO meter* were connected to a polygraph1*and pressure and CO curves
recorded on a chart recorder1. A continuous base-apex ECG also was obtained.
4.2

J Experimental design - During the study, horses were cross-tied and hay

and water were provided ad libitum. Twelve horses were used in a nested factorial
design. Horses were pre-treated with either E. coli 055:B5 endotoxin” at 35 ng/kg or an
equivalent volume o f 0.9% NaCl solution via an infusion pump" over a 30-minute
period. The pre-treatments were randomly assigned. Horses in each pre-treatment
group were randomly assigned to one of two treatment groups: 0.9% NaCl or ATPMgCl2°. Immediately upon completion of the pre-treatment infusion (endotoxin or 0.9%
NaCl), horses were administered their assigned treatment (100 /Anole ATP/kg and 100
/Umole MgCl2/kg at an infusion rate o f 0.3 mg of ATP/kg of body weight/min or an
equivalent volume o f 0.9% NaCl solution over the same period). The formulation of
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ATP-MgCl2 has been described (18,20). Two weeks later, horses were pre-treated with
the opposite solution (endotoxin or 0.9% NaCl) but received the same treatment (ATPMgCl2 or 0.9% NaCl). The 4 groups were designated: S/S (0.9% NaCl/0.9% NaCl); L/S
(LPS/0.9% NaCl); S/A (0.9% NaCl/ATP-MgClj); and L/A (LPS/ATP-MgClJ. Clinical
signs and hemodynamic variables were determined at baseline (BL - prior to the start o f
the pre-treatment), post-infusion (PI - end of the pre-treatment infusion), 0.05 (5
minutes after starting the treatment infusion) and at 30-minute intervals for 6 hours (hrs)
after starting the treatment infusion. Arterial blood gas analyses were determined at BL,
PI, 0 .5 ,1 ,1 .5 ,2 ,4 ,6 ,8 , and 12 hrs. Complete blood counts were determined at BL,
0 .5 ,1 ,1 .5 ,2 ,4 , 8,12,18, and 24 hrs. Serum biochemical profile data were determined
at BL, 2 ,6 ,1 2 ,1 8, and 24 hrs. All horses were un-instrumented at 6 hrs, with the
exception of the transverse facial and pulmonary artery catheters, which were removed
at 12 hrs, and one jugular venous catheter, which was removed at 24 hrs.
4.2.4 Clinical signs of disease - Heart rate (beats/min), respiratory rate
(breaths/min), rectal temperature (°C), mucous membrane color, capillary refill time
(CRT; seconds), and behavior were monitored.
4.2.5 Hemodynamic variables - Hemodynamic variables that were measured
included heart rate (beats/min), systolic, diastolic, and mean systemic and pulmonary
arterial pressures (SAP, DAP, MAP and SPAP, DPAP, MPAP, respectively; mm Hg),
MRAP (mm Hg), and CO (L/min). Three measurements were taken at each time for
each pressure variable. Five measurements were taken for CO at each time, and the 3
middle values were used in the analyses. Cardiac index (Cl; CO

kg of body weight;

ml/min/kg), systemic vascular resistance (SR^ [MAP-MRAP] * CO; mm Hg/L/min),
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and pulmonary vascular resistance (PR^ MPAP * CO; mm Hg/L/min) were calculated
(21). Specific ECG alterations were recorded.
4.2.6 Metabolic variables - Heparinized facial arterial blood samples (2 ml
each) were collected anaerobically and stored on ice until analyzed11for pH, partial
pressure of carbon dioxide (PaC02; mm Hg), partial pressure of oxygen (Pa02; mm Hg),
percentage oxygen saturation (Sa02; %), bicarbonate concentration (HC03‘; mEq/L),
total C 02 (TC02; mmol/L), and base excess. All samples were analyzed within 10
minutes of collection. Systemic arterial oxygen content (Ca02; ml/dl) was calculated as
the sum of oxygen bound to hemoglobin (Hb) and oxygen dissolved in plasma ([Hb x
%Sa02 x 1.34] + [Pao2 x 0.003]) (18). Oxygen delivery (Do2; ml/min) was estimated as
the product of Cao2 and CO (DOj = Ca02 x CO) (18).
4.2.7 Hematologic variables - Jugular venous blood (3 ml) was collected into
tubes containing EDTA. The samples were analyzed for PCV (%), total solids
concentration (g/dl), complete blood countq and white blood cell differential, and
fibrinogen concentration (mg/dl).
4.2.8 Serum biochemical variables - Jugular venous blood (6 ml) was collected
into tubes containing lithium heparin and analyzed' for plasma glucose (mg/dl),
aspartate transaminase (AST; U/L), y-glutamyltransferase (GGT; U/L), alkaline
phosphatase (ALP; U/L),creatine kinase (CK; U/L), total bilirubin (mg/dl), albumin
(g/dl), globulin (g/dl), BUN (mg/dl), creatinine (mg/dl), calcium (mg/dl), phosphorus
(mg/dl), sodium (mmol/L), potassium (mmol/L), chloride (mmol/L), anion gap
(mmol/L), and magnesium (mg/dl).
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4.2.9

Statistical analyses - The study was considered a mixed effect, nested

factorial design, with horses nested within treatments. Data were considered continuous
and followed a normal distribution based on the Shapiro-Wilk statistic with failure to
reject the null hypothesis o f normality at p<0.05. Non-normal data was transformed.
The data were summarized and graphed as mean ± SEM.
Data were analyzed using a mixed effect general linear model, which accounted
for the random effect of horse nested within treatments, and repeated measurements on
each horse. Interaction effects were included. Where there were significant effects of
time and interactions of treatment, toxin and time at P<0.05, pre-determined multiple
comparisons were made, using adjusted least squares means maintaining an experimentwise error of a = 0.05. Within group comparisons were made to each groups
corresponding BL values to describe behavioral changes over time. Treatments that
behaved differently over time were implied to be different Since S/S and S/A groups
functioned as control groups, between group comparisons were made for L/S and L/A
groups only when both changed similarly over time from their corresponding BL value.
SAS version 8.0 (PROC MIXED, PROC UNIVARIATE)* was used for all analyses.
4J Results
43.1

Clinical signs of disease - Heart rate was significantly increased in S/A

and L/A horses (Fig. 4.1). Respiratory rate was significantly increased in S/A and L/A
horses (Table 4.1). Rectal temperature was significantly increased in S/A, L/S and L/A
horses (Table 4.1). No significant differences in rectal temperature were observed
between L/S and L/A horses. There were no consistent changes in mucous membrane
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Figure 4.1 - Mean (±SEM) heart rate and cardiac index in horses pretreated with either
endotoxin (35 ng/kg over 30 minutes) or an equivalent volume of 0.9% NaCl
immediately followed by treatment with either ATP-MgCl2 (100 (imole/kg ATP and
100 |lmoIe/kg MgCl2 at an infusion rate of 0.3 mg ATP/kg/min) or an equivalent
volume o f 0.9% NaCl. *denotes significant (p £ 0.05) differences from baseline values.
Treatment groups that behaved differently over time were implied to be different.
Between group comparisons were only made for the LPS/ATP-MgCl2 and LPS/0.9%
NaCl groups when both changed similarly over time from their corresponding baseline
value. Different letters (a,b) indicate significant differences (p £ 0.05) between L/A and
L/S groups.
Key - BL = baseline; PI = end of the pre-treatment infusion; 5m Post = 5 min after
discontinuation of the treatment infusion.
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S

Table 4.1 - Mean (±SEM) respiratory rate and rectal temperature in horses pretreated
with either endotoxin (35 ng/kg over 30 minutes) or an equivalent volume of 0.9% NaCl
immediately followed by treatment with either ATP-MgCl2 (100 |imole/kg ATP and
100 flmole/kg MgCl2 at an infusion rate of 0.3 mg ATP/kg/min) or an equivalent
volume of 0.9% NaCl. ^denotes significant (p £ 0.05) differences from baseline values.
Key - BL = baseline; PI = end of the pre-treatment infusion; 5m Post = 5 min after
discontinuation of the treatment infusion.
R esp irato ry R ate (breaths/m in)

R ectal T em p eratu re (° Q

T im e (h rs)

L/A

S/A

L/S

S/S

L/A

S/A

L/S

S/S

BL

13.33

16.00

1933

19.33

37.75

37.88

37.67

37.93

PI

13.33

16.00

18.00

18.67

37.92

37.78

37.78

37.97

.05

37.33*

27.33*

18.67

1533

37.93

37.88

37.83

37.88

J

30.67*

21.33

18.40

17.33

38.15

37.93

37.95

37.95

1

24.00*

20.00

20.00

16.67

3837*

38.10

38.15*

38.05

1.5

22.67*

20.67

16.67

16.00

38.58*

3828

38.53*

38.07

2

22.00

24.00

16.00

16.80

39.13*

38.33

39.00*

3825

2.5

2133

2133

18.00

17.33

3920*

3828

38.93*

38.35

3

2333*

2133

24.00

1733

3930*

3835

39.12*

3825

5m Post

26.00*

16.00

2333

1733

39.08*

38.38*

38.95*

3827

3.5

25.33*

16.00

2533

18.00

39.07*

38.32

38.90*

38.32

4

27.67*

16.67

22.00

18.00

38.85*
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38.78*
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38.43*

38.60*

3823

5

24.67*

14.67
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38.12
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1733

20.00

16.67

38.75*
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38.12

8
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18.00

18.00
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3828

10

18.67

20.67

14.67

17.33

38.55*

38.18

38.18*

38.12

12

16.67

16.67
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16.00

38.37*
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38.07
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18.67
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20.00

18.67
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24

19.00

19.67
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18.00

37.57

37.75
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154

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

color and CRT across time for any group. The majority of L/S and L/A horses exhibited
signs o f transient abdominal pain with subsequent anorexia and depression after
endotoxin administration. The behavioral alterations persisted for approximately 2 hrs.
43.2

Hemodynamic variables - CO was significantly increased in S/A and L/A

horses from 0.05 to 3 and 1 to 3 hrs, respectively, and decreased in S/A horses at S hrs.
There was a significant increase in L/S horses only at I hr. Cl followed a similar pattern
as CO (Fig. 4.1) MAP significantly increased in L/S and L/A horses and decreased in
S/A horses (Fig. 4.2). Systolic and diastolic systemic arterial pressures followed a
pattern similar to that of MAP. There was a significant transient increase followed by a
decrease in SRLduring the ATP-MgCl2 infusion in L/A horses. Upon discontinuation of
the infusion, SRLtransiently increased (Fig 4.2). In S/A horses, SRLsignificantly
decreased during the ATP-MgCl, infusion (Fig. 4.2). In L/S horses, there was a
significant transient increase in SRL(Fig. 4.2). In L/S, L/A and S/A horses, MPAP
significantly increased (Fig. 4.3). Systolic and diastolic pulmonary arterial pressures
followed a pattern similar to MPAP. There was a significant transient increase in PRLin
the L/A, L/S and S/A groups (Fig. 4.3). In L/A and S/A horses, PRLsignificantly
decreased toward the end of the infusion (Fig. 4.3). There was a significant transient
increase in MRAP at 0.05 in both the L/S and L/A groups. Comparisons between L/S
and L/A from MRAP could not be performed, because the groups were not equal at BL.
In L/A and S/A groups, MRAP was significantly decreased at 0.5 to 2.5 hrs, 5 min post
infusion and 5 to 5.5 hrs and 0.5 hr to 5 min post-infusion, respectively.
4.33 Metabolic variables - Arterial pH was significantly increased in L/S
horses from PI to 8 hrs, except at 6 hrs. A significant decrease across time for PCO was
2
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Figure 4.2 - Mean (±SEM) mean arterial pressure and systemic vascular resistance in
horses pretreated with either endotoxin (35 ng/kg over 30 minutes) or an equivalent
volume o f 0.9% NaCl immediately followed by treatment with either ATP-MgCl, (100
|!mole/kg ATP and 100 (imole/kg MgCl2 at an infusion rate of 0.3 mg ATP/kg/min) or
an equivalent volume of 0.9% NaCl. See Figure 4.1 legend for key.
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0

Figure 4.3 - Mean (±SEM) mean pulmonary artery pressure and pulmonary vascular
resistance in horses pretreated with either endotoxin (35 ng/kg over 30 minutes) or an
equivalent volume of 0.9% NaCl immediately followed by treatment with either ATPMgCl2 (100 |imole/kg ATP and 100 (imole/kg MgCl2 at an infusion rate of 0.3 mg
ATP/kg/min) or an equivalent volume of 0.9% NaCl. See Figure 4.1 legend for key.

158
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Mean Pulmonary Artery Pressure
I— ILPS/ATP-MaCt,
5 0 . 9 % NaCKATP-MgClz
H L P S /0 .9 % NaCl

»b

mm Hg

0 8 0 .9 % NaCVO.9% NaCl

i t **

*

39*
30.
29. lid

PI

OS

S

1

IS

3

2S

3

Sm PM

IS

4

Tima (hrs)

mm HgfL/mln

Pulmonary Vascular Resistance

I

A

X

x* r

X,

PI

009

S

t

19

2

09

3

Sm P atf

29

*s

s

ss

Tim (hrs)

159
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

•

observed in the L/A, L/S and S/S groups. In L/A horses, PO was significantly
2

decreased from O.S to 2 hrs. Bicarbonate concentrations and base excess were
significantly decreased across time in all groups. TC02 was significantly decreased in
17A, L/S, and S/S groups across time. The %Sao2 was significantly decreased in L/A
horses from 0.5 to 2 hrs. There was a significant increase in Cao2 in L/A and S/A
horses at 0.5 and 2 to 6 hrs and at 0.5 to 4 hrs, respectively. Do, significantly increased
in L/A and S/A horses from 1 to 2 hrs and 0.5 to 2 hrs, respectively.
43.4

Hematologic variables - Red blood cell count was significantly

increased in L/A, S/A, and S/S horses at 0.5,2 to 8, and 18 hrs, 0.5 to 4 hrs, and 18 to
24 hrs, respectively. Hemoglobin was significantly increased in L/A and S/a horses at
0.5,4 to 8, and 18 hrs and I to 2 hrs, respectively. Platelets were significantly decreased
in the L/A group at 0.5 to 2 and 12 to 24 hrs. There were significant, transient,
inconsistent decreases in platelets in the other 3 groups. Fibrinogen concentration was
significantly decreased in L/A horses at 4 hrs. White blood cell count was significantly
decreased and then increased in L/A, L/S, and S/A horses (Fig. 4.4). Percentage
neutrophils were significantly decreased in L/A from 0.5 to 2 hrs and then increased in
L/A, L/S, and S/A beginning at 4 hrs (Fig. 4.4). Percentage band neutrophils were
significantly increased in L/A at 4 hrs. Percentage lymphocytes were significantly
decreased across time in L/A, L/S, and S/A horses. Percentage monocytes were
significantly increased in L/S and S/S groups at 6 hrs and at 8 and 12 hrs, respectively.
There were no changes in percentage basophils across time for any group. Percentage
eosinophils were significantly decreased in L/A and L/S groups at 0.5 to 24 hrs and 6
hrs, respectively.
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Figure 4.4 - Mean (±SEM) white blood cell count and neutrophils in horses pretreated
with either endotoxin (35 ng/kg over 30 minutes) or an equivalent volume of 0.9% NaCl
immediately followed by treatment with either ATP-MgCl2 (100 p.mole/kg ATP and
100 |imole/kg MgCl2 at an infusion rate of 0.3 mg ATP/kg/min) or an equivalent
volume of 0.9% NaCl. See Figure 4.1 legend for key.
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f

4 3 3 Seram biochemical variables - There were no consistently significant
changes across time for glucose, AST, and sodium. Numerous mild changes were
observed across time in all groups for the remaining serum biochemical variables (Table
4.2).
4.4 Discussion
Intravenous ATP-MgCl2 after low-dose endotoxin administration to clinically
healthy, conscious, adult horses failed to attenuate the clinical, hemodynamic, metabolic
and hematologic alterations that occur secondary to endotoxin exposure (9,22). The
combination o f endotoxin and ATP-MgCl, appeared to potentiate the pulmonary
hypertension, leukopenia, and neutropenia that occurred when endotoxin was given
alone. Finally, endotoxin and ATP-MgCl2 combination led to thrombocytopenia.
Pulmonary hypertension has been documented to occur in horses given
endotoxin (9,23) or ATP-MgCl2 (18,19). The pulmonary hypertensive effects of ATPMgCl2 and endotoxin in the present study appeared to be additive. However, the
pulmonary hypertension and secondary hypoxemia in the L/A group was transient.
Furthermore, oxygen delivery was increased in this group owing to an increase in CO.
Therefore, the pulmonary hypertension and hypoxemia observed in the L/A horses may
not be clinically significant since oxygen delivery was increased.
The development of pulmonary hypertension secondary to ATP-MgCl2
administration appears to be unique in horses. Pulmonary hypertension secondary to
cardiac abnormalities in children (24) or in piglets secondary to sepsis (25) can be
successfully reversed with administration of ATP-MgCl2. Attenuation of pulmonary
hypertension secondary to endotoxin administration was not observed in the present
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Table 42 - Mean (±SEM) serum biochemical variables in horses pretreated with either
endotoxin (35 ng/kg over 30 minutes) or an equivalent volume o f 0.9% NaCl
immediately followed by treatment with either ATP-MgCl2 (100 |imole/kg ATP and
100 llmole/kg MgCl2 at an infusion rate o f 0.3 mg ATP/kg/min) or an equivalent
volume o f 0.9% NaCl. ^denotes significant difference (p £ 0.05) from baseline value.
Key - L/A = LPS/ATP-MgCl2; S/A = 0.9% NaCl/ ATP-MgCl2; L/S = LPS/0.9% NaCl;
S/S = 0.9% NaCl/0.9% NaCl.
Tim e (hours)
V ariable

G lucose
(m g/dl)

AST (U /L)

GGT (U /L)

A ik. Phos.
(U /L)

C K (U /L)

B ilirubin
(m g/dl)

G roup

0

2

6

12

18

24

L/A

101.5*6.9

97.7*5.2

109.7*3.8

110*3.4

106.7*31

104.8*3.1

S/A

101*4.5

89.2*5.2

100.5*4.7

100*3.8

101.2*1.3

99.7*3.2

US

96.8*2.5

91.7*4.6

106.5*4.0

101.5*3.8

97.5*23

104.7*38

S/S

95.17*12

1203*6.8*

95.2*18

100*2.5

96.3*1.9

107.7*5.0

UA

342*30.7

355.5*30.7

361*41.0

3493*36.1

331.7*323

322.7*34.6

S/A

277.5*25.8

3053*263*

2973*31.9

303.3*30.0

288.17*27.0

287.7*25.9

US

235.2*29.6

233.5*25.6

230*27.6

246.8*31.0

236.67*29.5

234.8*27.1

S/S

217.5*16.7

222*18.6

223.8*21.0

235.7*18.9

230.7*18.5

223.7*18.7

UA

10.83*0.7

23*4.7*

193*4.0*

19.7*5.6*

183*43*

18*43*

S/A

15*16

16.3*15

15.3*13

15.2*2.2

15.2*1.9

14.3*1.9

US

16.5*5.3

16.7*5.5

173*5.4

17.3*5.8

18.5*5.8

17.5*5.7

S/S

19.5*7.72

19.83*7.71

19.17*7.98

20.5*8.11

21*8.02

19.5*7.5

UA

160.5*9.1

4703*753*

3163*43.6*

235.7*113*

219*10.9

208*11.5

S/A

150.7*133

223*44.7*

1813*20.4

170.5*20.4

161.3*17.3

161.8*15.7

US

144*10.1

1618*11.7

169*11.1

170*11.4

166.3*10.4

166.3*10.4

S/S

147.7*13.7

1513*110

1483*11.1

161.5*11.1

1603*9.9

1563*8.8

UA

253.3*26.9

2793*31.8

297.7*34.6*

2763*37.5

2338*31.5

222.8*35.9

S/A

233.7*37.5

2753*293*

2713*303*

257.3*28.0

233.5*27.8

240.7*29.1

US

194.2*20.1

191.5*17.7

1773*16.9

190.7*21.0

1803*18.8

181.7*19.0

S/S

173.8*19.6

184.5*23.0

185*23.9

2063*27.1

186.7*19.8

174*18.6

UA

11*0.4

13*03

23*03*

3.1*03*

37*03*

235*0.2

S/A

1.9*0.4

1.8*0.1

1.9*03

2.1*03

1.9*03

1.9*03

US

1.4*03

1.4*03

1.5*03

1.6*03

1.5*03

1.4*03

S/S

1.5*03

1.4*0.1

1.4*0.1

1.6*03

13*03

1.5*03
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Table 42 - continued.

Total
Protein
(g/dl)

Albumin
(g/dl)

G lobulin
(g/dl)

BUN
(m g/dl)

C reatinine
(m g/dl)

Calcium
(m g/dl)

Phosphorus
(m g/dl)

L/A

7.4*02

7.6*01

7.5*0.1

7.5*01

7.4*02

7.1*02

S/A

6.7*02

7.4*01*

71*01*

71*01*

71*0.1*

71*0.1*

L/S

70*0.2

7.0*01

7.0*01

71*01*

71*02*

71*0.1

S/S

6.7*02

6.8*01

6.8*01

71*01*

71*02*

7.1*02

L/A

3.3*0.1

3.4*00

3.4*0.1

3.4*0.1

3.3*0.!

3.2*0.1

S/A

3.1*0.I

31*0.1*

31*0.1

3.4*0.0*

3.3*0.0

31*0.0

L/S

3.0*0.1

3*0.1

3*0.1

312*0.1*

3.1*0.1

3.1*0.1

S/S

2.9*0.1

3.0*0.1

3.0*0.1

3.17*0.1*

31*0.1*

3.1*0.1*

L/A

4.1*0.2

41*01

4.2*01

4.1*01

4.1*02

3.9*02

S/A

3.6*0.2

4.1*01*

3.9*01

41*01*

4.1±0.1*

41*0.1*

L/S

4*0.2

4.0*01

4*0.2

4.3*01

41*02*

4.1*02

S/S

3.8*03

3.9±0.3

3.9*03

4.1*01

4.1*01

4.0*0.3

L/A

17.7*0.8

201*01*

20*01*

18.2*1.0

17.7*12

17*1.0

S/A

18*1.2

19.3*10

18.5*11

18.7*11

181*12

18*1.1

L/S

14.8*1.1

151*1.0

14.7*1.0

13.8*1.0

14.5*0.9

14.8*12

S/S

15.8*1.

16.5*0.8

14.5*1.0

14.3*0.6

15.2*0.9

15.3*0.6

L/A

1.3*0.1

1.6*0.!*

1.5*0.1

1.3*0.1

1.2*0.0

11*0.1*

S/A

1.2*01

1.4*0.1*

1.2*0.1

11*0.1

!.I*0.1

11*0.1

L/S

11*0.1

1.4*0.1

11*0.1

11*0.1*

11*0.1*

11*01*

S/S

1.33*0.11

112*0.12

11*0.1

13*0.1

11*0.1

11*0.06

L/A

12.0*0.2

11.6*01

11.8*0.2

12.1*0.1

123*0.1

121*0.1

S/A

11.9*02

121*01*

123*0.2

123*0.1

124*0.1*

121*0.2

L/S

12*01

11.7*01

12*0.4

126*0.1*

125*02*

12.4*0.1

S/S

11.7*01

11.9*01

121*01*

126*02*

126*02*

123*0.1*

L/A

3.6*01

5.7*01*

31*01*

24*0.1*

20*0.1*

21*0.1*

S/A

19*01

41*01*

3.7*01*

26*0.1

24*0.1*

24*0.1*

US

3.1*01

19*013

212*0.17*

227*0.07*

115*019*

215*0.08*

s /s

3.1*0J

218*010*

242*0.15*

243*0.12*

218*0.13*

205*0.16*
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Table 4.2 - continued

Sodium
(mmoI/L)

Potassium
(mmol/L)

Chloride
(mmol/L)

Anion Gap
(mmol/L)

Magnesium
(mg/dl)

L/A

135.5±0.5

135*0.6

137*0.7

135.7*1.1

135.8*0.7

136.8*0.7

S/A

135.2*0.8

1375*05*

136*1.0

1361*1.2

136*0.8

136.7*0.4

L/S

135*0.7

135.8*1.1

1361*0.9

136.5*0.5

135.5*0.4

135.7*0.6

S/S

135.8*0.8

135.7*0.8

135.8*0.6

136.5*1.0

135.7*0.3

135*0.8

L/A

3.7±0.2

3.6*0.1

31*0.1*

3.7*01

45*01*

3.7*01

S/A

3.4*0.2

3.7*0.1

3.6*01

3.7*01

3.6*01

3.4*01

L/S

3.4*0.1

3*0.2

3.5*0.1

4.0*0.1*

35*0.1*

3.7*01

S/S

3.3*01

3.5*0.1

35*0.0*

3.7±0.1*

35*0.1*

3.6*01

L/A

100.7*0.7

101.3*0.7

102.8*0.8

102.7*1.2

103*1.0*

102.5*0.8

S/A

102*1.1

103.2*0.7

102.3*0.9

101.8*0.9

102.7*0.6

102.2*0.5

L/S

99*0.9

100.8*0.4

104*05*

103*0.7*

1025*0.4*

1025*05*

S/S

99.7*0.5

1018*0.6*

1035*0.6*

1025*05*

1025*05*

101.3*0.9

L/A

6.1*0.8

10.6*0.4*

85*01*

7.4±I.O

8.7*05*

7.1±0.9

S/A

6.5±0.9

95*1.0*

8.0*0.5

8.2*0.6

81*0.6

5.8*1.0

US

6.7*0.9

7.3±0.6

61*0.7

8.6*11

7.8*1.0

6.8*11

S/S

5.3±0.5

6.2*1.0

6.1*0.8

7.6±0.6*

7.4*1.0

61*1.0

UA

1.8*0.1

25*0.1*

1.9*0.1

1.7*01

1.8*0.0

1.8*01

S/A

1.7*0.1

2.6*0.!*

15*0.1*

1.7*01

1.7*01

1.8*01

US

1.7±0.l

1.6*0.0

1.8*0.1

1.8*01

1.8*01

1.8*0.0

S/S

1.6*0.1

15*0.1*

15*0.1*

15*01*

15*0.1*

1.8*01
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study. The mechanism involved in ATP-MgCI2-induced pulmonary hypertension in
horses is not known but may be due to differences in purinergic receptor density in the
pulmonary vasculature. ATP can cause vasoconstriction or vasodilatation, principally
by activation of purinergic P2X or P2Y receptors, respectively (26). Unlike P2Y
receptors which are located on vascular endothelium and require generation of second
messengers, P2X receptors are located on vascular smooth muscle cells and use ligandgated ion channels to induce a response (26). Therefore, response time is faster with
activation o f P2X receptors. There may be a greater density of P2X receptors in the
equine pulmonary vasculature compared with other species. Additionally, when ATPMgClj is administered into the external jugular vein, the pulmonary vasculature is the
first major vascular bed encountered. Therefore, it will be exposed to the highest
concentration of ATP. When ATP circulates through the lung, the majority of ATP is
degraded to other adenine nucleotides and nucleosides by ectonucleotidases (27).
Adenosine, a breakdown product o f ATP, can activate adenosine/Pl receptors
(principally A^ located on vascular smooth muscle cells leading to vasodilatation.
Vascular beds downstream from the lungs will be exposed to higher concentrations of
ATP degradation products than ATP itself, thereby causing systemic vasodilatation,
which was observed in this study.
Horses administered endotoxin, irrespective of treatment, developed systemic
hypertension, whereas horses administered ATP-MgCl2 alone developed systemic
hypotension. Intravenous administration of ATP-MgCl2 has been documented to cause
a rate-dependent decrease in MAP and SRl, principally via vasodilatation (18,19). The
decrease in SRl despite the presence o f systemic hypertension in L/A horses was

. . .
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secondary to an increase in CO, which was not observed in L/S horses. The reduction in
SRl observed in L/A horses could lead to improved peripheral perfusion.
White blood cell count decreased in horses administered endotoxin, and the
magnitude o f the decrease was more pronounced in the group receiving ATP-MgCl2.
Neutropenia was only documented in the L/A group. Horses receiving ATP-MgCl2or
LPS alone developed a mild, transient leukopenia without a corresponding neutropenia.
The development of leukopenia in S/A horses and the difference in the
leukocyte/neutrophil response between L/A and L/S horses may be due to upregulation
o f adhesion molecules by ATP. Adenine nucleotides have been documented to act
directly on leukocytes to enhance expression o f the CD1 lb/CD 18 adhesion molecule
(28). Additionally, ATP has been demonstrated to stimulate leukocyte adherence to
cultured endothelial cells via P2Y and P2U receptor-mediated events (29).
One potential explanation for the apparent negative effects of ATP-MgCl2 on
pulmonary artery pressure and leukocyte/neutrophil counts in the L/A group, compared
with the L/S group, may be that the response to endotoxin in the L/S group was not as
marked. In contrast to a previous study o f endotoxin administration in horses (9), the
L/S horses in this study did not develop tachycardia, hypoxemia, or neutropenia.
Another possible explanation would be that endotoxin was present in our ATP-MgCl2
preparation. When the ATP-MgCl2 solution was analyzed using the Limulus
amoebocyte lysate assay, an endotoxin dose equivalent to 1 pg/kg o f body weight was
detected. Although speculative, we do not believe this dose would cause alterations in
clinical signs or hemodynamic and clinicopathologic variables. However, there are no
reports in the literature o f this dose o f endotoxin being administered to horses, so
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definitive conclusions regarding the contribution of the endotoxin in our ATP-MgCl2
solution to the overall changes observed in the L/A horses cannot be made. Based on the
results o f this study, we cannot be certain whether ATP-MgCl2truly potentiated the
negative effects produced by endotoxin administration.
In the L/A, but not L/S, horses developed thrombocytopenia during the ATPMgCl2 infusion. Endotoxin has been demonstrated to induce platelet aggregation in
horses (30). ADP is an agonist of platelets and is present in platelet dense granules
along with ATP (31,32). Following exposure to endotoxin, ADP is released from
platelet dense granules, contributing to platelet aggregation (33,34). The combination of
endotoxin and ATP-MgCl2, some of which will circulate as ADP, most likely
contributed to the development of thrombocytopenia, via platelet aggregation, observed
in the L/A group.
In conclusion, ATP-MgCl2administration was not protective during
experimentally-induced endotoxemia in clinically, healthy, conscious adult horses.
Furthermore, the use of ATP-MgCl2 during endotoxemia may worsen the hemodynamic,
metabolic and hematologic status o f affected horses. However, the pulmonary
hypertension and hypoxemia that developed in the L/A group was transient and
accompanied by an increase in oxygen delivery. Since ATP and other adenine
nucleotides are released from cells during shock, the potential role of adenine
nucleotides in the development o f hemodynamic derangements, leukocyte adherence,
and coagulopathies during endotoxemia warrants further investigation.
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4.5 Product Information
•Quik-Cath 2N-11-10, Baxter Healthcare Corporation, Deerfield, 111.
bIntramedic polyethylene tubing model PE205, Becton Dickson, Sparks, Md.
Tentalumen thermodilution catheter 41216-01, Abbott Critical Care Systems, Abbott
Laboratories, Hospital Products Division, North Chicago, 111.
dAngiocath 382269, Becton Dickson Infusion Therapy Systems Inc, Sandy, Utah.
‘Intramedic polyethylene tubing model PE260, Becton Dickson, Sparks, Md.
faormosol, Abbott Laboratories, North Chicago, 111.
“Injector 500, Columbus Instruments, Columbus, Ohio.
hArrow radial artery catheterization set RA-04020, Arrow International Inc, Reading,
Pa.
T)TX plus DT-6012, Becton Dickinson Infusion Therapy Systems Inc, Sandy, Utah.
jCardio Max Q model 85 thermodilution cardiac output computer, Columbus
Instruments, Columbus, Ohio.
‘'Polygraph model 7D, Grass Instruments, Quincy, Mass.
'Chart recorder model 25-60, Grass Instruments, Quincy, Mass.
"Lipopolysacccharide L2880, Sigma-Aldrich Inc, St. Louis, Mo.
"Life care pump model 4, Abbott Laboratories, North Chicago, III.
"Adenosine 5-triphosphate disodium salt A3377 and magnesium chloride hexahydrate
M2670, Sigma-Aldrich Inc, S t Louis, Mo.
PpH/blood gas analyzer model 238, Bayer Corp, Norwood, Mass.
••Baker systems 9110 plus, Biochem Immunosystems Inc, Allentown, Pa.
rAU 600, Olympus Corporation Clinical Instrument Division, Irving, Tex.
*SAS statistical software, version 8.0, SAS Institute, Cary, NC.
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CHAPTER 5. IN VITRO RESPONSES OF EQUINE COLONIC
ARTERIAL AND VENOUS RINGS TO ADENOSINE
TRIPHOSPHATE
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5.1 In tro d u ctio n

In horses, strangulating volvulus o f the ascending colon is a disease
characterized by colonic luminal obstruction and vascular occlusion, which results in
colonic ischemia, mucosal necrosis and vascular thrombosis (1). In experimental
models of complete arteriovenous occlusion of the ascending colon, colonic blood flow
has been shown to remain significantly below baseline values for at least 4 hours after
surgical correction (2). The disease is associated with a high mortality, which may be
related to a sustained reduction of blood flow and hypoperfusion (due to increased
vascular resistance) after surgical correction and continued ischemic injury. Endothelial
damage in the colonic vasculature occurs subsequent to ischemia-reperfusion, and this
damage can be exacerbated by endotoxin (3). Therefore, the sustained decrease in
colonic blood flow may be associated with endothelial damage in the colonic
circulation, leading to the release of vasoconstrictive agents and loss of endotheliumderived vasorelaxants, which subsequently may lead to vasoconstriction.
Extracellular purines have important and diverse effects on many biological
processes, including regulation of vascular tone (4). Adenosine triphosphate (ATP) is
principally an endothelium-dependent vasodilator that is rapidly metabolized and has a
short duration of action (5). The vasodilatory effects o f ATP are mediated primarily
through activation o f purinoreceptors located on both the endothelium and vascular
smooth muscle (6). The purinergic 2Y (P2Y) receptors located on endothelial cells,
when activated by ATP, couple to G proteins to activate phospholipase C leading to the
formation of inositol-3-phosphate (IP3) and mobilization of intracellular Ca2+(4).
Vasodilatation occurs by Ca2+-dependent activation o f endothelial nitric oxide synthase
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(eNOS) with subsequent generation of nitric oxide (NO) and by generation of
endothelial-derived' hyperpofarizing factor (EDHF) (4). Generation of protein kinase C
and subsequent phosphorylation o f mitogen-activated protein kinase appears to be the
pathway by which P2Y receptors on endothelial cells mediate prostacyclin synthesis and
release to generate additional vascular relaxation (7,8). P2Y receptors are also present
on vascular smooth muscle and mediate vasodilatation. The mechanism underlying
smooth muscle cell relaxation is not known but may involve activation o f K+channels
(9). When ATP is degraded by ectonucleotidases into adenosine, an adenosine
purinoreceptor (predominantly Aj) is activated, leading to vascular smooth muscle
relaxation (10).
We have recently evaluated the local colonic and systemic hemodynamic
alterations associated with intravenous infusion of a combination of ATP and
magnesium chloride (ATP-MgClj) in clinically healthy, anesthetized, adult horses (11).
Administration of ATP-MgCl2 at an infusion rate o f 0.3 mg of ATP/kg o f body
weight/min resulted in a significant decrease in colonic vascular resistance, principally
via vasodilatation (11). These results suggest that ATP-MgCl2 could have beneficial
effects during low-flow conditions o f the gastrointestinal tract by regulating vascular
tone.
Since endothelial damage has been demonstrated to occur during colonic
ischemia and reperfusion, the effects of ATP on regulation o f vascular tone may be
diminished or abolished owing to loss o f endothelial-derived vasorelaxants, specifically
NO. The purpose o f this study was to evaluate the effects o f ATP on vasomotor tone
(specifically the vasodilatory response) of isolated equine colonic arterial and venous
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rings in the presence and absence of endothelium and in the presence o f a nitric oxide
synthase inhibitor, N“-nitro-L-arginine methyl ester (L-NAME). We hypothesized that
ATP would cause vasodilatation in a concentration-dependent manner in both colonic
arteries and veins. Secondly, the magnitude o f the vasodilatory response in the arteries
would be significantly attenuated with endothelial removal or the addition of L-NAME.
Finally, we predicted that there would be no significant differences between veins with
intact endothelium, denuded endothelium and those treated with L-NAME. Because
veins have been shown to produce a weak response, compared with arteries, during
endothelium-dependent relaxation (12) and the predominant site of action of nitric oxide
is arterial resistance vessels (13), endothelium removal or blockade of nitric oxide in
veins should minimally affects the vasodilatory response.
5.2 M aterials and Methods
5.2.1

Horses - This study was approved by the Institutional Animal Care and

Use Committee o f Louisiana State University. Segments of mesenteric vessels were
collected from the left ventral colon of fourteen adult horses destined for euthanasia for
reasons unrelated to cardiovascular or gastrointestinal tract diseases. Horses were
deemed free of gastrointestinal and vascular disease and were euthanatized with an
overdose of sodium pentobarbital* (100 mg/kg, IV). The vessels were collected and
placed in chilled, oxygenated (95% 0 2 and 5% CO ) Tyrode’s solution until used. The
2

composition of Tyrode’s solution is: 136.87 mM NaCl; 2.68 mM KC1; 11.90 mM
NaHC03; 5.55 mM Dextrose; 1.81 mM CaCl2; 1.07 mM MgCl2; and 0.36 mM

NaHjPCV
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5.2.2

Experim ental design - The colonic artery and vein were cleansed of

excess connective tissue and cut into 4-nun wide rings. Each ring was placed in an
organ bath containing oxygenated Tyrode’s solution at 37 °C. One side of the vessel
ring was fixed to the floor o f an organ bath and the other side attached to a forcedisplacement transducer1’ which was interfaced with a polygraph0(14,15). An initial
tension of 2 g was applied to the rings, which were allowed to equilibrate for 4S
minutes. Preliminary studies and previous reports from our laboratory have
demonstrated that 2 g tension applied to equine colonic vessels resulted in optimum
vessel responsiveness (14,16). The bath solutions were replaced at 15-minute intervals
and tension readjusted to 2 g each time, except following the final wash.
5.2.2.1

T rial I - Arteries and veins (n=7 horses) with intact endothelium

(endo +) and endothelium that was removed by gentle mechanical debridement (endo -)
(16,17) were used. Sixteen tissue baths were used during this phase of the study. Two
runs were performed for each horse in order to accommodate the 4 vessel type
combinations (artery endo + and endo - and vein endo + and endo -). The vessel types
were randomly assigned to each run for each horse. After equilibration, each ring was
precontracted with a single dose of 10*7 M and 1.8 x 10*8 M endothelin-l (ET-l)d for
arteries and veins, respectively (Table 5.1). The ECS0(concentration required to
produce 50% maximum contraction) values for colonic arteries and veins are 2.3 x 10'7
M and 6.7 x 10*8 M, respectively (18). The doses o f ET-1 used in the present study were
selected based on results o f the study by Venugopal and colleagues (18) and from pilot
studies in our laboratory. The selected doses produced a minimum of 500 mg of
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Table 5.1 - Mean (±SEM) mg o f stable contraction and mg of stable contraction/mg of
vessel dry weight induced by endothelin-l(10'7 M for arteries and 1.8 x 10'8 M for veins)
for colonic arterial (A) and venous (V) rings with (+) and without (-) intact endothelium
(Trial I) or in the presence of 10"4 M Nw-nitro-L-arginine methyl ester (LN) (Trial II).
No statistical comparisons were performed on this data.

Vessel Type

T rial

mg Tension

mg Tension/mg Dry Weight

A+

I

1322±105.2

156.0±22.06

A-

I

2433±178.0

315.2±42.9

LNA+

n

1319±101.2

167.1±9.9

V+

i

1936±136.7

155.1±16.6

V-

i

1445±105.0

142.5±13.0

LNV+

n

2624±232.4

265.5±33.5
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contraction, which was the minimum response that was stable, as well as relatively
consistent responses in all vessel types utilized. Vessel rings that did not attain 500 mg
o f tension were rejected. Stock solutions of ET-l were prepared in distilled water (10*2
M) and stored in 70-ia1aliquots at -70 °C until used. On the day of the experiment, the
ET-l stock solution was thawed and appropriate dilutions were made with distilled
water. When the contractile response reached a plateau, a non-cumulative concentration
(10’8to 10'3M) response curve for ATP* was determined over 30 minutes for each vessel
type. The ATP was prepared in distilled water immediately prior to performing the
concentration-response curve. Additionally, 2 rings for each vessel type received only
ET-l to serve as a time controls.
5.2.2.2

T rial II - Arteries and veins (n=7 horses) with intact

endothelium were obtained from a different group of horses than those used in Trial I.
Eight tissue baths were used during this phase of the study. Similar to Trial 1,2 runs
were performed on each vessel type (artery endo + and vein endo +), with the order
randomized for each horse. The vessels were incubated with freshly prepared 10“*M
N"-nitro-L-arginine methyl ester (L-NAME)f for 30 minutes before determining the
non-cumulative concentration-response relationship for each dose of ATP. The same
concentrations of ATP were used as in Trial I. Similar to Trial I, the ATP and L-NAME
were prepared fresh daily. For each vessel type, one ring received only ET-l to serve as
a time control. Additionally, one ring from each vessel type was treated with 10"4 M
ATP in the absence o f L-NAME to serve as a positive control in order to compare
whether significant differences in relaxation response to 10"* M ATP existed between
vessels used in Trial I and n.
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Separate arterial and venous rings from each horse were prepared (endo + and
endo - for Trial I and endo + for Trial D) and placed in neutral-buffered formalin. The
vessels rings were processed and stained with hematoxylin and eosin. Cross-sectional
segments were examined histologically to evaluate the integrity, or lack thereof, o f the
endothelial and smooth muscle layers.
5.23 Data processing and statistical methods - The percentage relaxation for
each vessel type was calculated based on the relaxation from the stable contraction
induced by ET-1 to the resting tension, which was considered 100%. The percentage
relaxation was calculated at 1 ,3 ,5 ,7 ,9 ,1 1 ,1 3 and 15 minutes after application o f the
ATP. Fifteen minutes was selected as our end-point because the contraction induced by
ET-1 in the time-control vessels was stable during this time period, which indicates that
any relaxation that occurred during that time was an effect of the ATP and not
secondary to loss of the pre-contraction generated by ET-1. A curve was generated from
these points and the area under the curve (AUC) was estimated using the trapezoid
method (19). The AUC represents the integrated percentage relaxation over time and
thus is represented by the units percentage relaxation time (% minutes). Only the area
above the x-axis (relaxation) was included in the calculation.
The AUC was considered continuous. The AUC followed a normal distribution
based on the Shapiro-Wilk statistic with failure to reject the null hypothesis o f normality
at p^O.05.
The AUC was evaluated using a fixed effect linear model assuming a nested
factorial design. To account for the fact that different vessel types were performed on
different horses, the model was set up to include a fixed effect o f trial. Trial I included
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vessel types A+, A-, V+, and V-. Trial 2 included vessel types LNA+ and LNV+. Thus,
vessel type was nested within trial with concentration (the repeated effect) factored over
vessel type. The interaction term o f vessel type and concentration was used as the error
term to test for significant main effects. Where there were significant effects o f
concentration and of the interaction of vessel type and concentration at p^O.05, selected
ad hoc comparisons were made, using least square means. Comparisons were made
within vessel types for all concentrations to the ET-1 control, maintaining an overall
type I error o f 0.05. Comparisons were made among vessel types at concentrations 10*3
M and 10*4 M, maintaining an overall type I error o f 0.05. Thus, unless specified, p is £
0.05 where a significant difference is noted.
To confirm that the horses of each trial behaved similarly, the AUC for 1O'4 M
ATP concentration for vessel types in Trial I were compared to 10-4 M ATP
concentration (without L-NAME) in Trial 2 using the methodology described above.
PROC UNIVARIATE, PROC MIXED and PROC GLM8 were used for all analyses.
S3 Results
Histologic evaluation o f each representative vessel ring indicated the presence of
intact endothelium and smooth muscle in endo + vessels and complete removal o f
endothelium without damage to the smooth muscle in endo - vessels. The data from
Trial I and Q studies demonstrated relaxation of colonic arteries and veins with and
without intact endothelium and those pre-treated with L-NAME in response to ATP
(Table 5.2; Figure 5.1 and 5.2). Concentrations o f ATP from lO-6 to 10'3 M induced a
concentration-dependent initial, rapid, and transient contraction followed by relaxation
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Table 5.2 - Mean (±SEM) % maximum relaxation and % maximum attenuation for
colonic arterial (A) and venous (V) rings with (+) and without (-) intact endothelium or
in the presence of I O'4 M Nu-nitro-L-arginine methyl ester (LN) in response to 10-4 M or
10° M ATP over a 15-minute time period. The % maximum attenuation is based on the
relative change between (-) and (LN) vessels compared to the (+) vessels. A negative
value indicates less relaxation and a + value indicates more relaxation. The time to
attain maximum relaxation may vary among and between vessel types. No statistical
comparisons were performed on this data.

|

lO^M ATP

lO^MATP
% Maximum
Attenuation

% Maximum
Relaxation

% Maximum
Attenuation

Vessel Type

% Maximum
Relaxation

A+

36.71±4.39

A-

24.42±9.16

-30.06±22.19

33.99±12.52

-45.17±18.45

LNA+

36.98±9.29

-1.425±18.54

75.09±14.76

33.80±25.62

V+

56.94±9.47

V-

36.65±5.98

-29.16±12.58

41.28±4.15

-30.31±6.47

LNV+

34.30±7.60

-29.52± 17.98

62.47±5.85

6.35±10.72

56.90±5.94

59.46±3.55
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Figure 5.1 - Time-response curve for mean (±SEM) percent relaxation o f equine
colonic arterial (A) and venous (V) rings to 10"4 M ATP that were precontracted with
endothelin-l. Because percentage relaxation was not used in the study to identify
significant differences within and between vessel type/treatment, no statistical
comparisons were made.
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Figure 5.2 - Mean (±SEM) percent relaxation time (area under the curve) of equine
colonic arterial (A) and venous (V) rings after 15 minutes o f exposure to ATP (10*8 to
10'3 M) following precontraction with endothelin-1. Endo + = intact endothelium;
Endo - = endothelium removal; LN = endo + vessels incubated with 10"4M N“-nitro-Larginine methyl ester (L-NAME); C = time control (ET-1 only). Within group
comparisons were made at 10"4 M and 10*3 M ATP. Different letters (a,b) indicate
significant differences (p £ 0.05) between vessel types within that concentration of
ATP.
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in all vessel types. There was a significant effect of ATP concentration, vessel type and
their interaction on the percentage relaxation time (Figure 5.2). There were no
significant differences between the time control vessel rings. There was no significant
difference in the time control vessel rings (ET-1 only) during the 15-minute evaluation
period.
53.1

T rial I - At 15 minutes, ATP concentrations of 10"4 M and 10'3M caused

significant relaxation, for endo + arteries and veins and endo - veins. Significant
relaxation for endo - arteries was only observed at 10*3 M ATP. Endo + and endo vessels at 10*3 M and 10-4M ATP revealed significant differences in relaxation from the
stable contraction induced by ET-1 in arteries and veins (Figure 5.2). When the
relaxation response between arteries and veins was compared, there were no significant
differences in relaxation between endo + arteries and veins at 10*3 M ATP and endo arteries and veins at 10‘3M and 10-4 M ATP. However, endo + arteries relaxed
significantly less than endo + veins at 10-4M ATP.
5 3 3 T rial II - There was no significant difference in relaxation response
between the vessels treated only with lO-4 M ATP from Trial I and Trial II. At 15
minutes, significant differences in relaxation from the stable contraction induced by ET1 was observed for L-NAME-treated arteries and veins at I O'4 M and 10*3 M ATP.
There were significant differences in percentage relaxation time between endo - arteries
and veins (Trial I) and their L-NAME-treated arteries and veins (Trial II) at 10*3 M ATP
and endo + veins (Trial I) and their L-NAME-treated counterpart (Trial II) at I O'4M
ATP (Figure 53). There were no significant differences in relaxation response between
L-NAME-treated arteries and veins at 10'3 or lO"4 M ATP.
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5.4 Discussion
The results of this study yielded several important findings. First, ATP can
overcome ET-1-induced contraction. Second, the relaxation response of equine colonic
arterial and venous rings to ATP is dose-dependent. Third, removal of endothelium
attenuates but does not eliminate the relaxation response to ATP in both colonic arteries
and veins. Fourth, the contribution of NO to the relaxation response is minimal and
appears to be more appreciable in veins. Finally, the vascular response to ATP is
biphasic at high concentrations (initial transient contraction followed by slow
relaxation).
In contrast to numerous studies that have demonstrated that the mechanism of
ATP-induced vasodilatation is principally mediated by NO, the results of the present
study suggest that NO does not appreciably contribute to the endothelium-dependent
component o f the relaxation response to ATP in normal equine colonic vessels. A study
by Simonsen and colleagues evaluating the effect of ATP on vasomotor tone of lamb
isolated coronary small arteries demonstrated that mechanical removal o f the
endothelium, but not inhibition of NOS, partially reduced the relaxations elicited by
exogenously added ATP (20). The results indicated that ATP relaxed lamb coronary
small arteries through receptors located on both smooth muscle and endothelial cells.
Furthermore, the results exclude the possibility that NO is the mediator o f the

•

endothelial component of the relaxations to ATP in that particular vessel preparation
(20). The results o f the present study correlate with results from the study by Simonsen
and colleagues and our in vivo study (11), which failed to identify a significant increase
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in colonic arterial and venous plasma NO concentrations in horses administered ATPMgCl^ despite the development o f profound colonic vasodilatation.
Several possible explanations for the observations noted in the present study and
the in vivo colon study (11) exist. Although not evaluated, prostacyclin may play an
important role in endothelium-dependent ATP relaxation in equine colonic arterial and
venous rings. Further studies using indomethacin to block prostacyclin synthesis would
be necessary to elucidate the role of prostacyclin in ATP-induced vasodilatation.
Additionally, activation of P2Y receptors with subsequent IP3 formation and Ca2+
mobilization can lead to the synthesis of endothelium-derived hyperpolarizing factor,
which may also contribute to the vascular relaxation response (4).
Another possible explanation for the apparent lack of involvement of NO in the
vasodilatory response to ATP would be that we did not completely inhibit NOS. The
dose of L-NAME used in this study (10-4M) is comparable to other studies that have
evaluated the role o f NO in the vascular response in horses (15,17,21). Concentrations
o f L-NAME ranging from 10"* M (21) to 10° M (17) have been used and shown to be
effective in blocking NO production. In our initial pilot studies, we compared colonic
vascular responsiveness to acetylcholine in the presence of 10'5 M and 10"4 M L-NAME.
Our results indicated that lO"4 M yielded better blockade than 10‘s M (unpublished data).
Furthermore, results from an in vivo L-NAME pharmacokinetic study in horses
demonstrated that systemic and pulmonary hypertension rapidly develops following an
IV bolus injection of L-NAME (40 mg/kg) (personal communication). Therefore,
incomplete blockade o f NOS is unlikely to explain the results obtained in this study.

188

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

One observation that was not expected was the blockade of the endotheliumdependent component o f the relaxation response of colonic veins to I O'4 M ATP when
incubated with 104 M L-NAME. The same blockade was not observed with I O'3 M
ATP or in the artery preparations. This finding is in contrast to studies that have
demonstrated that the predominant site of action of nitric oxide is arterial resistance
vessels (13). One reason to explain these findings would be that at physiologic
concentrations of ATP (104 M), endothelium-dependent relaxation in colonic veins is
NO-mediated. Although speculative, when superphysiologic concentrations of ATP
(10'3 M) were used, other endothelium-dependent vasodilators (prostacyclin and EDHF)
may become more important. The reason why L-NAME blocked the endotheliumdependent component of the relaxation response to 104 M ATP in colonic veins but not
arteries in the present study is not known and warrants further investigation.
Endothelin-1 was selected as our precontractile agent for several reasons. First,
since ATP historically is a slowly relaxing agent, we wanted a precontractile agent that
would sustain the contraction for a minimum of IS minutes in order to more fully
evaluate the effects o f ATP on in vitro vasomotor tone. Secondly, since ET-1 is the
most potent vasoconstricting agent presently identified and it has been implicated as a
cause o f decreased blood flow that commonly occurs during ischemia (22), we wanted
to determine whether ATP could overcome ET-1-induced vasoconstriction. Previous
studies in our laboratory demonstrated that a consistent, prolonged contraction could be
achieved in colonic arteries and veins with ET-1 (18) and our pilot studies showed that
ATP could overcome this ET-1-induced vasoconstriction (unpublished data).
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In order to evaluate relaxation responses in vascular ring preparations, the rings
must first be contracted to establish tension so a relaxation response can be detected.
One limitation of in vitro relaxation studies is the inability to control the amount of
stable contraction induced by a vasoconstricting agent or electrical field stimulation.
The magnitude o f the response to a vasodilating agent may vary depending upon the
amount of initial tension generated. The effect of various tensions on the relaxation
response to ATP was not evaluated in the present study. Therefore, interpretation of
results for the different vessel types used in this study may vary if the relaxation
response is significantly influenced by the initial tension generated.
In this study, we used an unstable form of ATP rather than a stable analog. The
ATP used in the present study was the same ATP that we have been using in our in vivo
studies (ATP combined with magnesium chloride) (11,23). Since significant
vasodilatation occurs in vivo with IV administration, the mechanism of the vasodilatory
response was important to determine. Particularly, determining whether the form of
ATP that would be used in clinical situations could cause vasodilatation in the absence
o f endothelium, as could occur during colonic ischemia, was vital to future studies
evaluating the efficacy of ATP during colonic ischemia.
Unlike our in vivo studies where we used ATP-MgCl2(11,23), we only
evaluated the in vitro effects of ATP in the present study. Magnesium has been
reported to be a potent vasodilating agent and has been demonstrated to potentiate
vasodilatation when combined with ATP in vivo (24). However, we do not believe that
magnesium was a major contributor to the vasodilatation response observed in the in
vivo studies. In an in vitro pilot study, we documented that addition of MgCl2 (10'12to
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lO^M) to ATP (equimolar concentrations) did not enhance the relaxation response of
equine colonic arterial and venous rings (with intact and denuded endothelium)
precontracted with endothelin-1, compared with ATP alone (unpublished data).
Additionally, MgCl2 alone did not cause appreciable relaxation of colonic vascular rings
(with intact and denuded endothelium) precontracted with endothelin-1 (unpublished
data).
Because the ATP used in the present study is subjected to degradation by tissue
ectonucleotidases to adenosine, it was not possible to determine whether ATP or
adenosine mediated the smooth muscle component of the vascular relaxation response.
As previously mentioned, both P2Y receptors, which respond to ATP, and A2 receptors,
which respond to adenosine, have been identified on vascular smooth muscle (4).
Additional studies using specific adenosine blockers would need to be performed in
order to determine what percentage o f the smooth muscle relaxation response was
attributable to ATP and what percentage was attributable to adenosine.
Numerous studies have documented that high concentrations o f ATP cause a
transient vascular smooth muscle contraction followed by a slow, sustained relaxation.
Similar results were observed in this study. The mechanism of ATP-induced
contraction is via activation of P2X receptors located on smooth muscle cells (25,26).
Ligand binding to the P2X receptor results in the rapid, non-selective passage of cations
(N a\ K \ Ca2+) across the cell membrane resulting in an increase in intracellular Ca2+,
membrane depolarization, and smooth muscle relaxation (25,26). Whether the same
mechanism for ATP-induced vasoconstriction occurs in the horse is not known. The
concentration-dependent initial, transient contraction induced by higher concentrations
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o f ATP combined with the lack of specific antagonists to block this response,
complicates interpretation of the relaxation effects of ATP.
The vascular rings used in the present study were collected from normal horses.
Mechanically removing the endothelium attempts to mimic the effect of diseases of the
colon that lead to endothelial dysfunction. However, disease mechanisms not tested in
this study could alter the vascular response to ATP, both in vivo and in vitro.
Additionally, the responses and mechanisms induced by ATP might be different along
the colonic vascular bed. The segments used in this study might not be predictive of
responses of the microvasculature, which are important to the various components of
the intestinal wall.
In the present study, exogenous ATP applied to both equine colonic arterial and
venous rings precontracted with ET-1 in vitro causes a biphasic response characterized
by initial, transient contraction followed by slow, substantial and sustained relaxation.
The relaxation response is attenuated by endothelium removal but it is not inhibited by
blocking NO production, suggesting a relaxation mechanism other than NO. Further
studies evaluating the role of prostacyclin and adenosine in the relaxation response need
to be performed to further define the mechanism of action of ATP-induced
vasodilatation. Since vasodilatation does occur in the absence o f endothelium, further
studies evaluating the efficacy of exogenously-administered ATP (in the form of ATPMgClj) to modulate vasomotor tone during colonic ischemia warrants investigation.
5.5 Personal Communication
Carlos R.F. Pinto, DVM, DACT, Department o f Veterinary Clinical Sciences, School of
Veterinary Medicine, Louisiana State University, Baton Rouge, LA 70803.
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5.6 Product Information
aBeuthanasia-D Special, Schering-Plough Animal Health Corp., Union, NJ.
'’Model FT03 force-displacement transducer, Grass Medical Instruments, Quincy, Mass.
'Model 7D polygraph, Grass Medical Instruments, Quincy, Mass.
dEndothelin-l E-7764, RBI/Sigma, Natick, Mass.
'Adenosine 5'-triphosphate disodium salt A3377, Sigma-Aldrich Inc, St. Louis, Mo.
fNu-nitro-L-arginine methyl ester N5751, Sigma-Aldrich Inc, St. Louis, Mo.
gSAS v 8.0, SAS Institute, Cary, NC.
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CHAPTER 6. QUANTITATION OF ADENINE NUCLEOTIDES
IN EQUINE COLONIC MUCOSAL TISSUE USING HIGH
PERFORMANCE LIQUID CHROMATOGRAPHY
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6.1 Introduction
Liquid chromatography (LC) refers to any chromatographic procedure in which
the moving phase is a liquid (1). Since LC is not limited by sample volatility or thermal
stability, it is ideally suited for the separation o f macromolecules and ionic species of
biomedical interest, labile natural products, and a wide variety of other high-molecularweight and/or less stable compounds. Chromatographic separation is the result of
specific interactions between sample molecules and the stationary and moving phases.
These interactions enhance the ability to control and improve separation. Numerous
column packings (stationary phases), solutions (moving phases), and detectors are
available in LC, which allow a wider variation of selective interactions and greater
possibilities for separation. Also, separated fractions can be easily collected. Recovery
is quantitative and separated sample components are readily isolated for identification
by supplementary techniques or other use. High performance liquid chromatography
(HPLC) refers to the use of high-pressure pumps to establish a controlled, rapid solvent
flow which results in more reproducible operation and, therefore, greater accuracy and
precision (1).
Gastrointestinal mucosal cells are highly metabolically active and, therefore,
require large quantities o f adenosine triphosphate (ATP) for maintenance o f normal
cellular function (2). Because of this, the mucosal layer is principally affected during
ischemia (2). One proposed mechanism for the increase in cellular permeability
observed during ischemia is decreased endogenous production of ATP. In an
experimental model o f ascending colon volvulus in ponies, mucosal ATP content
diminished 92% during ischemia and recovered to only 44% of control values upon
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reperfusion (3'. In cultured renal and intestinal epithelial cell lines, decreasing cellular
ATP content by inducing chemical hypoxia results in rapid opening of tight junctions,
which increases paracellular permeability (4,5). Therefore, mucosal ATP depletion,
which occurs during gastrointestinal ischemia, may cause rapid opening of tight
junctions leading to enhanced absorption o f bacteria and endotoxin into the splanchnic
circulation. These findings suggest that increased metabolic support to ischemically
injured colonic epithelium may be important in decreasing morbidity and improving
survival (3). Quantitation of adenine nucleotide content in equine colonic mucosal
tissue, using HPLC analysis, will provide information regarding the relationship
between ATP content, and its catabolites adenosine diphosphate (ADP) and adenosine
monophosphate (AMP), and alterations in epithelial cell permeability that occur during
ischemia. Furthermore, potentially increasing adenine nucleotide content in mucosal
tissue using pharmacologic agents (ie. ATP-MgCl^ to enhance mucosal cell recovery
can be determined using this technique.
Tissue levels of ATP, ADP, and AMP have been separated by HPLC in
numerous species and tissues (6). However, separation and quantitation o f adenine
nucleotides in equine colonic mucosal tissue has not been reported. The purposes of
this study were to validate an established method for adenine nucleotide separation (6)
in equine colonic mucosal tissue, to determine the inherent variability in the tissue and
extraction method, and to determine the stability of ATP, ADP and AMP in the tissue
across time.
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6.2 Materials and Methods
6.2.1 Animals - The study was approved by the Institutional Animal Care and
Use Committee o f Louisiana State University. Equine colonic mucosal tissue (20 mm x
300 mm strip) was obtained from one horse euthanatized (sodium pentobarbital, 100
mg/kg, IV) for reasons unrelated to gastrointestinal tract disease. The tissue was
harvested from the pelvic flexure region of the ascending colon immediately after
euthanasia and placed in oxygenated Ringer’s solution and transported to the laboratory.
Composition o f the Ringer’s solution (mM) included: 114 NaCl, 5 KC1,1.25 CaCl2 1.1
MgCl2, 25 NaHCOj, 0.3 NaH2P 0 4 and 1.65 Na,HP04. The mucosa was separated from
the submucosa in oxygenated Ringer’s solution and divided into multiple parents
sections. The sections were placed in cryotubes, immediately submersed in liquid
nitrogen until frozen and then stored at -70 °C overnight.
6.2.2 Adenine nucleotide quantitation - Twenty four hours after collection, the
frozen samples were lyophilized* (freeze-dried) and stored in a desiccator at -70 C until
analyzed. The extraction method used in this study was adapted from a technique
described by Wynants and colleague (6). On the day of analysis, frozen tissue samples
were weighed (7-13 mg dry weight) and placed in individual 10-ml conical tubes on ice.
Iced cold perchloric acid (1 ml o f 0.6 N HCL04/1.5 mg of tissue dry weight) was added
to each sample, and the samples were homogenized, using a tissumizerb. The samples
were centrifuged at 2,500 rpm (1,500 x g) at -10 C for 12 minutes. The tissue extracts
(supernatant) were removed and 1,200 pL was placed in individual 5-ml conical tubes
on ice. The samples were neutralized with 800 jiL o f iced cold potassium bicarbonate
(1.0 M) and then centrifuged at 2,000 rpm (1,000 x g) at -10 C for 15 minutes.
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Neutralized samples were filtered through a nylon filter* (0.45 urn), and the ATP, ADP
and AMP were separated by HPLC, using an Alltech Adsorbosphere C18 5 um column"*.
The column was eluted by gradient, using 0.15M ammonium phosphate and
methanol/acetonitrile (50:50), at a gradient of 100% to 93% of ammonium phosphate
over 10 minutes. Detection was performed by a diode-array detector* set at a peak
wavelength of 260 nm. The run time for each sample was 10 minutes with a 5 minute
post-run period. The peaks were quantified by area under the curve and compared with
peak areas of known standards of ATP, ADP and AMP. The limit of quantitation on the
column was 0.05 |lg/ml.
6.2

J Instrum ent Variability (Phase I) - One tissue sample from one parent

segment was processed for adenine nucleotide quantitation, using the above described
technique. The single sample was loaded into the instrument and quantified 18
consecutive times to determine the inherent variability of the instrument.
6.2.4 Sample/Method Variability (Phase II) - Six individual small samples
were obtained from one parent segment and processed individually for adenine
nucleotide quantitation, using the above described technique. The samples were
analyzed in duplicate to determine the variation inherent in the sample preparation and
extraction method.
6.2.5 Tissue Storage Stability (Phase HI) - Multiple parent segment of tissue
were crushed, using a chilled mortar and pestle, and combined to improve the
homogeneity of the individual samples. Three samples of ground tissue were analyzed
in duplicate for adenine nucleotide content, using the above described technique. The
analyses were performed at time 0 (2 days after collection; I day after lyophilization)
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and again at time 7,14,21,32,35,46, and 54 (days after the initial adenine nucleotide
quantitation) to determine stability o f adenine nucleotides in lyophilized tissue across
time.
6.2.6

Statistical Analyses - The variability inherent to the HPLC analysis of

ATP, ADP and AMP on a single sample run 18 times was summarized as the coefficient
o f variation (CV). The effect of sample and analysis run on the measurement of ATP,
ADP and AMP was analyzed using a fixed effect, two factorial general linear model.
Additionally, the inter-run coefficient of agreement was calculated. Thie effect of time
on ATP, ADP and AMP stability was analyzed, using a fixed effect, general linear
model accounting for the repeated measurements across time. Initial analysis accounted
for the effect of time, tissue and run. For ATP and ADP, there was no effect of run and
the data for each run was combined and re-analyzed with each run considered a
replicate. Comparisons were made to baseline (time 0) using Dunnett’s test for multiple
comparison maintaining an experiment-wise type I error of 0.05. For AMP,
comparisons were made to time 7 since there were only two measurements at time 0.
For all analyses, a p £ 0.05 was considered significant. A statistical software packagef
was used for the analyses.
63 Results
The CV for the instrument was 5.89% for ATP, 7.68% for ADP and 9.73% for
AMP. For sample/method variability, there was a significant effect of tissue sample
(p=0.001) for ATP, ADP and AMP and a significant effect of run (p=0.034) for AMP.
The inter-run coefficient o f agreement (Pearson’s p) was 0.99 for ATP and ADP and
0.98 for AMP. For the tissue storage stability, there was no significant effect of tissue
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or time for ATP and ADP. However, there was a significant effect of time (p=0.0135),
but not tissue, for AMP (Fig. 6.1).
6.4 Discussion
The CV for the instrument used in this study was less than 10% for all
nucleotides measured. The greatest variation during Phase I occurred in AMP
quantitation and this was associated with diminished resolution of the AMP peak.
Resolution relates to the relative separation of molecules and can affect the accuracy of
band area measurement (1). Minor differences in band area measurement could account
for the higher CV for AMP observed in this study. Another factor that can affect CV is
the stability of the extracted nucleotides. The total run time for the 18 samples was 285
minutes. Based on pilot work performed during the validation procedure, no
appreciable degradation o f ATP, ADP and AMP was observed over a 13-hour run time.
However, in this study we were unable to determine what portion of the CV could be
attributed to the instrument and what portion, if any, could be attributed to nucleotide
instability.
The inconsistency in adenine nucleotide content in mucosal samples during
Phase II o f this study was related to the sampling method rather than the extraction
method. Small samples were broken off from the parent sample after lyophilization and
then analyzed. Differences in cell type and cell content may exist across the parent
sample, which could account for the variation observed in this study. For Phase HI the
parent segments were ground in a chilled mortar prior to analyses to improve
homogeneity. Results o f statistical analyses of Phase m data revealed that no
tissue/method effect was present, indicating that we were able to eliminate variability.
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Figure 6.1 - Mean (± SEM) adenine nucleotide content in equine colonic mucosal tissue
across time. * Significant difference (p £ O.OS) from day 7.
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Based on these results, we believe the variability in our data was a result o f tissue
variability and not extraction method variability. Currently, the authors recommend that
each frozen sample be ground prior to lyophilization. Another option to minimize the
variability in the data, although less favorable, would be to increase the number of
replicates analyzed. The results of this study indicate that a minimum of 100 replicates
would be required.
Increases in retention time (RT) for AMP occurred during the analyses. Reasons
for generalized increases in RT include: low mobile-phase flow rate; low column
temperature; improper gradient setting; and increased column activity resulting in the
system not being equilibrated (1). However, AMP was the only nucleotide affected in
this study. During the analysis, material from the extracted samples accumulates at the
head o f the column. As the number of samples analyzed increases, the quantity of
accumulated material subsequently increases. Binding of AMP to the material may
delay its release from the column since the solubility of the AMP alone is not the same
as the solubility of bound AMP. This could result in an increase in RT. In this study,
the majority o f RT problems were observed toward the middle to end o f a run, which
would allow sufficient time for material to accumulate on the column and bind AMP.
In an attempt to decrease the amount of material at the head of the column, a pre-filter
and guard cartridge were utilized in this study. The authors recommend that the
maximum number o f samples analyzed in one run be limited to 12 in order to maintain

good resolution of the adenine nucleotide peaks.
The resolution of the chromatogram was excellent for the ATP and ADP,
however, diminished resolution o f the AMP peak was observed across time. As stated
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previously, binding of AMP to material on the head o f the column can affect resolution
quality. Another factor that can contribute to poor resolution is the age o f the column.
In this study, the column used contained silica. The silica bonds can break down across
time and form free silica hydroxyl groups. These groups can interact with the molecule
of interest resulting in chromatographic peaks that demonstrate poor resolution. Finally,
the mobile phase used in this study contained extremely high concentrations o f salts
which accumulate on the column and can affect resolution. The authors recommend
that the column be washed thoroughly with water (forward and reverse wash) between
runs to prevent accumulation of salts which can lead to damage to the column and
instrument.
In conclusion, quantitation o f adenine nucleotide content in equine colonic
mucosal tissue, using HPLC, provided reproducible results when the tissue was ground
into a homogeneous sample. The stability of the adenine nucleotides measured in this
study following lyophilization within 24 hours o f sample collection and stored in a
desiccator at >70 °C was greater than 30 days. The extraction method was simple and
required minimal equipment to accomplish (refrigerated centrifuge and a tissumizer).
The RT for the 3 nucleotides analyzed in this study was under 10 minutes, which allows
analysis of multiple samples in one run.
6.5 Product Information
‘FreeZone 4.5 liter freeze dry system, Model 77510, Labconco Corporation, Kansas
City, MO
‘TJltra-turrax T25, Tekmar Corporation, Cincinnati, OH
cNalgene 4-mm syringe filters #176-0045, Nalge Company, Rochester, NY
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dAbsorbosphere C l8 5U column, Direct-connect prefilter kit #28689, All-guard
cartridge system #96041, Alltech Associates, Deerfield, IL
eHP 1090 liquid chromatograph, Agilent Technologies, Wilmington, DE
TROC MEANS, PROC GLM, PROC REG, SAS version 6.12, SAS Institute, Cary, NC
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CHAPTER 7. IN VITRO DEPLETION OF ADENINE
NUCLEOTIDES IN EQUINE COLONIC MUCOSAL TISSUE
AFTER EXPOSURE TO AN ELECTRON TRANSPORT
INHIBITOR

207
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

7.1 Introduction
Because gastrointestinal mucosal cells are highly active metabolicallyand require
large quantities o f ATP for maintenance of normal cellular function, the mucosal layer
is principally affected during ischemia (1). Increased cellular permeability, which
occurs during ischemia and hypoxia, leads to translocation of bacteria and endotoxin
from the gastrointestinal tract lumen into the splanchnic and systemic circulation. One
mechanism that may be involved in the increase in gastrointestinal mucosal
permeability during ischemia is decreased endogenous synthesis of ATP.
The epithelial intercellular permeability barrier is maintained largely by the tight
junction (TJ) (2). Tight junctions are continuous, circumferential, intercellular contacts
between epithelial cells, which are responsible for generating and maintaining a passive
permeability barrier that regulates paracellular solute flow (3). In vitro studies have
demonstrated that a correlation exists between cellular ATP content and TJ integrity (4).
When cells in culture are experimentally depleted of ATP, disruption of signaling
processes occurs resulting in paracellular barrier dysfunction (4). During ischemia and
subsequent reoxygenation, several lesions occur in epithelial cells including
mispolarization o f some membrane proteins, perturbation of the actin cytoskeleton and
disruption of the permeability barrier (5,6). These lesions can be reproduced in cell
culture models for hypoxia-reoxygenation injury, using agents that deplete cellular ATP
(4).
Several reversible in vitro models which produce chemical hypoxia or oxygen
deprivation have been developed to deplete cellular ATP content. Chemical hypoxia
can be induced with antimycin A (AA, oxidative inhibitor) (4), sodium cyanide (7), or a
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combination o f AA plus 2-deoxy-glucose (glycolytic inhibitor) (2). Oxygen deprivation
can be induced by replacing oxygen with nitrogen gas (8). One of the most widely
utilized methods to produce chemical hypoxia with subsequent ATP depletion is AA.
Antimycin A interferes with electron flow from cytochrome bn in cytochrome reductase,
thereby inhibiting the electron transport chain and ATP synthesis (9).
Ascending colon volvulus is a common cause of gastrointestinal tract ischemia
in horses (10). In an experimental model o f ascending colon volvulus in ponies,
mucosal ATP content was found to diminish 92% after ischemia and recovered to only
44% o f control values upon reperfusion (11). The depletion o f mucosal ATP content
may lead to rapid opening of TJs and increased passage o f bacteria and endotoxin
through the paracellular pathway and into the splanchnic circulation. Early
reestablishment o f cellular ATP content following an intestinal ischemic event may help
minimize mucosal barrier disruption with subsequent passage of toxic mediators into
the splanchnic circulation, thereby decreasing morbidity and mortality.
Based on this information, we hypothesized that AA would deplete equine
colonic mucosal adenine nucleotide content and upon its removal, adenine nucleotides
would be repleted. The purposes of this study were to evaluate the effect of AA on
equine colonic mucosal adenine nucleotide content, and secondly, to determine the
stability o f adenine nucleotides in an in vitro system. The development of an in vitro
reversible model of ATP depletion for equine colonic mucosal tissue will enable
investigators to characterize the role of ATP in maintenance of cellular integrity.
Additionally, methods to modulate TJ integrity during adenine nucleotide depletion can
be evaluated.
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72 Materials and Methods
7.2.1 Animals - The study was approved by the Institutional Animal Care and
Use Committee o f Louisiana State University. Six horses euthanatized for reasons
unrelated to gastrointestinal tract disease were used. Immediately following euthanasia
(pentobarbital sodium*, 100 mg/kg, IV), a full-thickness tissue segment was collected
from the pelvic flexure region o f the left ventral colon. The tissue was rinsed of
intestinal contents, using 0.9% NaCl, and transported to the laboratory in preoxygenated
(95% 0 2-5% CO^, chilled Ringer’s solution. Composition of the Ringer’s solution
(mM) was: 114 NaCl, 5 KC1,1.25 CaCl2, 1.1 MgCl2, 25 NaHC03, 0.3 NaH2P 04 and
1.65 Na2HP04. The tissue was pinned on a rubber surface, with mucosal side up, and
submerged in oxygenated (95% 0 2-5% COj) Ringer’s solution at room temperature (2022 °C). Mucosal segments (6 mm x 6 mm) were harvested and placed in organ baths.
The segments were bathed in oxygenated (95% 0 2-5% COj) Ringer’s solution at a
volume of 10 ml and temperature of 37 °C.
7.2.2 Experimental Design - Four different organ bath conditions were used
(Table 7.1). All tissues were allowed an equilibration period of 15 minutes in the organ
bath prior to collection of the baseline (t= 0) sample. The remainder of the samples
were collected at 60,120,180 and 240 minutes after the baseline samples were
obtained. Baths 1 through 4 contained Ringer’s solution with 10 mM glucoseb (SCRS).
Baths 5 through 8 contained Ringer’s solution with no glucose added (SFRS). Baths
9-12 contained Ringer’s solution with no glucose added. After obtaining the baseline
sample, antimycin Ac (50 pM) was added to the bath solution (AA/D). Baths 13
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Table 7.1 - Organ bath/tissue design. Segments (6 mm x 6 m m ) o f equine colonic
mucosal tissue were placed in individual organ baths and bathed in oxygenated (95%
0 2-5% COj) Ringer’s solutions with the following treatments added at time = 0
minutes: SCRS - substrate-containing (10 mM glucose) Ringer’s solution; SFRS substrate-free Ringer’s solution; AA/D - 50 JIM antimycin A (AA) in SFRS; AA/R AA removed and replaced with SCRS only; Frozen - tissue removed from organ bath
and snap frozen in liquid nitrogen; NT - no tissue in organ bath.
Organ Bath

Omin

60 min

120 min

180 min

240 min

1

SCRS

Frozen

NT

NT

NT

2

SCRS

SCRS

Frozen

NT

NT

3

SCRS

SCRS

SCRS

Frozen

NT

4

SCRS

SCRS

SCRS

SCRS

Frozen

5

SFRS

Frozen

NT

NT

NT

6

SFRS

SFRS

Frozen

NT

NT

7

SFRS

SFRS

SFRS

Frozen

NT

8

SFRS

SFRS

SFRS

SFRS

Frozen

9

AA/D

Frozen

NT

NT

NT

10

AA/D

AA/D

Frozen

NT

NT

11

AA/D

AA/D

AA/D

Frozen

NT

12

AA/D

AA/D

AA/D

AA/D

Frozen

13

AA/D

AA/R

Frozen

NT

NT

14

AA/D

AA/R

AA/R

Frozen

NT

15

AA/D

AA/R

AA/R

AA/R

Frozen
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through 15 contained Ringer’s solution with no glucose initially (SFRS). After
collection o f the baseline sample, 50 pM AA was added (AA/D). After the 60-minute
sample collection, the Ringer’s/AA solution was removed and replaced with Ringer’s
solution and 10 mM glucose (AA/R).
7.2.3

Adenine nucleotide quantitation - At the appropriate time periods,

tissues were removed from the baths, snap frozen in liquid nitrogen and stored in
cryotubes at -70 C until lyophilized. Within 3 days o f collection, the samples were
lyophilizedd and stored in a dessicator at -70 °C prior to high performance liquid
chromatography (HPLC) analysis, which was performed within 10 days of sample
collection. The method for adenine nucleotide quantitation in equine colonic mucosal
tissue using HPLC has been described (12). Briefly, frozen lyophilized tissues were
weighed (7-13 mg) and placed in individual conical tubes on ice. Ice-cold perchloric
acid (I ml of 0.6 N HCL04/1.5 mg of tissue dry weight) was added to each sample, and
the sample tissues were homogenized, using a tissumizer6. Subsequently, the samples
were centrifuged (1,500 x g) at -10 °C for 12 minutes, the supernatant removed, and
1,200 pL o f the supernatant placed in individual conical tubes on ice. After neutralizing
the samples with 800 pL of ice-cold potassium bicarbonate (1.0 M), they were
centrifuged (1,000 x g) at -10 °C for 15 minutes. Neutralized samples were filtered
(0.45 pm nylon filter*) and the ATP, ADP and AMP were separated by HPLC, using an
Alltech Absorbosphere C l8 5pm column8. The column was eluted by gradient, using
0.15M ammonium phosphate and methanol/acetonitrile (50:50), at a gradient of 100%
to 93% o f ammonium phosphate over 10 minutes. Detection was performed by a diodearray detector11set at a peak wavelength o f260 nm. The peaks were quantified by area
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under the curve and compared with peak areas o f known standards o f ATP, ADP and
AMP.
7.2.4

Statistical Analyses - The study was considered a completely randomized

block design, blocked by tissue, with replication of each Treatment (n=2) within each
block. All continuous data were evaluated for normality, using the Shapiro-Wilk
statistic and considered to follow a normal distribution with failure to reject the null
hypothesis of normality at p £ 0.05. Non-normal data were transformed. The data were
summarized and graphed as mean ± SEM.
The data were evaluated using a mixed effect, general linear model accounting
for the random variance o f Horse and repeated measurements on each horse. A twosided hypothesis with a = 0.05 was used to determine significance o f the fixed effects.
Where there were significant fixed effects, including interactions, selected adjusted least
squares means comparisons maintaining an experiment-wise error of a =0.05 were
made within treatments to describe the changes over time. Thus, where a difference was
noted, the p-value was £ 0.05. Treatments that behaved differently over time were
implied to be different SAS version 8.01was used for the analyses.
7 3 Results
7.3.1

SCRS Group - There were no statistically significant differences in ATP

content across time compared with the baseline (t=0) value. There were significant
decreases in ADP and AMP content at 60-240 minutes and 120-240 minutes,
respectively (Figure 7.1 A).
73.2 SFRS Group - Both ATP and ADP significantly decreased across time.
ATP content significantly decreased at 240 minutes and ADP was significantly
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decreased at 60-240 minutes, compared with baseline values. There were no changes
in AMP content across time (Figure 7.1B).
73 3 AA/D Group - Significant decreases in adenine nucleotides were observed
in tissues exposed to 50 pM AA. Compared with baseline values, ATP and ADP were
significantly decreased at 60-240 minutes and 120-240 minutes, respectively. There
was an initial significant increase in AMP content at 60 and 120 minutes, which was
followed by a significant decrease at 240 minutes (Figure 7.2 A). When compared to 60
minute values, 120,180 and 240-minute ATP, ADP and AMP concentrations were
significantly decreased.
7.3.4 AA/D-AA/R Group - Adenine nucleotide content followed a similar
pattern as AA/D. However, no significant decrease in AMP was observed at 240
minutes (Figure 7.2 B). When compared with the 60 minute value, ATP concentrations
at 120,180 and 240 minutes were not significantly different. However, ADP and AMP
followed a pattern similar to the AA/D group.
7.4 Discussion
In the presence of glucose and oxygen, equine colonic mucosal ATP content was
stable in vitro for up to 4 hours. However, both ADP and AMP decreased. When
glucose was not present, ATP content remained stable for only 3 hours. Addition of AA
(50 |lM ) caused a time-dependent decrease in adenine nucleotide content. Removal of
AA-containing Ringer’s solution with subsequent solution replacement and addition of
glucose prevented further depletion o f ATP. However, unlike cell culture systems in
which ATP is repleted upon removal of AA and addition of substrate (4), we did not
observe ATP repletion in our whole tissue model.

214

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Figure 7.1 (A and B) - Mean (±SEM) ATP, ADP and AMP content in equine colonic
mucosal tissue. SCRS - substrate-containing (10 mM glucose) Ringer’s solution; SFRS
- substrate-free Ringer’s solution. * denotes significant difference from time 0.
p £ 0.05 considered significant.
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Figure 7.2 (A and B) - Mean (±SEM) ATP, ADP and AMP content in equine colonic
mucosal tissue. AA/D - 50 (iM antimycin A (AA) in SFRS; AA/D-AA/R - 50 JlM AA
in SFRS for 60 minutes followed by removal of AA and replacement with SCRS.
AA/D group: Significantly different from time 0 - ATP (60-240 min); ADP (120-240
min); AMP (60,120, and 240 min). Significantly different from time 60 - ATP, ADP,
and AMP (120-240 min).
AA/D-AA/R group: Significantly different from time 0 - ATP (60-240 min); ADP (120240); AMP (60 and 120 min). Significantly different from time 60 - ADP and AMP
(120-240 min).
p £ 0.05 considered significant.
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The intestinal epithelial tight junction restricts the paracellular permeation of
ions and nonelectrolyte substances (13). In one study using chemical hypoxia to deplete
ATP in cultured human intestinal epithelial cells, transepithelial resistance to passive
ion flow rapidly decreased, and the effect was reversible if control conditions were
restored within 1 hour (14). The decrease in resistance was demonstrated to be due to
an increase in paracellular, not transcellular, permeability (14). Clinically, ATP
depletion secondary to gastrointestinal tract ischemia may increase paracellular
permeability, leading to passage of bacteria and endotoxin into the systemic circulation.
Development of an in vitro reversible model of ATP depletion in equine gastrointestinal
mucosal tissue would enable investigators to characterize the role of ATP and other
adenine nucleotides in the regulation of paracellular permeability. Additionally,
potential therapies aimed toward increasing cellular ATP content to maintain TJ, as well
as cellular, integrity can be evaluated.
The reason(s) for the lack of reversibility of ATP depletion in our whole tissue
model, compared with cell culture systems, is unknown, but several possibilities exist.
First, the binding of AA to the tissue may be irreversible. Second, the cells may not be
able to take up and utilize the glucose that was added to the in vitro system following
removal of AA. Third, additional nutrients which were not present in the electrolyte
solution that we used, but are present in cell culture medium, may be required for cells
to synthesize ATP. Finally, tissues contain large quantities o f ectonucleotidases, which
degrade adenine nucleotides (15). The mucosal cells may have regenerated ATP, but
the ATP may have escaped into the extracellular environment, subjecting it to
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enzymatic degradation to a form (ie. adenosine, inosine, hypoxanthine) which was not
measured in this study.
In conclusion; equine colonic mucosal ATP content appears to be stable in an in
vitro system for a minimum of 3 hours in the presence or absence of substrate. Addition
o f an electron transport inhibitor markedly decreased ATP content. However, the
depletion o f ATP in our whole tissue model was not reversible. Additional studies
using other mitochondrial (and glycolytic) inhibitors and different substrates need to be
performed to determine whether a whole tissue in vitro model of reversible ATP
depletion can be developed.
7.5 Product Information
“Beuthanasia, Schering-Plough Animal Health Corp., Union, NJ.
b G8270, Sigma-Aldrich Inc., S t Louis, Mo.
CA8674, Sigma-Aldrich Inc., St. Louis, Mo.
dFreeZone 4.5 liter freeze dry system, Model 77510, Labconco Corporation, Kansas
City, MO
EUltra-turrax T25, Tekmar Corp., Cincinnati, Ohio.
'Nalgene 4-mm syringe filters #176-0045, Nalge Company, Rochester, NY.
“Absorbosphere C l8 5U column, Direct-connect prefilter kit #28689, All-guard
cartridge system #96041, Alltech Associates, Deerfield, EL.
hHP 1090 liquid chromatograph, Agilent Technologies, Wilmington, DE.
‘SAS version 8.0, SAS Institute, Cary, NC.
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SUMMARY
Intravenous infusion o f a combination of ATP and MgCI2 to clinically normal,
conscious, adult horses significantly increased CO (0.35 to 0.8 mg o f ATP/kg o f body
weight/min), decreased MAP and SRlCO.35 to 1.0 mg/kg/min), and caused mild
pulmonary hypertension (0.15,0.3, and 0.4 to 0.9 mg/kg/min) without a significant
change in PRL Magnitude o f the hemodynamic alterations was dependent on the rate of
infusion. The maximal safe infusion rate was 0.3 mg/kgt/min. All horses became
lethargic, and their appetities diminished at infusion rates £ 0.4 mg/kg/min. Five of 6
horses exhibited signs of mild abdominal discomfort at infusion rates > 0.7 mg/kg/min.
Flank sweating was observed in all horses at rates £ 0.45 mg/kg/min. Urine volume
and specific gravity and hematologic, biochemical, and arterial blood gas alterations
were detected during and after the infusion. The various hemodynamic and metabolic
alterations were without appreciable detrimental effects at rates of infusion ranging from
0.05 to 1.0 mg/kg/min.
In clinically normal, anesthetized, adult horses administered IV ATP-MgCl2 (0.1
to 1.0 mg/kg/min), systemic and colonic vascular resistance decreased in a ratedependent manner. The decrease observed was principally via vasodilatation. A rate of
0.3 mg/kg/min caused a significant decrease in systemic and colonic arterial pressure
and colonic vascular resistance without a signfkant corresponding decrease in colonic
arterial blood flow. No consistent signfrcant alterations in plasma colonic NO
concentrations were observed, despite profound vasodilatation o f the colonic arterial
vasculature. The results suggest that IV infusion o f ATP-MgCl2 combination to horses
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with gastrointestinal tract ischemia may be beneficial in maintaining colonic perfusion if
driving pressure is maintained above a critical level.
In clinically normal, conscious, adult horses, IVATP-MgCl2(dose - 100 pmole
ATP/kg and 100 pinole MgCij/kg; rate - 0.3 mg/kg/min) after low-dose (35 ng/kg)
endotoxin administration failed to attenuate the clinical, hemodynamic, metabolic and
hematologic alterations that occur secondary to endotoxin exposure. The combination
of endotoxin and ATP-MgCl2 appeared to potentiate the pulmonary hypertension,
leukopenia, and neutropenia that occurred when endotoxin was given alone. Finally,
endotoxin and ATP-MgCl2combination led to thrombocytopenia.
In isolated colonic arterial and venous rings collected from clinically normal
horses, exogenous ATP caused a concentration-dependent relaxation response. At
higher concentrations of ATP (10*6 tp 10'3 M), the vascular response to ATP was
biphasic, with an initial, rapid and transient contraction followed by relaxation.
Significant relaxation was detected at 10"4 M and I O'3 M. Removal of endothelium
attenutated but did not eliminate the relaxation response in both arteries and veins. The
mean maximum percentage attenuation of the relaxation response for endo - arteries and
veins was 45.17% and 30.31 %, respectively. The contribution of nitric oxide to the
relaxation response was minimal and appeared to be more appreciable in veins. The LNAME study paralleled our in vivo colon study, where no significant increases in either
plasma colonic arterial or venous nitric oxide concentrations were detected despite the
presence of profound vasodilatation of the colonic vasculature. The mechanism of
action o f the endothelium-dependent component of the relaxation response to ATP may
involve PGI2 or EDHF. However, nitric oxide cannot be definitely ruled-out. The ATP
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used was not stable and, therefore, was subject to degradation to other adenine
nucleotides (ie. adenosine), which would activate different mechanisms to cause
endothelium-dependent vasodilatation.
We validated an established method for adenine nucleotide separation for use on
equine colonic mucosal tissue utilizing HPLC. The limit of quantitation was 0.05
pg/ml. The method provided reproducible results when the tissues were ground into a
homogenous samples prior to extraction. No significant decreases in adenine
nucleotides were observed for at least 54-days when samples were lyophilized within
24 hours of collection and stored in a dessicator at -70 °C.
Finally, we evaluated the stability of adenine nucleotides in equine colonic
mucosal tissue in vitro and a potential reversible model o f adenine nucleotide depletion
in a whole tissue model. In the presence of glucose and oxygen, ATP was stable for £ 4
hrs. However, both ADP and AMP decreased. When glucose was absent, ATP
remained stable for £ 3 hrs. Addition of 50 pM antimycin A (electron transport
inhibitor) caused a time-dependent decrease in adenine nucleotide content. Removal of
antimycin A and addition of substrate prevented further depletion of ATP. However,
adenine nucleotide repletion was not observed in our whole tissue model.
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